AMARILLO - Super News und Empfehlung - 500 Beiträge pro Seite (Seite 2)

[Turboverdichter]

Amarillo BiosciencesBB: AMAR

Amarillo Biosciences IND Application Passes FDA Review

11 August 2006, 12:21pm ET

Company Reports on Other Corporate Developments

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that the Company's Investigational New Drug application (IND) for idiopathic pulmonary fibrosis (IPF) has successfully passed the FDA's 30-day review process and has been allowed to go into effect. A Phase II, 60-patient study to test low dose oral interferon as a treatment of chronic cough in IPF patients is on target to launch in the fourth quarter of 2006.
In other corporate developments, the Company announced:

Oral Warts Study in HIV Patients Launched

Investigators at six university-associated oral medicine clinics in the U.S. have been invited to participate in the Company's oral warts study. Clinical supplies are being packaged for an 80-patient, Phase II study that will be opened to enrollment in September 2006. The study is expected to take approximately one year to complete.

Phase II Behcet's Study Enrollment [/b]

Enrollment in the Company's Phase II study of Behcet's disease has reached 26 patients out of a targeted total of 90 patients. Additional sites are being added to the study with the goal of completing patient enrollment by the end of the year. Study results should be available by mid-2007.

Private Placement

Amarillo Biosciences has privately placed 1,200,000 shares of restricted stock for $660,000 with a European investor, bringing the total amount of capital raised in 2006 via the sale of restricted shares to $1,534,760. The recent financing will enable the company to fund its IPF study and launch its oral warts study.

Dietary Supplement

The Company has been developing a new human dietary supplement derived from cattle. This supplement has been tested and shown to boost the immune system. The Company plans to start sales of the dietary supplement in early 2007.

"Because of the millions of cattle in the Texas Panhandle, our close proximity is an ideal location to collect and commercialize this dietary supplement," said Joseph M. Cummins, President and CEO of ABI.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.


--------------------------------------------------------------------------------

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
Tel: [phone]
Tel: [phone]
Fax: [phone]
e-mail: Email Contact

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: [phone] x 13
Fax: [phone]
e-mail: Email Contact

[Turboverdichter]

Amarillo BiosciencesBB: AMAR

Management Team of Amarillo Biosciences, Inc., Discuss Upcoming Studies and Successful Passing of FDA's 30-day Review Process for Company's Investigational New Drug Application for Idiopathic Pulmonary Fibrosis at SmallCapVoice.com

17 August 2006, 09:06am ET

AUSTIN, Texas, Aug 17, 2006 (BUSINESS WIRE) --

SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guests are Joseph and Marty Cummins of Amarillo Biosciences (BB:AMAR). The interview focuses on the recent news that the Company's Investigational New Drug application (IND) for idiopathic pulmonary fibrosis (IPF) has successfully passed the FDA's 30-day review process and has been allowed to go into effect. The interview can be heard here at http://www.smallcapvoice.com/amar/amar-8-16-06.html.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

SOURCE: SmallCapVoice.com, Inc.

PAN Consultants, Ltd. (Investor Relations)
Philippe Niemetz, 800-477-7570 or 212-344-6464
Fax: [phone]
Copyright Business Wire 2006

[Cpt_Tenbagger]

schön ruhig hier.

und der kurs steigt heimlich an...

coole aktie

[Turboverdichter]

Antwort auf Beitrag Nr.: 23.707.586 von Cpt_Tenbagger am 31.08.06 20:03:39

Meinst du das Im Ernst!?

Ich bin wirklich alleine hier und seit geraumer Zeit scheint der Boden durchschritten!

[Turboverdichter]

Antwort auf Beitrag Nr.: 23.707.586 von Cpt_Tenbagger am 31.08.06 20:03:39

...und wieder 1 cent plus!

[DrTom2]

Du bist nicht alleine, zumindest nicht in der Aktie, nur machen nicht alle so viel Lärm ;-)
Gruß
Thomas

[Turboverdichter]

Antwort auf Beitrag Nr.: 23.730.899 von DrTom2 am 02.09.06 10:36:24

Ich hoffe, dass ich nicht nerve!

[DrTom2]

Antwort auf Beitrag Nr.: 23.730.970 von Turboverdichter am 02.09.06 10:54:08

Nein, tust du nicht, ausserdem ist es ja gut, daß sich jemand um die aktuellen News kümmert, da braucht man nicht alle Research-Arbeit selbst zu machen.
Also, am Ball bleiben und vielen Dank für den News-Service.

[Turboverdichter]

NASDAQ OTC Bulletin Board 0,85 +6,25% 21:37 08.09. 90.500

...ganz ordentlicher Umsatz heute und fast nur Käufer!

[Turboverdichter]

Antwort auf Beitrag Nr.: 23.836.354 von Turboverdichter am 08.09.06 22:49:07

...ohne News!

[Turboverdichter]

Amarillo Biosciences Retains Hance, Scarborough, Wright, Woodward & Weisbart for Public Policy Representation

13 September 2006, 1:22pm ET

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has retained Hance, Scarborough, Wright, Woodward & Weisbart (HSWWW), an Austin, Texas-based law firm, to represent ABI regarding federal and state governmental relations matters.

HSWWW will work with ABI toward the goal of achieving regulatory approval for ABI's low-dose interferon-alpha for oral delivery to humans and animals. HSWWW efforts will initially focus on obtaining sufficient government or private funding to conduct human influenza studies at a major research facility.

"Amarillo Biosciences needs proper public policy representation now in order to secure the funding necessary to carry out studies that we believe will ultimately lead us to FDA approval," said Dr. Joseph M. Cummins, President & CEO, ABI. "We believe that a large scale human influenza study on the use of low-dose oral interferon as a prophylactic and therapeutic agent will help validate our highly successful animal studies, and would be an excellent complement to our planned human influenza study set to commence in Australia in 2007. Hance Scarborough Wright has an excellent track record of representing clients on legal and public policy matters at all levels of government."

About HSWWW (www.hswww.com)

Hance, Scarborough, Wright, Woodward & Weisbart is a Texas-based law firm with offices in Austin, Dallas and Washington, D.C. HSWWW provides legal representation, government relations and business counseling for its clients. The firm sees its work as partnering with its clients to identify business opportunities, eliminate obstacles and manage risk. The firm was founded on the belief that in order to be successful, it must be as successful as our clients are in the matters in which we represent them. Hance, Scarborough, Wright, Woodward & Weisbart has effectively represented major international corporations, small to medium size businesses and entrepreneurial individuals both on the state and federal levels.

About Amarillo Biosciences, Inc. (www.amarbio.com)

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.


--------------------------------------------------------------------------------

Contacts:

Investor Relations:
Philippe Niemet
zPAN Consultants, Ltd.
Tel: [phone]
Tel: [phone]
Fax: [phone]
[e-mail]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: [phone] x 13
Fax: [phone]
e-mail:[e-mail]

[Turboverdichter]

Ganz ordentlich Umsatz heute!

[Cpt_Tenbagger]

Antwort auf Beitrag Nr.: 23.712.021 von Turboverdichter am 31.08.06 23:03:46

ja schon. hab immer noch meine 10k damals bei 0,40 euro gekauft. wird ein langfristinvest.

ver10fachen sollte klappen.

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.007.032 von Cpt_Tenbagger am 17.09.06 21:03:04

Meinst du wirklich!

[Radusel]

Den kenn ich doch hier

Stehst wohl auch auf so kleinere Werte, das Unternehmen is sogar verdammt klein, kann man denn da was erwarten ?

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.019.142 von Radusel am 18.09.06 14:40:53

Ja, aber man braucht Geduld!

[Turboverdichter]

Dutton Associates Announces Investment Opinion: Amarillo

Biosciences Rating Speculative Buy in Initiating Coverage by Dutton Associates

18 September 2006, 4:26pm ET

EL DORADO HILLS, Calif., Sep 18, 2006 (BUSINESS WIRE) --

Dutton Associates initiates coverage of Amarillo Biosciences (BB:AMAR) with a Speculative Buy and a price target of $1.90. The 18-page report by Dutton senior analyst Wayne M. Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.


Amarillo Biosciences is a biopharmaceutical company developing low-dose oral natural human interferon-alpha as a safe, cost-effective therapy for several diseases or their symptoms, including influenza and HIV-related oral warts. Interferon is known for its antiviral activity and immunomodulating effects. The distinct advantages and characteristics of Amarillo Biosciences interferon are its oral delivery and safety. Low-dose interferon-alpha is administered orally as a lozenge, which, importantly, is not swallowed, but is allowed to dissolve slowly in the mouth. Amarillo Biosciences has a Phase 2 clinical trial using oral low-dose interferon-alpha for Behcet's disease now underway and plans to begin enrollment in a Phase 2 clinical trial in October to treat oral warts in HIV-positive patients. An influenza trial may begin in 2007 provided funding is available. In addition, several of the Company's therapies under development have been granted Orphan Drug Designation by the FDA. The real potential money maker, however, is for treatment of influenza. Roche reported that 2005 sales of its prescription anti-influenza drug, Tamiflu(R), approached $1.3 billion.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 32 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 9/18/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

For more information on this release, or on enrolling a company for research coverage, please contact John Dutton at 916-941-8119.

SOURCE: Amarillo Biosciences

Dutton Associates
John Dutton, 916-941-8119
Copyright Business Wire 2006

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.019.142 von Radusel am 18.09.06 14:40:53

Na Dutton kennen wir ja, nich Radusel!??

[Radusel]

Jaja
Kann man mir Influenza eigendlich noch Geld verdienen? Die Medien ham das Thema wieder fallengelassen, da dürfte die Regierung doch auch kein Geld mehr locker machen. Zumindest nicht bis es zu spät is
Wie is denn des Marktpotential für des andre Ding da und welchen Ansatz hat das Medikament? Vergleichbar mit dem von Amazon Bios., oder? Hab hier beim Durchblättern was vom Stoppen des Gewichtsverlust gelesen, glaub ich, deshalb.
Habe leider ein miserables Englisch, was ich nur langsam auf vordermann bringe, deshalb meide ich amerikanische und canadische Unternehmen, obwohl die mir dann meistens mehr zusagen . blöd

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.032.166 von Radusel am 19.09.06 00:17:38

1. Du brauchst hier viel Geduld!

2. Die nächste Vogelgrippesaison kommt bestimmt und dann schaut man auch wieder genauer auf all das, was AMAR macht und das ist nicht eben wenig!

[Turboverdichter]

09/27/2006

Amarillo Biosciences Seeks $5 Million to Fund Oral Interferon Programs; Reiterate Speculative Buy

Amarillo Biosciences, Inc. (OTCBB: AMAR) announced yesterday that it seeks to raise up to $5 million to complete two clinical studies
of its low-dose oral interferon. Successful completion of these studies is necessary for Amarillo Biosciences to apply for FDA approval.
Amarillo Biosciences is currently sponsoring two Phase 2 clinical studies, a U.S.-based oral warts study in HIV-positive patients and an Istanbul-based study on Behcet's disease. The oral warts study is expected to cost $500,000 and to be completed by late 2007. The Behcet's disease study is being largely funded by Amarillo Biosciences's Turkish partner, Nobel Ilac, and is expected to be completed by late 2007. The balance of the $5 million that Amarillo Biosciences seeks will fund Phase 3 trials in 2008, which will be necessary to make an application to FDA for approval.
To date in 2006, Amarillo Biosciences has raised approximately $1.5 million in long-term equity financing, primarily from European
institutional and high-net-worth investors. The Company says that it continues to see interest from a number of European and U.S.
investors and intends to access these sources of financing.
In addition, Amarillo Biosciences recently retained a prominent Texas law firm to assist it in obtaining $5 million to $10 million in public-sector financing to fund a large-scale human clinical influenza study in 2007. Animal data generated in research sponsored by Amarillo Biosciences suggests that oral interferon reduces the amount of influenza virus in the respiratory tract. These positive influenza data from animals, and published human data generated by others, prompted the Company to seek public-sector funding for a large-scale human influenza study.

Behcet's Disease and Oral Warts Studies
To date, 36 patients with Behcet's disease have been enrolled in Amarillo Biosciences's Phase 2 clinical trial in Turkey with the goal of enrolling 90 patients by the end of the first quarter of 2007. Six clinical sites have agreed to participate in Amarillo Biosciences's Phase 2 clinical trial of oral interferon to treat oral warts in 80 HIV+ patients. The sites are in Baltimore, Boston, Chicago, Dallas, New York City and San Francisco. Enrollment is expected to begin in October 2006.

Influenza Data Presented in Shanghai
Last week, Manfred Beilharz, head of the Department of Microbiology and Immunology, School of Biomedical, Biomolecular and
Chemical Sciences, the University of Western Australia, presented data on his influenza studies at an international biotechnology
meeting in Shanghai, China. Funding from Amarillo Biosciences allowed Dr. Beilharz to discover that low-dose oral interferon protected mice against an otherwise fatal challenge of influenza virus. Dr. Beilharz's animal model is the same one used by U.S. government officials to test and evaluate immune modulators against influenza virus that might be useful in an influenza pandemic.
In Dutton Associates' September 18 initial report on Amarillo Biosciences, we observed that "the most significant impediment to
Amarillo Biosciences projected progress is its financial constraints. Although its oral interferon-alpha has several promising applications, the Company must secure adequate financing to continue its proper development." Therefore we support the Company's funding efforts, but continue to maintain a degree of caution in our opinion on Amarillo Biosciences until it gets on a firmer financial footing. We reiterate our very Speculative Buy rating on the Company's shares with an 18-month price target of $1.90.

[Turboverdichter]

...noch wer hier, oder turbo allein!?

[Radusel]

So ziemlich alleine...

Glaub ich leg mir hier ne ganz ganz kleine spekulative Position zu.

Allerdings ham se halt keinen Produktmix, da isch des Risiko halt so hoch....
Aber bei dem Börsenwert und einer entsprechenden Position wird das ja wohl passen
Da heißts halt kaufen und 5 oder 6 Jahre nich mehr anschaun....

[kleinerBiber]

Antwort auf Beitrag Nr.: 24.682.605 von Radusel am 17.10.06 16:48:52

Hallo,

es gibt nur ein Problem kaum einer verkauft.
Der Kurs wird in USA mit kleinen Mengen nach unten gebracht.

Tschüß...!!!!

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.694.991 von kleinerBiber am 18.10.06 09:15:55

Ja und Leute die long sind wie ich, die haben drunter zu leiden!

[kleinerBiber]

Antwort auf Beitrag Nr.: 24.696.729 von Turboverdichter am 18.10.06 10:49:58

Hallo Turboverdichter,

genau so meine ich das bin jetzt 10% im minus, hatte aber auch schon mal gut 150% Plus und habe gehalten.

Ich werde die Aktie auch weiter halten und wenn ich mal zu meinen gesteckten Kursen welche bekomme auf jeden Fall nachkaufen, den eins ist sicher wenn mal eine Gute Meldung kommt geht das Ding genauso schnell wieder hoch.

Tschüß .....!!!!!

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.701.218 von kleinerBiber am 18.10.06 14:40:51

Mein Minus ist noch größer!

Warum ging es aber jetzt 2 Tage so straff gen norden!? Gegenbewegung!?

[kleinerBiber]

Hallo,

würde mir darüber keinen Kopf machen, da wollen noch ein paar Leute in USA welche verunsichern um welche günstig einzukaufen.

Kurs wird mit kleinen Mengen hoch und auch wieder runter gehen.
Also werde ich abwarten ob ich auch noch ein paar abgreifen kann.

Bin ja ohne was zu tun wieder im Plus.

Tschüß und bei dieser Aktie braucht man Geduld....!!!!

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.719.629 von kleinerBiber am 19.10.06 13:35:13

Na ich bin erstmal froh, dass ich hier ja wohl doch nicht ganz alleine bin!

[kleinerBiber]

Hi,

sei doch froh und gebe dem Kurs Zeit.

Wenn erst die ganzen Puscher hier auftauchen sollte man langsam ans aussteigen denken.

Tschüß....!!!!

[DrTom2]

Jetzt geht aber ganz ordentlich die Post ab von 46 auf 65 $ct in 2 Tagen. In FRA wurden heute früh 5000 Stck zu 0,53 € gekauft.

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.740.736 von DrTom2 am 20.10.06 13:59:02

...möchte sein, denn ähnlich schnell ging es ja nach Süden!

[Turboverdichter]

+ 55 % in einer Woche!

[Turboverdichter]

AMARILLO BIOSCIENCE AMAR (BB)

Last Change / Pct Change
0.84 0.12 / 16.67 %

[Turboverdichter]

Antwort auf Beitrag Nr.: 24.878.069 von Turboverdichter am 26.10.06 22:14:37

Heute wurden über 160.000 Stk. gehandelt und ma Ende bleibt ein Plus von fast 14 %!!!

Das war der größte Tagesumsatz seit einem halben Jahr!

[Turboverdichter]

ABI Outlines $5 Million Capital Raising Program to Complete Regulatory Approval of Oral Interferon

Company Issues Progress Bulletin

Amarillo, Texas, September 26, 2006 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that it has commenced an effort to raise up to $5 Million to complete clinical studies of its low-dose oral interferon. Successful completion of these studies is necessary for ABI to apply for FDA approval.

Two Phase II studies are being conducted through 2007, a U.S. based oral warts study in HIV+ patients and an Istanbul-based study on Behcet’s disease. The oral warts study is estimated to cost ABI approximately $500,000 and is expected to be completed by late 2007. The Behcet's disease study is being largely funded by ABI’s Turkish partner, NOBEL ILAC and is expected to be completed by late 2007. The balance of the up to $5 Million that ABI intends to raise will fund Phase III trials in 2008, which will be necessary to make an application to FDA for approval.

To date in 2006, ABI has raised approximately $1.5 million in long-term equity financing, primarily from European institutional and high net worth investors. The Company continues to receive interest for long-term equity financing from a number of European and U.S. investors and intends to access this source of financing. In addition, ABI has recently retained a prominent Texas law firm to assist it in obtaining $5 -$10 million in public-sector financing to fund a large-scale human clinical influenza study in 2007. Animal data generated in ABI-sponsored research suggests that oral interferon reduces the amount of influenza virus in the respiratory tract. These positive influenza data from animals, and published human data generated by others, prompted the Company to seek public sector funding for a large-scale human influenza study.

Behcet’s Disease and Oral Warts Studies

A total of 36 patients with Behcet’s disease have been enrolled in ABI’s Phase II clinical trial in Turkey with the goal of enrolling 90 patients by the end of the first quarter of 2006. Six clinical sites have agreed to participate in ABI’s Phase II clinical trial of oral interferon to treat oral warts in 80 HIV+ patients. The sites are in Baltimore, Boston, Chicago, Dallas, New York City and San Francisco. Enrollment is expected to begin in October 2006.

Dr. Manfred Beilharz Presents in Shanghai

Last week, Manfred Beilharz, Head of the Nobel Prize-winning Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, the University of Western Australia, presented data on his influenza studies at an international biotechnology meeting in Shanghai, China. Funding from ABI allowed Dr. Beilharz to discover that low-dose oral interferon protected mice against an otherwise fatal challenge of influenza virus. Dr. Beilharz's animal model is the same one used by U.S. government officials to test and evaluate immune modulators against influenza virus that might be useful in an influenza pandemic.

ABI seeks Government Funding for Chronic Chough Study

ABI has noted that low-dose oral interferon relieves chronic coughing in patients with Sjogren's syndrome and idiopathic pulmonary fibrosis (IPF). Moreover, ABI has published that horses with chronic obstructive pulmonary disease or COPD, also called inflammatory airway disease, are significantly improved with low doses of oral interferon. ABI is seeking funding to treat chronic coughing in human COPD patients with oral interferon. COPD is reported to affect 10% of humans over the age of 40. Because COPD affects many millions of people and is not an Orphan Disease (a disease that affects fewer than 200,000 people in the U.S.), the study of COPD is too expensive for ABI to study beyond Phase II without a pharmaceutical partner. Initially, ABI is seeking a state government grant of $750,000 to conduct the Phase II clinical trial on 80 patients with chronic cough due to COPD or IPF. If the clinical data are as positive as expected, these Phase II data will be shared with potential Big Pharma partners.

About Amarillo Biosciences, Inc. (www.amarbio.com)

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren’s syndrome, Behçet’s disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2005. -END-

[DrTom2]

Da ist weiterhin ordentlich Dampf im Kessel, im bin gespannt auf die News dazu

[kleinerBiber]

Hallo,
na werden mal wieder welche dazu bewegt zu verkaufen, ist natürlich super zum nachkaufen.
Tschüß .....!!!!!

[Turboverdichter]

Amarillo Biosciences Reports Findings From Influenza Study at Trudeau Institute Study Confirms Efficacy of Oral Interferon as Therapeutic Agent Against Influenza


Wednesday Nov 15 2006 11:28:37 EST

AMARILLO, TX, Nov 15, 2006 (MARKET WIRE via COMTEX) --
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has received a final report on a study performed at the renowned Trudeau Institute of Saranac Lake, New York, entitled "Low Dose Oral Interferon Alpha Reduces Morbidity and Promotes Recovery from Influenza." The study examined the effects of low dose oral interferon alpha on four groups of mice challenged with influenza virus. The four groups were orally administered doses of 0, 1, 10, or 100 International Units (IU) of interferon for seven days before and 7 days after the influenza challenge. The mice receiving 10 IU and 100 IU of interferon lost less weight and had lower influenza viral titers than those in the placebo group (receiving no interferon) or the extremely low dose (1 IU) group. Prevention of weight loss in mice is a key indicator of a successful therapeutic agent in influenza studies.

The results suggest that oral IFN, administered at the proper dose, acts directly on the nasal and tracheal epithelial cells to induce an anti-viral state, which suppresses viral replication in the upper respiratory tract. Because of these findings, the Company has agreed to fund additional research at the Trudeau Institute to further support the Company's position that oral interferon will have a major role to play in addressing the impending influenza pandemic.

Other influenza studies in mice sponsored by the Company are being conducted by Manfred Beilharz, PhD, the Head of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, the University of Western Australia. Dr. Beilharz and members of his research department have 10 publications and 3 dissertations on the subject of orally administered interferon. Dr. Beilharz is the past President of the Australian Interferon Society and a world-renowned expert on interferon. Dr. Beilharz recently reported that a dose of 100 IU of interferon was beneficial in mice but a dose of 10,000 IU was not beneficial, thereby suggesting a bell-shaped response curve to oral interferon.

Amarillo Biosciences has previously announced that it intends to fund a human influenza trial conducted by Dr. Beilharz. The trial will test whether daily dosing with oral interferon can protect human volunteers from infection and reduce the severity of respiratory tract infections, compared to placebo. The study is expected to start in Australia in mid 2007 and continue for 6 months during which time 200 volunteers are expected to naturally encounter influenza viruses and other respiratory tract pathogens.

"It is encouraging that quality research laboratories in the US and Australia are obtaining similar results showing that oral interferon may have a role to play in controlling influenza virus," said Dr. Joseph Cummins, CEO and President of Amarillo Biosciences, Inc. Nearly 50 years ago scientists in England reported that an antiviral protein found in chicken embryos was inhibiting influenza virus. This "interfering" protein was called "interferon." "We have known for nearly 50 years that interferon inhibits influenza virus. Now we are working to establish an oral dose of interferon that can be used to help control influenza virus," said Dr. Joseph Cummins.

It has been published that low-dose oral interferon is safe and beneficial in the treatment of other human diseases such as measles, multiple sclerosis, hepatitis B and Sjogren's syndrome.

About the Trudeau Institute

The Trudeau Institute, Inc. is one the nation's leading independent biomedical research centers. Its mission is to make breakthrough discoveries that lead to improved human health. More information on the organization is available from its annual report, which is available on the Institute's website www.trudeauinstitute.org.

About Amarillo Biosciences, Inc. (www.amarbio.com)

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
Tel: [phone]
Tel: [phone]
Fax: [phone]
[e-mail]



Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: [phone] x 13
Fax: [phone]
e-mail:[e-mail]



SOURCE: Amarillo Biosciences, Inc.


Copyright 2006 Market Wire, All rights reserved.

[Turboverdichter]

AMAR: Announces Positive Study Results for Oral Interferon in Influenza
Wednesday Nov 15 2006 11:32:13 EST

Ridgeland, MS, NOV 15, 2006 (EventX/Knobias.com via COMTEX) --
By Fain Hughes, [e-mail]

Amarillo Biosciences, Inc. (AMAR) announced that it has received a final report on a study performed at the Trudeau Institute of Saranac Lake, New York, entitled "Low Dose Oral Interferon Alpha Reduces Morbidity and Promotes Recovery from Influenza." The study examined the effects of low dose oral interferon alpha on four groups of mice challenged with influenza virus. The four groups were orally administered doses of 0, 1, 10, or 100 International Units (IU) of interferon for seven days before and 7 days after the influenza challenge. The mice receiving 10 IU and 100 IU of interferon lost less weight and had lower influenza viral titers than those in the placebo group (receiving no interferon) or the extremely low dose (1 IU) group.

The results suggest that oral IFN, administered at the proper dose, acts directly on the nasal and tracheal epithelial cells to induce an anti-viral state, which suppresses viral replication in the upper respiratory tract. Because of these findings, the Company has agreed to fund additional research at the Trudeau Institute to further support the Company's position that oral interferon will have a major role to play in addressing the impending influenza pandemic.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx

Copyright 2004 Knobias.com, LLC, All rights reserved.

[xTRADERx]

Man man man...ist ja wirklich ruhig geworden um AMAR. Dabei fand ich die echt richtig gut - na ja, eigentlich immer noch. Liegen jetzt schon mehr als 8 Monate in meinem Depot. Ist wohl doch ein richtiges Langfrist-Investment. Vielleicht hol ich mir mal noch ein paar. Irgendwann muß es doch losgehen! *Daumendrück*

Die letzten News sind doch eigentlich alle sehr gut - nur der Kurs reagiert nicht so wirklich. Und nachdem die ganzen BB hier auch wieder still sind, geht im Moment wenigstens hier in Deutschland wohl gar nix. Na, auch gut.

Greetz & ne schöne Woche.

xTRADERx

Do your own DD!

[xTRADERx]

HAAAAAAAAAAAA!!!!

AMARILLO BIOSCIENCES
Amarillo Biosciences Enters Into License and Supply Agreement With CytoPharm for Low Dose Oral Interferon Use in Influenza and Hepatitis B in China and Taiwan
11/27/2006
CytoPharm to Conduct Clinical Trials and Seek Regulatory Approval for Amarillo Biosciences' Low Dose Oral Interferon

AMARILLO, TX and TAIPEI, TAIWAN, Nov 27, 2006 (MARKET WIRE via COMTEX News Network) --

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization.

Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek to obtain regulatory approvals in both China and Taiwan (the Territory) to launch ABI's low dose oral interferon in the Territory for influenza and hepatitis B (HBV) indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct clinical trials, which are expected to commence in 2007.

"With the fast growing economies and vastly improving health care systems in both China and Taiwan, patients' demands for newer and better drugs have become much stronger," said Dr. Ellson Chen, Chairman of CytoPharm, and founder of Vita Genomics. "HBV, known as the curse of Chinese people, is a major disease in the region, and governments spend billions of dollars and commit economic resources to deal with this deadly disease. This Agreement is the first example that CytoPharm is determined to work to improve the health and well-being in China and Taiwan."

Dr. Joseph M. Cummins, President and CEO of ABI, said, "This agreement is of major significance to ABI because our low dose oral interferon will be tested in patients with hepatitis B and influenza, two major diseases which impact millions of people worldwide annually. We are especially pleased by the professionalism and diligence which CytoPharm has demonstrated in our dealings to date, and are also pleased that they share our vision in the promise that our low dose oral interferon can be a therapeutic agent against a wide array of medical conditions."

Dr. Stephen T. Chen, President of STC International and an ABI Board member living in Taiwan, made the introduction of ABI to CytoPharm and was instrumental in negotiations of the License and Supply Agreement. "I am very pleased to see these two fine companies reach the Agreement to collaborate on the development of low dose interferon alpha. In my estimation, this product will be a huge success in the Asian marketplace," said Dr. Chen.

In addition, Dr. Z. John Gu, CEO of CytoPharm, commented, "The Agreement enables CytoPharm to continue its work on cytokine therapeutic uses, particularly in the areas of hepatitis, and other viral infections. This collaboration provides mutual benefits during commercializing low dose oral IFN. It also demonstrates CytoPharm's vision in working on biopharmaceuticals for pursuing better health in the regions."

"CytoPharm will conduct important clinical studies to demonstrate the efficacy of low dose oral interferon against influenza and hepatitis B," said Dr. Claus Martin, Special Consultant to ABI. "The clinical data generated will provide invaluable assistance in our efforts to bring low dose oral interferon into a number of countries with whom we have been holding discussions, including Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia."

Financial arrangements have not been disclosed, but according to the Agreement, CytoPharm will make payments to ABI upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.

About CytoPharm

CytoPharm is a closely held company focusing on the development of biopharmaceuticals for virus-infected diseases and cancers. It was founded in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. It acquired core technologies from GeneTrol Therapeutics, Inc., a California-based company through M&A. Its product pipelines contain a series of cytokines induced by its proprietary technologies, used for hepatitis, and cancers. Currently, its product is under clinical trials in China. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Media Contacts:
Z. John Gu, PhD
CytoPharm, Inc.
Tel: [phone]
Fax: [phone]
Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=6D6514C6AFC6881…

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: [phone]
Fax: [phone]
Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=F7C726FEB7A2AD3…

Investor Relations:
David Mu
CytoPharm, Inc.
Tel: [phone]
Fax: [phone]
Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=95AA9CB22566687…

Philippe Niemetz
PAN Consultants, Ltd.
Tel: [phone]
[phone]
Fax: [phone]
Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=D106C0E8E546CCE…


SOURCE: Amarillo Biosciences, Inc.

Copyright 2006 Market Wire, All rights reserved.

[xTRADERx]

Hier die News auch nochmal auf Deutsch - und nicht nur so ne Google- oder Babelfish-Übersetzung

IRW-Press: AMARILLO Biosciences: Amarillo Biosciences unterzeichnet Lizenz- und Lieferabkommen mit CytoPharm für den Einsatz von


Amarillo Biosciences unterzeichnet Lizenz- und Lieferabkommen mit CytoPharm für den Einsatz von "Low Dose Oral Interferon" bei Influenza und Hepatitis B in China und Taiwan

CytoPharm plant klinische Studien und wird die arzneimittelrechtliche Zulassung für "Low Dose Oral Interferon" von Amarillo Biosciences beantragen


Amarillo, Texas and Taipei, Taiwan, 27. November 2006 ? Wie Amarillo Biosciences, Inc. (ABI) (OTC-BB: AMAR) heute bekannt gab, hat das Unternehmen mit CytoPharm, Inc., einem in Taipei ansässigen taiwanesischen Biopharma-Unternehmen, ein Lizenz- und Lieferabkommen unterzeichnet. Die Muttergesellschaft von CytoPharm, Vita Genomics, Inc., ist das größte Biotech-Unternehmen in Taiwan und spezialisiert auf Pharmakogenomik sowie klinische Forschung in bestimmten Bereichen.

Nach den Bestimmungen dieses Abkommenss werden CytoPharm und ihre Tochtergesellschaft alle klinischen Studien durchführen und in China sowie in Taiwan (Zielregion) die arzneimittelrechtliche Zulassung für das niedrigdosierte orale Interferon ("Low Dose Oral Interferon" ) von ABI in der Zielregion für die Indikationen Influenza und Hepatitis B (HBV) beantragen. Im Vorfeld zu klinischen Studien, die in 2007 fortgeführt werden, hat CytoPharm in den Zielregionen Gespräche mit den Arzneimittelbehörden aufgenommen.

?Aufgrund des rasanten Wachstums der Volkswirtschaften und eines immer leistungsfähigeren Gesundheitswesens ist in China und Taiwan die Nachfrage der Patienten nach neuen, besseren Medikamenten stark gestiegen,? kommentiert Dr. Ellson Chen, Vorsitzender von CytoPharm und Gründer von Vita Genomics. ?HBV, der so genannte ?Fluch der Chinesen?, ist in dieser Region eine weit verbreitete Erkrankung und staatliche Behörden verwenden Milliarden von Dollar und wirtschaftliche Ressourcen zur Bekämpfung dieser tödlichen Geißel. Dieses Abkommen ist der erste Beweis, dass CytoPharm es mit der Verbesserung der Gesundheit und des Wohlbefindens der Menschen in China und Taiwan ernst meint.?


Dr. Joseph M. Cummins, Präsident und CEO von ABI, meint: ?Das Abkommen hat für ABI große Bedeutung. Unser niedrigdosiertes orales Interferon wird bei Patienten mit Hepatitis B und Influenza getestet, zwei häufigen Erkrankungen, von denen weltweit jährlich Millionen von Menschen betroffen sind. Wir waren sehr beeindruckt von der Professionalität und der Sorgfalt, die CytoPharm bei den geschäftlichen Verhandlungen demonstrierte. Wir freuen uns sehr, dass das Unternehmen unsere Vision teilt, unser niedrigdosiertes orales Interferon im Rahmen gemeinsamer Anstrengungen zu einem Therapeutikum gegen zahlreiche medizinische Probleme zu machen.?

Der in Taiwan heimische Dr. Stephen T. Chen, Präsident von STC International und Direktor bei ABI, führte beide Unternehmen zusammen und spielte bei der Aushandlung des Lizenz- und Lieferabkommens eine tragende Rolle. ?Ich freue mich sehr darüber, dass diese beiden renommierten Unternehmen eine Vereinbarung zur gemeinsamen Entwicklung eines niedrigdosierten Interferon alpha geschlossen haben. Meiner Einschätzung nach wird das Präparat auf dem asiatischen Markt ein durchschlagender Erfolg werden.? kommentiert Dr. Chen.

Dr. Z. John Gu, CEO von CytoPharm, fügt hinzu: ?Dieses Abkommen ermöglicht CytoPharm die weitere Forschung zum therapeutischen Einsatz von Zytokinen, insbesondere auf den Gebieten Hepatitis und andere Virusinfektionen. Beide Seite profitieren von der Kooperation während der Kommerzialisierung des Wirkstoffs, außerdem untermauert die Zusammenarbeit das Engagement von CytoPharm, mithilfe neuer Biopharmazeutika die Gesundheit der Menschen in der Zielregion zu fördern.?

?CytoPharm wird wichtige klinische Studien durchführen, um die Wirksamkeit von niedrigdosiertem oralen Interferon bei Influenza und Hepatitis B zu beweisen,? erläutert Dr. Claus Martin, Sonderberater bei ABI. ?Die erhobenen klinischen Daten werden uns maßgeblich dabei unterstützen, niedrigdosiertes orales Interferon in mehreren Ländern, mit denen wir bereits Gespräche aufgenommen haben, auf den Markt zu bringen, u. a. in Thailand, Brunei, Myanmar, den Philippinen, Malaysia, Singapur und Indonesien.?

Die finanziellen Vereinbarungen des Vertrages wurden noch nicht veröffentlicht, aber im Rahmen des Abkommens wird CytoPharm nach dem Erreichen bestimmter Meilensteine Zahlungen an ABI leisten und Tantiemen aus dem Verkauf von niedrigdosiertem oralen Interferon in der Zielregion an ABI zahlen.

Kurzporträt CytoPharm
CytoPharm ist ein Unternehmen, das auf die Entwicklung von Biopharmazeutika zur Behandlung von Virusinfektionen und durch Viren hervorgerufene Krebserkrankungen spezialisiert ist. Es wurde 2002 von Ho Tung Chemical, Vita Genomics sowie mehreren Banken und Wagniskapitalunternehmen gegründet. Über eine M&A-Transaktion wurden Kerntechnologien von GeneTrol Therapeutics, Inc., einem in Kalifornien ansässigen Unternehmen, erworben. Dank firmeneigener patentierter Technologien konnten mehrere Zytokine für den Einsatz bei Hepatitis und verschiedenen Krebserkrankungen entwickelt werden, die in naher Zukunft auf den Markt kommen sollen. Die entsprechenden Präparate werden gegenwärtig in klinischen Studien in China getestet. Sowohl CytoPharm als auch Vita Genomics sind an Ho Tung Chemical Inc. angegliedert, einem der größten Petrochemieunternehmen in Taiwan mit Umsätzen im Jahr 2005 von mehr als 35 Mrd. NT$ (Neue Taiwan $).

Kurzporträt Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc., ist ein US-amerikanisches Biotech-Unternehmen in einer globalen Partnerschaft mit der Hayashibara Group, die auch eine 13,5%ige Beteiligung an Amarillo Biosciences hält und mehr als 17,8 Mio. USD in Form von Krediten, Zuwendungen und Kapitalbeteiligungen bereitgestellt hat. Der Schwerpunkt des Unternehmens liegt auf der umfassenden und laufenden Forschung und Entwicklung eines niedrigdosierten, oral verabreichten Interferons zur Behandlung mehrerer Erkrankungen, u. a. Sjögren-Syndrom, Morbus Behçet und opportunistischer Infektionen bei HIV-positiven Patienten. In seiner 22-jährigen Firmengeschichte hat ABI fast 38 Mio. USD in die Entwicklung des oralen Interferons investiert. Der Großteil dieser Mittel floss in klinische Studien, um von der FDA die arzneimittelrechtliche Zulassung für orale Interferontherapien zu erhalten. Weitere Informationen sind auf der Website von ABI verfügbar: www.amarbio.com/.

Mit Ausnahme belegter Informationen stellen die Ausführungen, die in dieser Medienmitteilung bekannt gegeben werden, zukunftsgerichtete Aussagen dar, die mit Risiken und Unwägbarkeiten verbunden sind; dazu gehören Unwägbarkeiten in Bezug auf die Produktentwicklung, Unwägbarkeiten in Bezug auf die erforderlichen behördlichen und sonstigen staatlichen Genehmigungen, die Abhängigkeit von der firmeneigenen Technologie, die Unsicherheit der Marktakzeptanz von oral verabreichtem Interferon oder den weiteren Produktkandidaten des Unternehmens und sonstige Risiken, die von Zeit zu Zeit in Dokumenten aufgeführt werden, die das Unternehmen bei der US-Börsenaufsicht Securities and Exchange Commission einreicht. Siehe dazu insbesondere ?Nummer 1. Beschreibung der Geschäfte? des Unternehmens auf dem Formular 10-KSB für das Jahr, das zum 31. Dezember 2005 endete.

-ENDE-


Für die Richtigkeit der Übersetzung wird keine Haftung übernommen! Bitte englische Originalmeldung beachten!

-------------------------------------------------------------------------------
Mitteilung übermittelt durch IRW-Press.com
Für den Inhalt ist der Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.
-------------------------------------------------------------------------------
Betreffendes Unternehmen
Name: AMARILLO Biosciences
ISIN: US02301P1066

-------------------------------------------------------------------------------
Melden Sie sich mit Ihrer E-Mail-Adresse bei uns an:
[http://www.irw-press.com/anmelden]
-------------------------------------------------------------------------------
Sie können Ihre E-Mail-Adresse jederzeit abmelden bei:
[http://www.irw-press.com/abmelden]
-------------------------------------------------------------------------------

© IR-world.com
IR-World.com

[RiseTrade]

Ufta,,, da kommt was dickes auf uns zu.. die stand doch schonmal auf über 1,40 €€€ Heut kanns schnell rumms machen!

[RiseTrade]

Hat jem RT?!?!

[RiseTrade]

http://www.wallstreet-online.de/adserver/code.php?bid=10010

Netter Bericht und News na das kann heut was werden Umsätze und Kurs ziehen ja an!

[xTRADERx]

Antwort auf Beitrag Nr.: 25.741.975 von RiseTrade am 27.11.06 10:43:03

Wow, aktuell bei 0,61 EUR, ein PLUS von 29,79 Prozent!

Ups....

Das sieht mir verdammt genauso aus wie im Januar bis März!

Greetz

xTRADERx

Do your own DD!

[RiseTrade]

Amarillo, Texas and Taipei, Taiwan, 27. November 2006 ? Wie Amarillo Biosciences, Inc. (ABI) (OTC-BB: AMAR) heute bekannt gab, hat das Unternehmen mit CytoPharm, Inc., einem in Taipei ansässigen taiwanesischen Biopharma-Unternehmen, ein Lizenz- und Lieferabkommen unterzeichnet. Die Muttergesellschaft von CytoPharm, Vita Genomics, Inc., ist das größte Biotech-Unternehmen in Taiwan und spezialisiert auf Pharmakogenomik sowie klinische Forschung in bestimmten Bereichen.

[xTRADERx]

Antwort auf Beitrag Nr.: 25.741.975 von RiseTrade am 27.11.06 10:43:03

Stimmt, gefällt mir.

Und Recht haben die teilweise auch denke ich - bin ebenfalls sehr gespannt auf die Reaktion der Amis.


Greetz

xTRADERx

Do your own DD!

[RiseTrade]

Die Amis... die sind bei sowas noch ein Tick abgedrehter ( im Positiven sinne ) die werden heute richtig dick im Plus eröffnen... Die lieben doch ihre BT-Werte.

[Turboverdichter]

Freut mich, dass ich hier nicht mehr so alleine bin!

[xTRADERx]

Antwort auf Beitrag Nr.: 25.742.470 von Turboverdichter am 27.11.06 11:23:45

Jo, HY Turbo - ne, ich bin ja froh dass mein Baby mal wieder ans Rollen kommt.

Aktuell RT Frankfurt bei 0,65 EUR - und ich glaub es hat noch fast keiner gemerkt....

Greetz

xTRADERx

Do your own DD!

[RiseTrade]

Antwort auf Beitrag Nr.: 25.742.470 von Turboverdichter am 27.11.06 11:23:45

Dein Problem wird sein dass du uns so schnell nimmer los wirst

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.742.520 von xTRADERx am 27.11.06 11:27:39

Ich muss allerdings zur VORSICHT mahnen!!!

Weit mehr als 30% Aufschlag auf den US-Schlusskurs, dass kann ja fast nicht gut gehen!

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.742.554 von Turboverdichter am 27.11.06 11:30:01

http://www.wallstreet-online.de/adserver/click.php?bid=10009…



Seht mal was jetzt über den w : o -Ticker läuft!!

Au weia, jetzt müssen wir aufpassen, die Zcoker kommen!

[xTRADERx]

Antwort auf Beitrag Nr.: 25.742.554 von Turboverdichter am 27.11.06 11:30:01

Recht hast Du, ich find's auch ein bißchen sehr viel - naja, man weiß halt nie wie die Amis so reagieren - entweder übertreffen die uns noch oder wir kommen wieder ein bißchen zurück. Für den längerfristigen Investor ist das wahrscheinlich dann auch egal denke ich.

Greetz

xTRADERx

Do your own DD!

[JAY25]

68cent??

[JAY25]

[Maler33]

Hallo alle zusammen,

bin auch schon länger mit an Board,
hat es euch die Sprache verschlagen, weil es zur Zeit so ruhig ist???

Gruß Maler

[xTRADERx]

Antwort auf Beitrag Nr.: 25.743.509 von Maler33 am 27.11.06 12:47:06

ne, mir hats die Sprache verschlagen weil der Kurs jetzt bei 0,85 EUR steht...

[Maler33]

Antwort auf Beitrag Nr.: 25.743.556 von xTRADERx am 27.11.06 12:49:46

Ich hätte schon mit bißchen was gerechnet, aber das sowas passiert, ist echt der Hammer.

[xTRADERx]

Antwort auf Beitrag Nr.: 25.743.590 von Maler33 am 27.11.06 12:51:57

so ein anstieg an EINEM tag is wohl ein bisschen übertrieben und evtl. auch nicht wirklich gesund - WENN die amis nicht mitspielen - aber das weiss man ja nie. sonst kommt AMAR um 15:30 wieder etwas runter.

Innerhalb einer Woche hätte ich dagegen nix einzuwenden...naja, mal sehen.

Außerdem kommen jetzt vielleicht auch noch die Trader rein für nen schnellen Zock.

Greetz

xTRADERx

Do your own DD!

[mfierke]

Antwort auf Beitrag Nr.: 25.743.698 von xTRADERx am 27.11.06 12:59:55

ob sich heute nicht viele die Finger verbrennen, 80% im Plus da werden drüben die MM`S bestimmt nicht mit machen

[Maler33]

muss man sehen, aber ein großes Handelsvolumen gibt es drüben ja auch nicht, es kann also schon sein dass die MM´s hochtaxen, ob
und wieviel Handel statt findet werden wir sehen.

[Zocker_Nr.1]

88



ASK 90

[SlayGrosswildjaeger]

Realtime-Kurse

Zurück

Name AMARILLO BIOSCIENCES INC. Registered Shares DL -,01

WKN 917640

Börsenplatz Frankfurt

Datum 27.11.06

Abfrage 27.11.06 13:38:58

Kursstellung 27.11.06 13:37

Kurs 0,79

Gehandelte Stücke 130.981

Währung EUR

[amar]

kann ich von hier eigentlich nasdaq kaufen .. ? schon oder ?

[xTRADERx]

Antwort auf Beitrag Nr.: 25.744.238 von SlayGrosswildjaeger am 27.11.06 13:39:20

Gut so - hoffentlich kommts noch a bisserl zurück. Is ja nich mehr gesund...

Innerhalb einer Woche hätt ich da ja nix gesagt, aber in wenigen Stunden....und langfristig eh denk ich.

Greetz

xTRADERx

[JAY25]

[RiseTrade]

Guter Zock aber langfristig ist hier viel viel mehr drin... vorallem bei den News!!!

[SlayGrosswildjaeger]

Antwort auf Beitrag Nr.: 25.744.296 von xTRADERx am 27.11.06 13:44:06

Name AMARILLO BIOSCIENCES INC. Registered Shares DL -,01

WKN 917640

Börsenplatz Frankfurt

Datum 27.11.06

Abfrage 27.11.06 13:54:49

Kursstellung 27.11.06 13:54

Kurs 0,76

Gehandelte Stücke 139.731

Währung EUR

[JAY25]

[xTRADERx]

Auch bei den AMIS gibt's heute ne Empfehlung. Vom Stewart Report. Hier der Originaltext:

Amarillo Biosciences (NASDAQ/BB: AMAR): $0.63


Those of you who prefer the HotLine audio version over the e-mail transcript may have noticed that there was no recording to correspond with the Interim Special Report featuring ICRD. This was intentional. Since the Report was not scheduled, no one would have known to call. Moreover, I felt that the information from the Oct. 25 recording featuring Amarillo Biosciences held a good deal of value, so I wanted to leave it available … Until now.



What I have for you today is my take on what is likely the biggest single news announcement AMAR has ever made. As TSR goes to press, the announcement hasn’t even been released – not in America, anyway – and won’t be for a few more hours. Fortunately, it was posted in Taiwan on Sunday. Equally fortuitous is my friendship with Mel Shriner, whom I met when I lived in Singapore. Mel follows the stock and used the 14-hour time difference to call and give me the heads up.



The news release announces a contract between Amarillo Biosciences and CytoPharm – a key subsidiary of the largest biopharmaceutical company in Taiwan. The relationship was formed to prove the efficacy of AMAR’s low-dose oral interferon regimen against influenza and hepatitis B.



Hepatitis B – known as “The Curse of the Chinese People” – is a major disease in Taiwan and China. Both governments have spent billions of dollars and committed even more to deal with this deadly disease. Under the terms of the agreement, many of those dollars – both hard and soft – will be directed at Amarillo Biosciences. CytoPharm will conduct (and pay for) all clinical trials, which is worth a few million dollars. It will also seek to obtain regulatory approvals in both Taiwan and China, which is a soft-dollar win beyond value. CytoPharm will also make payments to Amarillo upon reaching certain milestones – milestones that, ironically, CytoPharm itself will be achieving on Amarillo’s behalf. Pretty slick if you ask me.



The whole process will commence in 2007. But keep in mind: Unlike the news release itself, this will not be an overnight thing. It will take time to perform the trials and obtain the approvals. Also, even though the financial benefits are large, the real win comes from the free research dollars being committed to the project, as well as the connections to high-level regulatory persons. This much cash and those kinds of connections are two things Amarillo didn’t have – at least until now. The deal is analogous to having a Kennedy call the President of Harvard and personally request your admission to the university, do the studying for you, take the tests for you, grant you a large student loan and then pay for it. Like I said, it’s pretty slick.



It’s also very similar to the win/win deal AMAR CEO Dr. Joseph Cummins cut with a leading Middle Eastern pharmaceutical company to address Behçet’s disease in Turkey. It’s not a significant disease in the U.S., unless you happen to be one of the 15,000 to 20,000 Americans who suffer its debilitating effects. It is, however, a massive health problem in Turkey, where 300,000 persons are afflicted.



So here’s what Dr. Cummins did. First, he arranged for the pharmaceutical company in Turkey to perform all the necessary clinical trials to gain approval in Turkey. A year from now, when the trials are completed, Amarillo will have a wired-in customer that will pay it a royalty on every interferon tablet sold. As with today’s deal in Southeast Asia, 100% of the research costs in the Middle East will be borne by a third party. Second, Dr. Cummins intends to take the research results to the FDA for approval in the U.S. The beautiful irony is that here, because Behçet’s affects so few, it falls under the Orphan Drug Act. The designation is important because the Act is specifically designed to expedite FDA approval, as well as assist with related costs. I probably sounded like “The Ugly American” when I asked Dr. Cummins if the FDA would accept medical trials performed somewhere in Turkey. Loosely quoted he said, “They’d better. From the outset, we involved FDA folks in establishing the protocol to be used. Furthermore, we have an Internet link to Turkey (with real-time video) to monitor the tests and be certain the protocol is being performed ‘To the Letter.’”



This monitoring occurs several times each day. Medical and humanitarian considerations aside, I’m impressed that Dr. Cummins was able to use the smallness of the disease in one country to fast track its approval by one government, while using a corporation in another country where the disease is rampant to pay for all costs associated with the drug’s development.



So. this brings you up to speed on some key developments – all of which are positive and none of which have been reflected in the share price, which has pulled back without reason. As for negatives, the only one I’m aware of was of my own making. In the last regular Report, I mentioned I’d be meeting with a dozen of Amarillo’s key players in Beverly Hills. That was to occur at the Peninsula Club on Halloween. Long-story short, I did make it to the Beverly Hills Hilton where, at some point, I became enormously distracted and missed the meeting altogether.



As soon as the calendar allows for the smoke to clear, I’ll phone Dr. Cummins for a recap, then provide details of everything I missed in the next HotLine. Until then, put the details aside and take a long look at the Big Picture … the one that juxtaposes our Texas micro-cap against the world-class players who have involved themselves in every aspect of its operations. The comparison is profound.



On the Board of Directors, it has, Thomas D’Alonzo, former president of Glaxo Smith Kline (NYSE:GSK); plus a room full of M.D.s, Ph.D.s and wealthy professional private investors like Thomas Ulie, CEO of First Island Capital in Seattle. Amarillo’s mentor and largest stockholder is Hayashibara, Japan’s largest biophar­maceutical company and, according to Fortune magazine, one of the world’s largest privately held companies. The law firm of Hance, Scarborough, Woodward & Weisbart has been retained to represent AMAR in government matters. Kent Hance, a senior partner in that firm and the man who once beat George Bush in a congressional race, is especially close to AMAR. Hance is also the new Chancellor of Texas Tech University, where he presides over three campuses, 31,000 students, 459 doctors and millions in State of Texas grants.



There’s also Manfred Beilharz, Ph.D., who heads a Nobel Prize-winning School at the University of Western Australia. He’s working feverishly around the globe on a series of clinical trials specifically designed to prove the efficacy of oral interferon in various animals. At the June stockholders meeting, he said that, when his paper gets published – probably in either Nature or Science – his School will get another Nobel Prize, he will be famous and Amarillo’s stockholders will be rich. He said this half jokingly – but only half.



We’ve also got Dr. Claus Martin, who from everything I’ve read is THE physician to Europe’s jet set and SE Asia’s elite – some of whom are royalty. Cumulatively, Dr. Martin and his international entourage’s 2006 investment in AMAR stock was about $1.5 million. That’s a sizeable figure for private finance, but his contacts on both continents are probably more valuable than his cash. For 2007, Dr. Martin will embark on a number of trips to guarantee his investment.



Point of fact: In today’s CytoPharm release, Dr. Martin was identified as “Special Consultant” to AMAR and was quoted as saying, “The clinical data generated will provide invaluable assistance in our efforts to bring low-dose oral interferon into a number of countries with whom we have been holding a number of discussions, including Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia.”



One other point: Never mind the 29 patents, or the $30 million invested in the technology, or the new money being invested in the Turkish studies, or the even newer money associated with this morning’s release out of Taiwan. Instead consider all the NYSE-traded companies out there with market caps in the hundreds and hundreds of millions – companies that would kill for the kind of tight-knit international investor network that Amarillo, presently valued at just $14 million, already enjoys.



Virtually everyone listed above came to the table in 2006 and they’re working for little to nothing, trading their clout for stock or the simple opportunity to prove Amarillo right about oral interferon. So, ask yourself: What does this say about the Company’s future? What does it say about the future of the Company’s stock? My answer? BUY more shares – and hold onto them tight.



As always, thank you for subscribing.



Greetz

xTRADERx

[NextLevelTrader]

So sah es damals aus, als stockreport.de sich Amarillo vorgenommen hat!

Schaut euch den Januar 2006 an.

Bei 40 Cent mit rund 1 Mio. Stücken ging es los!

und dann innerhalb von 2 Monaten auf 1,40 Euro!

Das waren Zeiten...

[kleinerBiber]

Hallo,

erst einmal vielen Dank für die Leute die mir Ihre Aktien zwischen 0,45 und 0,55 € überlassen haben weil Sie immer nur auf das schnelle Geld schauen.
Bei dieser Aktie sollte eine gewisse Geduld Voraussetzung sein.
Der Gewinn den wir jetzt haben wird auch wieder mal zurückgehen und einige werden dann dumm kucken aber langfristig wird sie Ihren weg machen.

Tschüß kleinerBiber....!!!!

[RiseTrade]

Antwort auf Beitrag Nr.: 25.745.665 von kleinerBiber am 27.11.06 15:17:06

Süss!!! kleiner Biber...Oh gott wie niedlich

net bös gemeint! mit EK 0,50 € bist sehr gut dabei!

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.745.743 von RiseTrade am 27.11.06 15:20:19

Hallo,

warum sollte ich das Dir böse nehmen, bin jetzt schon über 1Jahr dabei und habe die Spanne bei sehr geringen Umsatz zum nachkaufen genutzt.
Mein Einstiegskurs war nie in Gefahr.

Tschüß....!!!!

[NextLevelTrader]

Antwort auf Beitrag Nr.: 25.745.870 von kleinerBiber am 27.11.06 15:27:29

glückwunsch!

so werden gewinne an der börse gemacht.

das ständige hin und her macht nur die taschen leer

[xTRADERx]

Antwort auf Beitrag Nr.: 25.745.903 von NextLevelTrader am 27.11.06 15:29:14

So, USA RT bei 0,84 USD und steigend

[xTRADERx]

USA RT 0,87 USD

[NextLevelTrader]

USA RT 0,90 USD

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.745.903 von NextLevelTrader am 27.11.06 15:29:14

Jo,

und jetzt sind auch schon wieder genug Kandidaten am Start unten verkaufen und oben wieder einsteigen.

So dann mal sehen was die Ammis machen.

[RiseTrade]

Antwort auf Beitrag Nr.: 25.746.051 von kleinerBiber am 27.11.06 15:35:29

nee meinte des über den Namen.. EK ist echt gut!!!

[Zentimeter]

Antwort auf Beitrag Nr.: 25.746.092 von RiseTrade am 27.11.06 15:37:34

der Kurs kommt zurück
wird noch spannend heute

[Maler33]

Die Ami´s überholen uns gleich im Volumen und das nach noch nicht mal einer halben Stunde.

[xTRADERx]

Antwort auf Beitrag Nr.: 25.746.408 von Maler33 am 27.11.06 15:51:51

Schon geschehen.

RT 274.300 Stücke an der OTC-BB

[Maler33]

Antwort auf Beitrag Nr.: 25.746.659 von xTRADERx am 27.11.06 16:04:02

wenn das so weiter geht könnten die nach 20.00 Uhr noch weiter
anziehen, oder?

[Zentimeter]

Antwort auf Beitrag Nr.: 25.746.758 von Maler33 am 27.11.06 16:09:10

Luft für heute schon raus?
SK um 0,8?

[xTRADERx]

Kann sein dass die Amis nach 20 Uhr noch hochziehen - kann allerdings auch sein dass die bei um die 0,80 USD schließen - wäre für mich auf jeden Fall gesünder - aber man weiß es halt nicht...sonst wär's ja auch keine Börse und würde nur halb soviel Spaß machen.

ABER: wenn wir nur halbwegs in USA auf diesem Niveau bleiben dann sind wir morgen auf allen Top-Listen und dann kommt morgen nochmal n Riesenschub rein! Ich glaube nicht, daß soooo viele in USA bisher schon Amarillo auf Ihrer Watchlist haben. Und heute haben wir da schon jetzt Rekordvolumen seit April.

Meine Meinung!

Greetz

xTRADERx

Do your own DD!

[Zentimeter]

Antwort auf Beitrag Nr.: 25.746.878 von xTRADERx am 27.11.06 16:16:31

der Unternehmenswert
rechtfertigt locker ein 5-faches - 10-faches
aber das interessiert halt die Börse nicht

[mfierke]

Antwort auf Beitrag Nr.: 25.746.878 von xTRADERx am 27.11.06 16:16:31

in den Tops un ddie Shorter sind auch dann da

[JAY25]

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.746.941 von Zentimeter am 27.11.06 16:18:45

Zukunft wird leider an der Börse kaum noch gehandelt, es zählen nur Zahlen und das ist halt ein Problem.

[Zentimeter]

Antwort auf Beitrag Nr.: 25.747.128 von kleinerBiber am 27.11.06 16:28:00

so ist es Biber
und daher können wir auch schnell wieder auf 0,7 abtauchen

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.747.201 von Zentimeter am 27.11.06 16:32:01

Das Gute an der Aktie ist das zwischen 0,6 und 0,8 US Dollar wenig gehandelt wurde, also müsste der Abgabedruck eher gering sein.
Aber der Druck ab 0,8 der enttäuschten wenn es nicht weiter hoch geht.

Tschüß kleinerBiber.....!!!!

[Zentimeter]

Antwort auf Beitrag Nr.: 25.747.534 von kleinerBiber am 27.11.06 16:50:10

dw
das wars

[Spekufuchs]

Zur Zeit 0,80 $.

[Zentimeter]

Antwort auf Beitrag Nr.: 25.749.084 von Spekufuchs am 27.11.06 18:02:03

hier kann man schon langsam SK tippen
nichts mehr los
0,75 USD denke ich

[Spekufuchs]

Zur Zeit wieder bei 0,815 $.
Tendenz steigend.

[fortuna924]

Antwort auf Beitrag Nr.: 25.750.823 von Spekufuchs am 27.11.06 18:53:37

mal eine alte Empfehlung

Company: Amarillo Biosciences, Inc.
Symbol: OTC BB: AMAR
Current Stock Price (9/21/06): $0.80
Target stock price: $4.00-6.00 within 18 months.

Amarillo Biosciences, Inc. (OTC BB: AMAR) is a biotech company developing, a potentially multi-billion dollar “blockbuster” drug platform based on oral low-dose interferon.



AMAR already has three drug candidates in Phase II clinical trials, targeting rare diseases.Clinical evidence shows that AMAR’s oral interferon formulations can successfully treat a wide range of diseases ranging from cancers to the flu virus - addressing multi-billion dollar market opportunities.


We believe that AMAR’s shares - recently traded at $0.80 - are drastically undervalued, and could potentially be worth $4-6.00 per share - once Wall Street wakes up realizes AMAR’s true upside potential...


“Magic Bullet”

Interferon alpha, is a protein that occurs naturally in the body in very small amounts, and stimulates the immune system. While the exact way in which it works is not fully understood, interferon has a wide range of biological effects, including strengthening the immune system, slowing down or stopping cancer, and viruses. Interferon has been described as a “magic bullet” because of it’s potential to treat a wide range of diseases.

[Spekufuchs]

Mit der heutigen Meldung sind dies doch gute Perspektiven.

Wenn wir heute in USA SK von 0,80 $ erreichen, kommt die Aktie in viele Watchlisten.

[fortuna924]

Antwort auf Beitrag Nr.: 25.751.307 von Spekufuchs am 27.11.06 19:06:09

sorry hatte nicht alles eingefügt

Company: Amarillo Biosciences, Inc.
Symbol: OTC BB: AMAR
Current Stock Price (9/21/06): $0.80
Target stock price: $4.00-6.00 within 18 months.

Amarillo Biosciences, Inc. (OTC BB: AMAR) is a biotech company developing, a potentially multi-billion dollar “blockbuster” drug platform based on oral low-dose interferon.



AMAR already has three drug candidates in Phase II clinical trials, targeting rare diseases.Clinical evidence shows that AMAR’s oral interferon formulations can successfully treat a wide range of diseases ranging from cancers to the flu virus - addressing multi-billion dollar market opportunities.


We believe that AMAR’s shares - recently traded at $0.80 - are drastically undervalued, and could potentially be worth $4-6.00 per share - once Wall Street wakes up realizes AMAR’s true upside potential...


“Magic Bullet”

Interferon alpha, is a protein that occurs naturally in the body in very small amounts, and stimulates the immune system. While the exact way in which it works is not fully understood, interferon has a wide range of biological effects, including strengthening the immune system, slowing down or stopping cancer, and viruses. Interferon has been described as a “magic bullet” because of it’s potential to treat a wide range of diseases.

Amarillo Biosciences (OTCBB:AMAR) 12:41 EST

Last: $0.81
Change: +0.18
% Change: +28.57%
Volume: 460K



Open: $0.79 Day High: $0.90
Prev Close: $0.63 Day Low: $0.78
Bid: $0.80 Ask: $0.81


52 Week Range: $0.39 - $1.73 Market Cap: 18.10M
1 Month Range: $0.56 - $0.85 Shares Outstanding: 22.35M
Earnings: -$0.04 P/E Ratio: -20.25

Quote delayed at least 20 mins.


Latest Press Releases
09/26/06
ABI Outlines $5 Million Capital Raising Program to Complete Regulatory Approval of Oral Interferon
09/13/06
Amarillo Biosciences Retains Hance, Scarborough, Wright, Woodward & Weisbart for Public Policy Representation
08/17/06
Management Team of Amarillo Biosciences, Inc., Discuss Upcoming Studies and Successful Passing of FDA's 30-day Review Process for Company's Investigational New Drug Application for Idiopathic Pulmonary Fibrosis at SmallCapVoice.com
08/10/06
Joseph Cummins, President and CEO of Amarillo Biosciences, Inc., Discusses Recent News in an Audio Interview at SmallCapVoice.com
07/07/06
Amarillo Biosciences Submits Investigational New Drug Application to Test Oral Interferon in Idiopathic Pulmonary Fibrosis

Today, Interferon is a highly successful drug treatment for a host of cancers, and viral diseases - a $5 billion global market, led by Pharma giants such as Roche, Biogen, and Schering Plough.
The downside to this “miracle drug” is that very high doses of interferon must be injected into the bloodstream, (because the kidney’s natural filtration removes interferon from the blood), and these high doses usually result in severe side-effects. Injections and costly doctor visits, also make Interferon unaffordable for most of the population.

AMAR has discovered a better solution...

AMAR’s researchers discovered that delivering Interferon orally, (as an easy to take lozenge which is absorbed in the mouth) in low-doses produces some of the same benefits as injectable interferon - without the side-effects - and at about a tenth of the price. AMAR’s discoveries are now protected by 13 patents giving it exclusivity on the oral use of interferon to treat numerous diseases.

Why is this such a big idea? Because an easy to take lozenge opens up the possibility of treating scores of diseases, effectively and economically. AMAR’s low cost interferon treatment opens the doors to millions of patients around the world, who otherwise would not be able to afford it.


AMAR’s billion dollar “blockbuster drug” pipeline potential.

Clinical data shows that oral low dose interferon is a promising treatment for diseases such as:

Chronic Hepatitis B & CInfluenza (including Bird Flu H5N1)Behcet’s disease
Fibromyalgia
Sjogren’s syndromeOpportunistic HIV+ infectionsMultiple sclerosis
And many other infectious and immune disease

These markets represent billions of dollars in global sales potential, each year.

AMAR’s Clinical Strategy

AMAR’s strategy is to first target “orphan diseases” (rare diseases with patient populations of under 200,000), because this offers potentially the fastest, and least-expensive way to get FDA approval for oral interferon.

Once these drugs are on the market, there will be a clear path to expanding oral low-dose interferon into larger markets like influenza, hepatitis, and multiple sclerosis, etc.

It should be also be noted that once a drug is FDA approved, many doctors will prescribe it “off label” to treat other diseases where it has shown promising results in clinical research.

Amarillo is now in Phase II trials for three such rare diseases, including: Idiopathic Pulmonary Fibrosis, Oral Warts in HIV+ patients, and Behcet’s Disease. Regulatory approval of oral Interferon as a drug treatment for these diseases, could lead the way for the full, billion dollar potential, of Amarillo’s oral delivery platform to be realized.


The AMAR Investment Opportunity
AMAR’s interferon technology platform is a HUGE story - addressing potentially multi-billion dollar market opportunities - and there is alot of compelling clinical data which supports AMAR’s claims.

It’s fairly common that a stock with multiple drugs in Phase II trials, and upside potential like AMAR’s, would trade at a $100 million+ valuation.

By contrast - AMAR’s stock, at a recent $0.80, is being valued at just under $20 million (based on the 25 mil shares outstanding).

Let’s do the math: If investors decide to value AMAR based on biotech “comps” - the stock could rocket 500%!

- - And the stock could still have plenty of room on the upside if/when AMAR receives regulatory approval for marketing it’s drugs.


So why is AMAR’s stock so cheap, today?
We believe this “valuation gap” exists because investors attention have been focused entirely on AMAR’s current progress on orphan drugs (The Phase II trials in: Idiopathic Pulmonary Fibrosis, Oral Warts in HIV+ patients, and Behcet’s Disease). These are not the huge markets which investors get really excited about. For example, the market potential for Oral Warts in HIV+ is just $170 million. Behcet’s Disease just $40 million. Pulmonary Fibrosis, which affects over 200,000 patients in the US and Europe, approaches the $1 billion mark. For AMAR, regulatory approval of these orphan drugs would not be the end game. Rather, it’s an expedient means to pave the way for oral interferon as a treatment for major markets.

We believe the market has missed the big picture - which is AMAR’s huge upside potential if/when it’s oral low-dose interferon treatment is approved for markets like:

Chronic Hepatitis B & C
Influenza (including Bird Flu virus H5N1)
Fibromyalgia
Wasting cancer patients
Respiratory synctytial virus
Measles
Oral mucositis cancer
Opportunistic HIV+ infections
Multiple sclerosis
Let’s suppose that AMAR’s low-dose oral Interferon is eventually approved as a drug treatment for some or, even all of these diseases.... That could transform AMAR into a billion dollar biopharma company overnight. Let’s be clear, there is no “sure thing” when it comes to the biotech business. For every success story there are dozens of failures. Any investment in a biotech stock is speculation. But based on interferon’s established commercial track record, and the low toxicity risk of AMAR’s formulations, the odds of eventual FDA approval and market success are increased.



The "Perception bet"

In our opinion, the only smart way to bet on biotech stocks like AMAR, is the “perception change bet”. That means buying the stock now, in the knowledge that once the masses of investors realize what the real upside potential of AMAR is, they will be willing to pay a hefty premium.
So the real question is: What is AMAR’s upside potential, and how much should that potential be valued at right now?

Here are the Value Drivers to consider:

AMAR's Proven technology
AMAR is leveraging the advantages of interferon’s track record as an already commercially successful drug - combined with the low toxicity risk of AMAR’s low-dose formulation. We believe this combination greatly increases AMAR’s chances of getting regulatory approval.

AMAR's Billion-dollar pipeline potential What's most exciting about AMAR, is the potential for building a multi-billion dollar pipeline of “blockbuster” drugs based on oral-low dose interferon. Decades of clinical research by scientists around the world, suggest interferon’s enormous potential for successfully treating scores of diseases. AMAR’s unique low-dose formulation, and oral delivery platform may just be the key to unlocking interferon’s promise.

AMAR's Compelling Valuation- At current prices AMAR stock appears to be a bargain, compared to other biotech companies at similar stages of development. Typically, companies with multiple drugs in Phase II sell for $100 million+. This means that AMAR shares could be worth $4.00+, when this “valuation gap” closes.

AMAR’s Investor Validation
Further adding credibility that Amarillo Biosciences is the "real deal", is the $17 million invested by Hyashibara (a billion dollar Japanese pharmaceutical company) into AMAR over the past 15 years. This is notable because Japanese drug companies tend to be quite conservative.

Amarillo’s blockbuster potential is perhaps also the reason why Thomas W. D'Alonzo, the former president of drug giant Glaxo USA, has recently joined Amarillo’s Board of Directors.

Multiple catalysts for stock surge-There are several exciting catalysts already in place which can send AMAR stock through the roof when triggered. They include:

Clinical Milestones - As AMAR’s three drug candidates move through the clinical process over the next few years, a steady output of news releases will be moving AMAR into the spotlight, and investors’ attention.

The “Bird Flu Play” - One of the most interesting investment aspects of AMAR is its growing recognition as a compelling “bird flu stock”. That’s because AMAR’s interferon treatment has shown very promising results treating influenza in animal research studies conducted at the Nobel Prize-winning research department at the University of Western Australia.
“Bird Flu can kill one billion people in six months”, according to Dr. Dmitry Lvov, Head of the Russian Virology Institute.

Can history repeat itself?

Leading scientists, and health experts agree: it is only a matter of time before this killer virus sets off a global pandemic - killing millions of people around the world. The World Health Organization, believes that a global influenza outbreak is inevitable - and that up to 25% of the worlds population could fall ill.

In 1918-1919 the Spanish Flu killed over 50 million worldwide. Most of the victims were healthy adults. Now, scientists at the Center for Disease Control, and the Armed Forces Institute of Pathology have determined that the killer virus was initially a bird flu that learned to infect people. They were shocked to discover that today’s H5N1 bird flu virus is learning the same deadly tricks. Right now, thanks to air travel, a killer virus can spread from Hong Kong to New York City, to London - in just a few days - potentially killing millions of people.


Based on clinical research, AMAR’s scientists believe that low-dose oral interferon offers a highly promising treatment for “Bird Flu” H5N1.
Most interestingly, oral low-dosage interferon already has a long and successful history in treating influenza, in the former Soviet Union, and China.

One thing is for sure: Whenever Bird Flu hits the news, investors start loading up on “bird flu stocks” like AMAR, sending share prices through the roof on speculative fever. Getting positioned in AMAR’s shares now, is a good long-term bet for event-driven investors.


Risk Factors:
We believe buying the shares of any development stage biotech company is a PURELY SPECULATIVE investment. AMAR fits into this category of course. The two biggest challenges facing the company include the FDA approval process (which is always unpredictable) and limited capital.


BOTTOM LINE:
We believe that AMAR’s shares are deeply undervalued today, and have multiple catalysts in place which can drive the stock price up 500%+, over the next 18 months. Although highly speculative, AMAR represents a very compelling risk/reward ratio for investors looking for exponential profit opportunities.

[xTRADERx]

Antwort auf Beitrag Nr.: 25.751.584 von fortuna924 am 27.11.06 19:14:05

von wem ist denn die empfehlung? DANKE

[fortuna924]

Antwort auf Beitrag Nr.: 25.752.042 von xTRADERx am 27.11.06 19:27:12

Starwood Research Institute

[Zentimeter]

Antwort auf Beitrag Nr.: 25.752.042 von xTRADERx am 27.11.06 19:27:12

ich werde hier dabei bleiben
sehe hier Analogien zu Transition Therapeutics
Interferone scheinen wieder im Trend zu sein und wahrscheinlich zu wirken

[RiseTrade]

Antwort auf Beitrag Nr.: 25.752.540 von Zentimeter am 27.11.06 19:41:21

Richtig so°°°!!!°°°

[kleinerBiber]

Oder mit einer Hana Biosciences und was daraus werden kann, na ja Geduld ist angesagt.

[Turboverdichter]

Da sitzen ja die "Topeinsteiger von heute jetzt schon wieder auf einem Minus von rund 30 % !

Das konnte ja nicht gut gehen...

...und alles nur wegen der einen Meldung!

Dabei war doch schon vorher klar, wie gigantisch das Potenzial von AMAR ist! Warum war ich denn hier monatelang allein und jetzt drehen hier alle durch!!?

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.754.958 von Turboverdichter am 27.11.06 21:14:35

Turboverdichter,

alleine wahrst Du nie, aber es gab ja auch nichts zu erzählen.

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.755.533 von kleinerBiber am 27.11.06 21:24:35

Ich weiß doch...


Mir tut es nur leid, wenn heute Leute zu weit über 80 cent reingesprungen sind, nur wegen einer Empfehlung!!!! :O

So weit über Pari, das ist doch Wahnsinn!

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.755.697 von Turboverdichter am 27.11.06 21:27:20

Hi,
Glaube die Fehler haben wir alle schon mal gemacht, nur so lernt man.

[az-maja]

aktuell 0,75 $....

[fortuna924]

Antwort auf Beitrag Nr.: 25.756.588 von az-maja am 27.11.06 21:49:03

mit kleinen Stückzahlen den Kurs gedrückt. 77.000 zu 0,827 aus dem ASK gekauft. Was meint ihr wie es morgen weitergeht? Kommen morgen die ersten Empfehlungen ?

[Zentimeter]

Antwort auf Beitrag Nr.: 25.757.106 von fortuna924 am 27.11.06 22:06:26

hammerhart
Teil der news vom 26,09,06

ABI seeks Government Funding for Chronic Chough Study

ABI has noted that low-dose oral interferon relieves chronic coughing in patients with Sjogren's syndrome and idiopathic pulmonary fibrosis (IPF). Moreover, ABI has published that horses with chronic obstructive pulmonary disease, or COPD, also called inflammatory airway disease, are significantly improved with low doses of oral interferon. ABI is seeking funding to treat chronic coughing in human COPD patients with oral interferon. COPD is reported to affect 10% of humans over the age of 40. Because COPD affects many millions of people and is not an Orphan Disease (a disease that affects fewer than 200,000 people in the U.S.), the study of COPD is too expensive for ABI to study beyond Phase II without a pharmaceutical partner. Initially, ABI is seeking a state government grant of $750,000 to conduct the Phase II clinical trial on 80 patients with chronic cough due to COPD or IPF. If the clinical data are as positive as expected, these Phase II data will be shared with potential Big Pharma partners.

[gagi47]

ich sehe SK=0,80$

[CFalko]

Da bin ich heute doch noch noch ganz günstig rein

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.757.756 von Zentimeter am 27.11.06 22:28:00

Jaaa, jetzt sind es Pferde, früher waren es schon mal Katzen...

Das alles befindet sich noch in den Entwicklungsphasen... Ich mahne Geduld an! Solche Prozesse dauern sehr lange, bis endlich mal Geld fließt... Die positive Nachricht ist im Moment kurzfristig eine andere...

[Maler33]

Guten Morgen,

na keiner mehr da, schade ,aber ist meistens so wenn der große Schub vorbei ist.
Was denkt Ihr, wird es noch bißchen weiter gehen oder werden wir erstmal so um die 0,60.- versuchen einen Boden zu bilden?

[CFalko]

Könnte heute noch richtig hoch gehen ... Die Amis reagieren
oftmals erst am darauf folgenden Tag

[Maler33]

Naja, eine Reaktion habe ich gestern schon gesehen,
mit sehr viel höherem Volumen bei den Ami´s als sonst.
Wenn, denke ich müsste noch eine Empfehlung kommen.

[Zentimeter]

Antwort auf Beitrag Nr.: 25.764.205 von Maler33 am 28.11.06 09:31:00

es ist auch möglich, dass sich jetzt große Adressen bis 1 Dollar und mehr eindecken
vielleicht haben sie auch Studien erstellt mit Kursen zwischen 2-6 USD

fällt mir aber schwer daran aktuell zu glauben und selbst wenn, könnten sie später vielleicht noch günstiger einkaufen

Fakt ist auch das der Anstieg gestern eher das Minimum als das Maximum war.

Interferone gelten als risikoarm und aktuell wieder als sehr chancenreich

wäre super wenn heute der Dollar fällt

[Zentimeter]

Antwort auf Beitrag Nr.: 25.764.317 von Zentimeter am 28.11.06 09:37:56

Zitat Empfehlung
"
Die heute veröffentlichte Mitteilung sehen wir aber in einem ganz anderen Licht. Alleine die Ankündigung für Verträge in Malaysia im März reichte für eine Verdoppelung der Kurse, ein sicheres Indiz, dass viele Portfoliomanager und Börsenbriefe ein Auge auf Amarillo geworfen haben. Wenn man die heutige Ankündigung unter diesem Licht sieht, stösst Amarillo u.E. in eine ganz neue Dimension vor, welche ein neues Zeitalter für die Unternehmung einleitet und die Ihnen die Möglichkeit bietet, gerade zu einem Zeitpunkt in Amarillo zu investieren, bevor sich das enorme Potential der Firma auch im Aktienkurs niederschlägt. "

es könnte weiter rauf gehen

[Zentimeter]

Antwort auf Beitrag Nr.: 25.765.391 von Zentimeter am 28.11.06 10:50:30

Kursziel ist immer noch 2 Euro in 6 Monaten
leider haben die Jungs weniger Ahnung als jeder von uns

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.766.550 von Zentimeter am 28.11.06 12:09:13

Was wäre denn ein sinnvolles Kursziel!?

[Maler33]

m. M. nach haben wir einen Widerstand bei 0,66.- der erst nachhaltig überwunden werden muss, damit es weiter aufwärts geht.




Ich weis, dass jetzt einige wieder sagen, dass man die T. A. bei einem solchen Wert nicht verwenden sollte, aber dafür sollte es gut sein.

[Zentimeter]

Antwort auf Beitrag Nr.: 25.767.104 von Maler33 am 28.11.06 12:48:43

selbst richtig erkannt
man kann die T. A. bei einem solchen Wert nicht verwenden

[Zentimeter]

Antwort auf Beitrag Nr.: 25.767.605 von Zentimeter am 28.11.06 13:22:46

Orderbuch sieht aktuell nicht schlecht aus
denke es geht weiter up

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.766.770 von Turboverdichter am 28.11.06 12:23:10

Rating: Speculative Buy

11/27/2006

Amarillo Biosciences Agrees To Oral-Interferon Use Against Influenza and Hepatitis B In China And Taiwan; Reiterate
Speculative Buy
Amarillo Biosciences, Inc. (OTCBB: AMAR), today announced that CytoPharm, Inc., will conduct clinical trials and seek regulatory
approvals to use Amarillo Biosciences' low-dose oral interferon in both China and Taiwan to treat influenza and hepatitis B.
Clinical trials are expected to begin in 2007. Terms of the deal were not disclosed, but CytoPharm will make milestone payments
to Amarillo Biosciences and will pay royalties on sales.
CytoPharm is a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest
biotech company in Taiwan specializing in pharmacogenomics and a specialty Clinical Research Organization. Founded in 2002,
CytoPharm's focus is the development of biopharmaceuticals for virus-infected diseases and cancers. The agreement will enable
CytoPharm to expand its work on cytokine therapeutic uses, particularly in the areas of hepatitis and other viral infections.
Dr. Ellson Chen, Chairman of CytoPharm, and founder of Vita Genomics, said that fast-growing economies and improving health
care systems in the two locations are driving "patients' demands for newer and better drugs." Hepatitis B is a major regional
disease that costs governments billions of dollars to treat its potentially deadly consequences.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, cited the "major significance" of the agreement because of
the opportunity to test the Company's low-dose oral interferon "in patients with hepatitis B and influenza, two major diseases
which impact millions of people worldwide annually." Dr. Cummins said he was pleased that CytoPharm shares Amarillo
Biosciences' vision that "low-dose oral interferon can be a therapeutic agent against a wide array of medical conditions." Amarillo
Biosciences expects that the data generated from these clinical trials could help the Company eventually advance the use of lowdose
oral interferon into other Asian countries.
The license and supply agreement was negotiated by Dr. Stephen T. Chen, President of STC International and an ABI Board
member living in Taiwan, who believes that "this product will be a huge success in the Asian marketplace."
We reiterate our September 18 Speculative Buy on Amarillo Biosciences with an 17-month price target of $1.90. This rating
assumes that the Company will achieve its clinical goals and sell, license, or partner one or more of its development programs
within our target time frame.



Also Dutton hat seine Einstellung nicht geändert und ich sehe das genau so! AMAR hat beträchtliches Potenzial, aber kurzfristig wachsen die Bäume nicht in den Himmel!

1,90 auf Sicht von 17 Monaten ist allemal realistisch!

[Zentimeter]

Antwort auf Beitrag Nr.: 25.768.586 von Turboverdichter am 28.11.06 14:27:37

solche Meinungen brauchen wir
kurzfristig nicht und so weiter
ein guter Kontraindikator

[JAY25]

[Zentimeter]

Antwort auf Beitrag Nr.: 25.769.705 von JAY25 am 28.11.06 15:31:29

wer hier in BRD zu über 0,7 EURO rein ist
da kann man sagen Mahlzeit
--------
wenn man heute so schaut könnte es allein 6 Monate dauern bis wir wieder bei 0,9 USD sind

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.769.355 von Zentimeter am 28.11.06 15:13:57

Wie meinst du das!?

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.779.753 von Turboverdichter am 28.11.06 20:48:54

Was meinst du mit Kontarindikator? Meinst du ernsthaft, dass es hier kurzfristig einen richtigen Anstieg gibt?

[Zentimeter]

Antwort auf Beitrag Nr.: 25.779.853 von Turboverdichter am 28.11.06 20:52:23

möglich ist alles
Interferone sind wieder Thema
ich weis es nicht

[Zentimeter]

Antwort auf Beitrag Nr.: 25.781.246 von Zentimeter am 28.11.06 21:35:27

news fast verpufft
aber trotzdem langfristig Topwert

[Zentimeter]

Antwort auf Beitrag Nr.: 25.792.970 von Zentimeter am 29.11.06 13:23:52

news
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Joseph Cummins, President & CEO, will present the Company to fund managers, analysts and investment bankers at the Wall Street Reporter Magazine "Small-Cap Discovery Conference" on December 5, 2006 at The Princeton Club in New York City. (The Princeton Club is located at 15 West 43rd Street (between 5th and 6th Avenues), New York, NY.)

The Amarillo Biosciences presentation is scheduled for 9:20 a.m. EST. The Company's shareholders and those interested in the Company are welcome to attend the conference. Dr. Cummins will discuss the partnership in China and Taiwan announced this week with CytoPharm. Dr. Cummins will also discuss ongoing Phase 2 clinical trials in oral warts in HIV+ patients and in Behcet's disease. The Company's plans for influenza studies will also be discussed.

Beginning at 8:30 am, live presentations by medical, resource, and technology companies from Australia, Canada and the U.S. can be accessed via the "Small-Cap Discovery Conference" webpage www.wallstreetreporter.com/sdc and clicking on the link to the live conference. Webcasts of the presentations will also be available following the live conference.

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.793.249 von Zentimeter am 29.11.06 13:38:09

... ABI) (OTC BB: AMAR) announced today that its President and CEO, Dr ... Magazine will be hosting its sixth annual "Small-Cap Discovery Conference" on September 15, 2005, in New York ...




Das hatten wir doch alles schon mal!

Die ganzen Zocker werden nun wieder rausgeschüttelt! War wohl nichts zu holen...

[Kaptnadoc]

Antwort auf Beitrag Nr.: 25.793.249 von Zentimeter am 29.11.06 13:38:09

Zentimeter,
hast du den Link dieser News ?
Danke im voraus

[Kaptnadoc]

Ok, habs gefunden

Dr. Cummins will discuss the partnership in China and Taiwan announced this week with CytoPharm. Dr. Cummins will also discuss ongoing Phase 2 clinical trials in oral warts in HIV+ patients and in Behcet's disease. The Company's plans for influenza studies will also be discussed.

[Zentimeter]

Antwort auf Beitrag Nr.: 25.793.327 von Turboverdichter am 29.11.06 13:42:05

hier nichts zu holen

wenn nicht hier wo dann
Zocker brauchen wir nicht

[kleinerBiber]

Antwort auf Beitrag Nr.: 25.795.882 von Zentimeter am 29.11.06 15:19:24

Jo,

das sehe ich auch so geben wir der Sache Zeit, ist meist besser als hochgezockt.

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.800.663 von kleinerBiber am 29.11.06 17:52:14

Sorry...

...ich dachte ihr wollt hier nur das schnelle Geld!

Hat mich ehrlich gesagt angestunken, diese "Explosion" vor ein paar Tagen...

[kleinerBiber]

Einige die gezockt haben werden wir wohl nicht mehr sehen,es sei den Sie lassen die Aktien liegen.

Aber das glaube ich nicht...!!!!!

[Turboverdichter]

[Zentimeter]

Antwort auf Beitrag Nr.: 25.820.993 von Turboverdichter am 30.11.06 11:26:46

sobald Grippe- und Hepatitis-Studien am Menschen starten und ohne Scheitern der aktuellen Studien schätze ich den Wert auf vorläufig 100 Million USD
die Zielmarke des Börsenbriefes ist realistisch

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.825.223 von Zentimeter am 30.11.06 14:33:24

...da warte ich erstmal ab! Bin in den letzten Jahren nicht nur einmal in dieser Branche auf die Schna**e gefallen!

[Zentimeter]

Antwort auf Beitrag Nr.: 25.832.395 von Turboverdichter am 30.11.06 18:33:03

bei Interferone fällst du aber nicht auf die Schnauze
weil die Wirkung praktisch schon erwiesen ist, vielleicht keine Heilung aber eine ausreichende Wirkung für eine Zulassung
und Nebenwirkungen können nicht stark sein
darum steigen Firmen wie die genannte big ein

[kirroyal]

Antwort auf Beitrag Nr.: 25.838.325 von Zentimeter am 30.11.06 21:13:42

Ist heute kein Handel ?

[isirgan]

Dutton Associates Announces Investment Opinion: Amarillo Biosciences Speculative Buy Rating Reiterated in Update Report by Dutton Associates
Dutton Associates updates its coverage of Amarillo Biosciences, Inc. (OTCBB:AMAR), maintaining its Speculative Buy rating and a 15- to 18-month price target of $1.90. The 12-page report by Dutton Associates senior analyst Wayne M. Lottenville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals. Amarillo Biosciences is a biopharmaceutical company developing low-dose oral natural human interferon-alpha as a safe, cost-effective therapy for several diseases or their symptoms, including influenza and HIV-related oral warts. The Company has a Phase 2 clinical investigation using oral low-dose interferon-alpha for Behcet's disease now underway and plans to begin enrollment in a Phase 2 clinical trial in December to treat oral warts in HIV-positive patients. Influenza and chronic cough trials may begin in 2007.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 28 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The current cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 9/18/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.


Dutton Associates, LLC
John M. Dutton, 916-941-8119



Source: Business Wire (December 1, 2006 - 12:00 PM EST)

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.865.680 von isirgan am 01.12.06 19:00:24

[Zentimeter]

Antwort auf Beitrag Nr.: 25.832.395 von Turboverdichter am 30.11.06 18:33:03

Boden erreicht
wann kaufen große Adressen?

[Turboverdichter]

Antwort auf Beitrag Nr.: 25.929.020 von Zentimeter am 04.12.06 16:38:54

[Zentimeter]

Antwort auf Beitrag Nr.: 25.939.570 von Turboverdichter am 04.12.06 21:31:31

einfach lecker die Kurse zum Einstieg

[Zentimeter]

Antwort auf Beitrag Nr.: 25.967.238 von Zentimeter am 06.12.06 11:16:40

wer jetzt nicht kauft ist selbst schuld

[Zentimeter]

Antwort auf Beitrag Nr.: 26.002.085 von Zentimeter am 07.12.06 17:31:54

und wie gehts weiter
2 Euro in 5 Monaten

1 Dollar wäre schon eine feine Sache

[xTRADERx]

Kontinuierlicher guter Newsflow - hier die aktuellste Nachricht:

Amarillo Biosciences Announces Phase II Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

2006-12-11 01:00 ET - News Release

AMARILLO, TX -- (MARKET WIRE) -- 12/11/06

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that four clinical sites are ready to enroll patients in a Phase 2 study to test low-dose interferon alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts. Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is a group of DNA viruses, human papilloma viruses, which induce hyperplastic lesions in the oral soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia.

Oral warts cause a significant reduction in quality of life due to their deleterious effects on patient appearance and potential for causing discomfort during routine activities such as eating and talking. Current treatment modalities include physical interventions such as cryosurgery, electrocoagulation, CO2 laser and excision; however, the rate of recurrence is high.

Two previous studies have been conducted and demonstrated the ability of interferon alpha lozenges to significantly reduce oral wart load in HIV-positive patients. If, as anticipated, ABI's new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase 3 study before filing an NDA (New Drug Application), seeking marketing approval for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.

Clinical sites in Chicago, New York, Boston and Dallas are approved to start the study. Two additional sites in San Francisco and Baltimore will be added to the study shortly. In all, 80 patients will be enrolled in a study in which treatment will last 24 weeks. Interested patients are urged to contact Martin Cummins, Director of Clinical and Regulatory Affairs at 806-376-1741 ext. 14 or email: [e-mail]. Patient enrollment will begin after January 1.

The FDA's Office of Orphan Products Development has granted Orphan Drug Designation to ABI for natural human lymphoblastoid interferon-alpha in the treatment of papillomavirus warts in the oral cavity of HIV-positive patients.

"Our company's mission is to obtain FDA approval for our low dose oral interferon alpha," said Dr. Joseph M. Cummins, President and CEO, ABI. "This Phase 2 clinical study, in conjunction with our ongoing Phase 2 clinical study in Turkey on Behcet's disease, are two important steps in attaining our objective," added Dr. Cummins.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.



Greetz

xTRADERx

DYODD

[Zentimeter]

Antwort auf Beitrag Nr.: 26.097.769 von xTRADERx am 11.12.06 09:37:04

oh mit news geht es weiter
bin gespannt wann sich große Adressen erste Postionen sichern

[Zentimeter]

Antwort auf Beitrag Nr.: 26.099.415 von Zentimeter am 11.12.06 10:57:10

heute gar kein
schnell sein-Kursziel 2 Euro-vor Amerika Positionen sichern

[Zentimeter]

Antwort auf Beitrag Nr.: 26.099.582 von Zentimeter am 11.12.06 11:05:47

wo bleibt der Umsatz in der Perle

[Zentimeter]

Antwort auf Beitrag Nr.: 26.128.002 von Zentimeter am 12.12.06 16:22:57

Hallo 0,8 Euro-Käufer
jetzt müßt ihr kaufen nicht verkaufen
Adam Ries grüßt

[Kostobeeky]

Halloooooooooooooooooo!?

Seid ihr alle tot?

Es geht doch wieder aufwärts. Und die nächste Vogelgrippe kommt bestimmt.

Gruß Kosto

[kleinerBiber]

Hallo,

natürlich nicht mache noch meinen Winterschlaf.

Tschüß....!!!!

[kleinerBiber]

Ach ja gibt auch eine neue Mitteilung von heute.....!!!!


Amarillo Biosciences Recaps Progress in 2006

AMARILLO, TX -- (MARKET WIRE) -- 01/05/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced the following developments:

The year 2006 was a milestone for ABI and set the stage for an even more significant year in 2007. In the past year, ABI laid the groundwork to conduct a series of clinical trials on four continents in 2007.

In Turkey, ABI began enrollment of a Behcet's disease study. In the United States, we are in the final stages of site registration for a six-city Phase 2 clinical trial on oral warts in AIDS patients. In Australia, a human influenza study is planned in mid 2007. In Taiwan and China, we look forward to clinical trials for chronic active hepatitis B and human influenza later this year. These developments, in conjunction with a number of other ongoing studies in humans and animals, will pave the way for the realization of our ultimate objective: FDA approval for our low dose oral interferon.

Behcet's Disease Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Enrollment in Turkey for Behçet's disease currently stands at 51 patients. We must reach 90 patients to complete the Phase 2 clinical trial. Enrollment is expected to be completed in the first or second quarter of 2007, and data analysis will begin approximately 12 weeks after the last patient is enrolled. Our Turkish partner Nobel Ilac, one of the largest pharmaceutical companies in Turkey, is funding the study. Nobel Ilac may be able to use the Phase 2 data to seek approval in Turkey, assuming the data are compelling.

Oral Warts Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Our Phase 2 clinical trial will test low-dose interferon alpha lozenges administered orally to subjects who have oral warts and are also positive for human immunodeficiency virus (HIV). Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is the DNA virus, human papillomavirus, which induces hyperplastic lesions in the oral soft tissue such as warts and focal epithelial hyperplasia. We have already registered five clinical sites in San Francisco, Chicago, New York City, Boston, and Dallas for this study. A site in Baltimore is expected to register in January and all sites are expected to begin enrollment in January 2007.

CytoPharm Licensing and Supply Agreement, Hepatitis B and Human Influenza Clinical Trials for Taiwan and China

Approximately a month ago, ABI entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.

Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch ABI's low dose oral interferon for influenza and hepatitis B indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct clinical trials, which are expected to commence in 2007.

Texas Tech University Idiopathic Pulmonary Fibrosis and COPD Studies

Eighteen patients completed a pilot study of the use of interferon lozenges in the treatment of idiopathic pulmonary fibrosis (IPF) at Texas Tech University. As previously announced, the principal investigator, Lorenz Lutherer, presented findings from the study at the Company's annual shareholders' meeting. Dr. Lutherer reported that more than half of his patients treated for at least one year showed no signs of disease progression as assessed by pulmonary-function testing and high-resolution CT scans of their lungs. IPF is normally rapidly progressive, so the fact that half of the patients have shown no progression of the disease during interferon lozenge treatment is encouraging. However, the most surprising observation from our research is that low-dose oral interferon relieves chronic coughing in patients with IPF or Sjogren's syndrome. Moreover, ABI has published that horses with chronic obstructive pulmonary disease or COPD, also called inflammatory airway disease, are significantly improved with low doses of oral interferon. Coughing, a component of COPD in horses is relieved by oral interferon.

An SBIR grant was submitted to NIH in November in cooperation with Dr. Lutherer. If funded, this grant application will allow the Company to conduct a Phase 2 study to verify that oral interferon stops chronic coughing.

Two new patent applications were filed in 2006. One of these new patent applications contained claims on the use of oral interferon to relieve chronic coughing. The other new application pertained to animal health.

COPD Initiative

ABI is seeking funding to treat chronic coughing in human COPD or IPF patients with oral interferon. COPD is reported to affect 10% of humans over the age of 40. Because COPD affects many millions of people and is not an Orphan Disease (a disease that affects fewer than 200,000 people in the U.S.), the study of COPD would require a large study population and is, therefore, too expensive for ABI to study beyond Phase 2 without a pharmaceutical partner. If the clinical data from Phase 2 are as positive as expected, these Phase 2 data will be shared with potential pharma partners.

Federal Funding

ABI retained Hance, Scarborough, Wright, Woodward & Weisbart an Austin-based law firm to represent ABI regarding federal governmental and private source funding for influenza studies. In 2007, we will be aggressively working on obtaining federal funding for clinical trials to be conducted in 2007 and 2008. Beyond federal funding, ABI is seeking investor funding so we can complete all our clinical studies.

Consultant agreement with Claus Martin, MD

Dr. Martin has helped ABI by introducing companies in India, South America and SE Asia. Through Dr. Martin's efforts, ABI was able to enter a License and Supply Agreement in Malaysia with Bumimedic.

Influenza

Animal trials were conducted in 2006 in Australia, New York and Nebraska. An oral dose of interferon was found which protected mice against a fatal influenza challenge. Animal research will continue in 2007 in Australia and New York. Human trials, as mentioned above, are expected in Australia, Taiwan, and China.

Dietary Supplement

In December 2006, Hayashibara Biochemical Laboratories granted ABI a 5-year extension of our Supply Agreement for anhydrous crystalline maltose (ACM). The company sells ACM as Maxisal to individuals and to pharmacies for the patented relief of dry mouth (xerostomia). The Company plans to license Maxisal to a distributor for nationwide sales in 2007.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
[e-mail]
Tel: [phone]
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail:[e-mail]
Tel: [phone] x 13
Fax: [phone]

[Kostobeeky]

Hallo du kleiner Nager,

schön, dass du noch da bist. Hoffe, wir bekommen noch viel Spaß mit unserer Amarillo.

Gruß Kosto

[Turboverdichter]

Hallo AMARs,

Gesundes Neues Jahr noch!

Stimmt, es war in letzter Zeit etwas ruhig hier...

...aber was sollte man auch besprechen!?

[Turboverdichter]

Antwort auf Beitrag Nr.: 26.698.377 von kleinerBiber am 05.01.07 19:15:18

...und was Dutton dazu sagt:

01/05/2007

Amarillo Biosciences Clinical Trial Enrollment Progresses;

Reiterate Speculative Buy

Amarillo Biosciences, Inc. (OTCBB: AMAR), said Thursday that enrollment in Turkey for the Company's Behcet's disease study has
reached 50 patients. The Company hopes to complete enrollment of 90 patients in its Phase 2 clinical trial using low-dose oral
interferon-alpha in the first or second quarter of 2007. Data analysis is expected to begin 12 weeks after the last patient is enrolled. The study is funded by Nobel Ilac, one of the largest pharmaceutical companies in Turkey. In a letter to shareholders on Thursday, Amarillo´Biosciences' CEO Joseph M. Cummins said that Nobel may be able to use the Phase 2 data to seek approval in Turkey, assuming the data are compelling.
Cummins also said that Amarillo Biosciences has also registered five clinical sites in San Francisco, Chicago, New York City, Boston, and Dallas for its Phase 2 clinical trial using low-dose oral interferon-alpha lozenges to treat HIV-positive subjects who have oral warts.
Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is the DNA virus, human papillomavirus, which induces hyperplastic lesions in the oral soft tissue such as warts and focal epithelial hyperplasia. Another clinical site in Baltimore is expected to register in the near future, and all sites are expected to begin enrollment this month.

We reiterate our September 18 Speculative Buy on Amarillo Biosciences with a 15- to 18-month price target of $1.90. This rating assumes that the Company will achieve its clinical goals and sell, license, or partner one or more of its development programs within our target time frame.

[kleinerBiber]

Antwort auf Beitrag Nr.: 26.700.779 von Kostobeeky am 05.01.07 21:12:43

Hallo Kostobeeky,

das hoffe ich auch und solange noch wenige sich um den Wert kümmern,
werde ich weiter Sammeln.

Tschüß kleinerBiber....!!!!

[ALeverkuehn]

Gibt es News bei Amarillo?

Heute 10% im Plus!!
Ich will eigentlich erst bei 0,68 rein, denn dann ist der Weg nach oben frei.

Gruß AL

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.134.417 von ALeverkuehn am 23.01.07 17:55:54

Keine News...

...aber typisch AMAR... große Ausschläge bei kleinem Umsatz!



...aber abwarten:


Dear Shareholder,

The year 2006 was a milestone for ABI and set the stage for an even more significant year in 2007. In the past year, ABI laid the groundwork to conduct a series of clinical trials on four continents in 2007.

[kleinerBiber]

Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

AMARILLO, TX -- (MARKET WIRE) -- 02/08/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that patients are now being enrolled in its FDA Phase 2 study testing low-dose interferon alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts. Six clinical sites are participating in the study in San Francisco, Chicago, Boston, Dallas, Baltimore and New York City.

Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is a group of DNA viruses, human papilloma viruses, which induce hyperplastic lesions in the oral soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia.

Oral warts cause a significant reduction in quality of life due to their deleterious effects on patient appearance and potential for causing discomfort during routine activities such as eating and talking. Current treatment modalities include physical interventions such as cryosurgery, electrocoagulation, CO2 laser and excision; however, the rate of recurrence is high.

Two previous studies demonstrated the ability of interferon alpha lozenges to reduce oral wart load in HIV-positive patients. If, as anticipated, ABI's new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase 3 study before filing an NDA (New Drug Application), seeking marketing approval for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.

Clinical sites will enroll 80 patients in a study for which treatment will last 24 weeks. Interested patients are urged to contact Martin Cummins, Vice President, Clinical and Regulatory Affairs, via phone: [phone] ext. 14 or email: [e-mail] for clinical site information.

The FDA's Office of Orphan Products Development has granted Orphan Drug Designation to ABI for natural human lymphoblastoid interferon-alpha in the treatment of papillomavirus warts in the oral cavity of HIV-positive patients.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
E-mail: Email Contact
Tel: [phone]
212-344-6464
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
E-mail: Email Contact
Tel: [phone] x 13
Fax: [phone]

[kleinerBiber]

Amarillo Biosciences Announces the Publication of Influenza Data

AMARILLO, TX -- (MARKET WIRE) -- 02/12/07 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that the publication of data on the use of oral interferon for influenza is now available online in the Biochemical & Biophysical Research Communications (BBRC). These data indicate that oral interferon is life saving to treated mice given an otherwise fatal infection. These mice data are important because the mouse model is used by government laboratories to evaluate antivirals for testing in humans. The principal author of the online article in BBRC is Dr. Manfred Beilharz, Head, Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, M502, The University of Western Australia, Western Australia, 6009.

The Company is generating animal and human data in an effort to motivate government decision makers to consider the use of oral interferon in the management of pandemic influenza. As an alternative to other antivirals, the Company believes oral interferon fits one of the treatment priorities outlined by the National Strategies for Pandemic Influenza (Homeland Security), May 2006.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: Email Contact
Tel: [phone]
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: Email Contact
Tel: [phone] x 13
Fax: [phone]

[Turboverdichter]

02/13/2007

Amarillo Biosciences Announces the Publication of Influenza
Pretreatment Data; Reiterate Speculative Buy

Amarillo Biosciences, Inc. (OTCBB: AMAR), has announced that the publication of data on the use of oral interferon for influenza is
now available online in Biochemical & Biophysical Research Communications. The data indicate that oral interferon is life-saving to treated mice given an otherwise fatal infection. These mice data are important because the mouse model is used by government laboratories to evaluate antivirals for testing in humans.
The data is available at www.sciencedirect.com under the title, "Protection from lethal influenza virus challenge by oral type 1 interferon," or under the principal author, Dr. Manfred Beilharz, who is head of microbiology and immunology at the School of Biomedical, Bimolecular and Chemical Sciences, The University of Western Australia. Beilharz concludes that: "These results provide strong support for the application of low dose type 1 [interferon] pretreatment to human influenza control."
Amarillo Biosciences is generating animal and human data in an effort to motivate government decision-makers to consider the use of oral interferon in the management of pandemic influenza. As an alternative to other antivirals, the Company believes oral interferon fits one of the treatment priorities outlined by the National Strategies for Pandemic Influenza (Homeland Security), May 2006.
We reiterate our September 18 Speculative Buy rating on Amarillo Biosciences' stock and maintain a price target of $1.90 per share
with a target date of April 2008. This rating assumes that the Company will achieve its clinical goals or license or sell one or more of its development programs within the target time frame.




Hughhhhh! Dutton hat gesprochen!

[Turboverdichter]

Es wird langsam wieder interessant hier!
Still und heimlich klettert das Pappierchen...

[Kostobeeky]

Ob der Anstieg mit dem Ausbruch der Vogelgrippe zusammenhängt?

Kosto

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.895.528 von Kostobeeky am 22.02.07 12:36:54

Möglicherweise auch das! Ich habe bei AMAR in letzter Zeit immer wieder einen Anstieg beobachtet, wenn sich diesbezüglich nachrichten verdichteten...

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.898.643 von Turboverdichter am 22.02.07 15:02:10

...aber auch die geringen Umsätze bedenken!

[wieni]

Hallo, ist es schon jemand aufgefallen, daß es einen Insiderkauf bei Amarillo am 20.02.07 gegeben hat?

wieni

[hausbesitzer]

Hallo, wie kommst du darauf das es Insiderkäufe gab.

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.901.262 von wieni am 22.02.07 16:32:28

Ich sehe nur das!


29 January 2007 Cummins Joseph M Sell 10,000 0.78 to 0.78 $7,800
19 December 2006 Cummins Joseph M Sell 6,500 0.67 to 0.67 $4,355
1 December 2006 Cummins Joseph M Sell 2,500 0.75 to 0.75 $1,875
29 November 2006 Cummins Joseph M Sell 10,000 0.72 to 0.72 $7,200
27 November 2006 Cummins Joseph M Sell 5,000 0.8762 to 0.8762 $4,381

[wieni]

Antwort auf Beitrag Nr.: 27.903.495 von Turboverdichter am 22.02.07 17:36:03

Date Name Shares Stock Transaction
02/20/2007 GARY COY
Chief Financial Officer & Vice President 25,000 AMAR Open Market Purchase
Cost $11,250.00

Link

http://www.marketwatch.com/tools/quotes/insiders.asp?siteid=…

wieni

[wieni]

Dies könnte der langersehnte Startschuß sein!!!

wieni

[CFalko]

0,77 / 0,81 ... das sieht gut aus

[CFalko]

hmmm ... keine Käufer da?

[kleinerBiber]

Hi,

hat einer 10000 Stück verkauft, warum weiß er wohl selbst nicht....!!!

Tschüß kleinerBiber

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.904.317 von wieni am 22.02.07 18:01:20

DANKE! Ein Insiderkauf hat doch aber nichts mit einem Startschuss zu tun!?

[wieni]

Antwort auf Beitrag Nr.: 27.928.722 von Turboverdichter am 23.02.07 17:27:53

Glaubst du nicht das ein Chief Financial Officer & Vice President ein bischen mehr weiß und von einem steigenden Kurs ausgeht?

Sieht man ja deutlich am Volumen in USA.

wieni

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.928.856 von wieni am 23.02.07 17:32:00

...und deshalb hat Cummins in letzter Zeit dauernd verkauft!?

[wieni]

Antwort auf Beitrag Nr.: 27.928.969 von Turboverdichter am 23.02.07 17:35:25

Ich verstehe nicht warum du negativ auf Insiderkäufe reagierst.
Manchmal braucht man dringend Geld,außerdem hat er immer zur richtigen Zeit verkauft. Verkaufst du nie, du Basher.

wieni

[Turboverdichter]

Der Startschuss bei AMAR ist 2005 gefallen!

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.929.206 von wieni am 23.02.07 17:42:49

Cummins hat verkauft, egal wie der Markt stand. Das hatte wohl nicht viel mit der Lage zu tun...

Basher!?

Bist du dicht?

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.929.206 von wieni am 23.02.07 17:42:49

The year 2006 was a milestone for ABI and set the stage for an even more significant year in 2007. In the past year, ABI laid the groundwork to conduct a series of clinical trials on four continents in 2007.

[wieni]

Antwort auf Beitrag Nr.: 27.929.396 von Turboverdichter am 23.02.07 17:48:31

Also nach meiner Info hat Cummins am 12.01.2006 das letztemal verkauft und zwar 2500 Stück und deshalb machst du so ein Theater?

wieni

02/20/2007 GARY COY
Chief Financial Officer & Vice President 25,000 AMAR Open Market Purchase
Cost $11,250.00

12/01/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 2,500 AMAR Open Market Sale
proceeds of $1,875.00

11/29/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 10,000 AMAR Open Market Sale
proceeds of $7,200.00

11/27/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 5,000 AMAR Open Market Sale
proceeds of $4,400.00

10/26/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 10,000 AMAR Open Market Sale
proceeds of $8,000.00

10/26/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 5,000 AMAR Open Market Sale
proceeds of $3,950.00

09/14/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 10,000 AMAR Open Market Sale
proceeds of $8,400.00

08/29/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 5,000 AMAR Open Market Sale
proceeds of $4,100.00

08/24/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 10,000 AMAR Open Market Sale
proceeds of $8,000.00

08/24/2006 JOSEPH M CUMMINS
Chairman, President & Chief Executive Officer 5,000 AMAR Open Market Sale
proceeds of $4,100.00

[wieni]

Antwort auf Beitrag Nr.: 27.929.492 von Turboverdichter am 23.02.07 17:51:39

Lieber Turboverdichter der Startschuß den ich angesprochen habe, bezog sich auf den Aktienkurs - alles klar.

wieni

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.929.597 von wieni am 23.02.07 17:54:50

Ich mache kein Theater, aber wenn ein Insider 25.000 kauft, lässt mich das auch relativ kalt....


....auch wenn es mich in meiner Sache noch sicherer macht!

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.929.705 von wieni am 23.02.07 17:58:11

Bei mir auch!

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.929.792 von Turboverdichter am 23.02.07 18:00:22

Das Papier hat sich seit Herbst 2005 vervierfacht und wenn man sich die Zockerblase vom Frühjahr 2006 wegdenkt, dann sieht man einen schönen Anstieg...

[Turboverdichter]

Allein seit Jahresbeginn wieder über 30 % gestiegen...

...

[wieni]

Antwort auf Beitrag Nr.: 27.929.792 von Turboverdichter am 23.02.07 18:00:22

Dann sind wir ja uns einig

wieni

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.930.850 von wieni am 23.02.07 18:37:36

Na aber!

[Turboverdichter]

Na das sieht doch gut aus!

[Zocker_Freak]

das gefällt mir sehr gut!

Amarillo wurde auch schon mal Ende 2005 von stockreport.de empfohlen!

Bin damals zu 0,45 Euro reingekommen und habe meine Stücke immer noch, weil es damals für mich ein Langzeit Investment war!

Es macht sich bezahlt!!

[Zocker_Freak]

Antwort auf Beitrag Nr.: 27.976.391 von Zocker_Freak am 26.02.07 11:51:46

Hier sieht man sehr schön, wie die Aktie damals nach oben geschossen ist!!

Es war sogar Anfang 2006 (man beachte das Volumen)

[Turboverdichter]

Antwort auf Beitrag Nr.: 27.976.433 von Zocker_Freak am 26.02.07 11:53:17

Diesmal schießen wir drüber, wenn auch nicht so schnell!

[Turboverdichter]

Gibt's ne Meldung oder drückt da wer?!

[CFalko]

Was ist denn heute los? Gabs News?

[Tronje43]

Antwort auf Beitrag Nr.: 28.006.253 von CFalko am 27.02.07 16:34:24

Schanghai?

[Turboverdichter]

Das gestrige Minus in den USA und das von heute müssen wir hier an einem Tag ertragen!?

Die Umsätze sind im Limit...

[gerdass]

Antwort auf Beitrag Nr.: 19.798.779 von xTRADERx am 20.01.06 11:39:24

[Turboverdichter]

Antwort auf Beitrag Nr.: 28.136.521 von gerdass am 06.03.07 00:41:37

>????

[CFalko]

Nun bewegt sich wieder was

[kleinerBiber]

Hallo,

der Umsatz müsste nur mal steigen.......aber das wird auch noch.....!!!

[Turboverdichter]

AMARILLO BIOSCIENCES INC. 0,91 USD +0,09 +10,98%

[Turboverdichter]

DUTTON UPDATE!

GAAAAAAAANZZZZZZZZZZZZZ FRISCHHHHHHHHHHHHHH!

03/17/2007

Amarillo Biosciences To Announce Annual Financial Results;

Reiterate Speculative Buy

Amarillo Biosciences, Inc. (OTCBB: AMAR), should announce financial results for 2006 by the end of March. In our last update report on the Company on December 1, we projected Amarillo Biosciences would lose $3.1 million, or $0.14 per share, in 2006 on operating expenses of $3.0 million. For the final quarter of 2006, we projected that Amarillo Biosciences would lose $793,000, or $0.03 per share, on operating expenses of $770,000.
In its quarterly SEC filing, the Company is also expected to provide updates on the progress of two clinical trials. In early January Amarillo Biosciences said that enrollment in Turkey for the Company's Behcet's disease study had reached 50 patients. The Company hopes to complete enrollment of 90 patients in this Phase 2 clinical trial in the second quarter of 2007. And in December Amarillo Biosciences announced that four clinical sites were ready to enroll patients in a Phase 2 study to test low-dose interferon-alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts.
We reiterate our September 18 Speculative Buy rating on Amarillo Biosciences' stock and maintain a price target of $1.90 per share with a target date of April 2008. This rating assumes that the Company will achieve its clinical goals or license or sell one or more of its development programs within the target time frame.
We will publish our regular update on Amarillo Biosciences with revised financial and clinical projections in the near future.

[Turboverdichter]

Amarillo Biosciences Issues Clinical Progress Report and Schedules Annual Meeting

Wednesday March 21, 2007 13:22:56 EDT


AMARILLO, TX, Mar 21, 2007 (MARKET WIRE via COMTEX News Network) --
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following progress report on two of its clinical studies:

Enrollment in Turkish Behcet's Disease

Nobel Ilac Sanayii Ve Ticaret A.S., the leading Turkish pharmaceutical company that is co-sponsoring a Behcet's Disease study with ABI, has confirmed that two new clinical sites have been approved by the Turkish Ministry of Health to commence enrollment of patients with Behcet's disease. Two new sites are being added to accelerate enrollment of 90 patients with the goal of completing the Phase 2 trial in 2007. Approximately 90 patients have been screened for enrollment and 59 have been started on treatment as of today's date. The double-blinded Phase 2 study is testing the efficacy of interferon lozenges versus placebo in the treatment and prevention of mouth ulcers. The treatment duration is 12 weeks. Other products used to treat mouth ulcers in Behcet's Disease, such as corticosteroids, have significant side effects. ABI's non-toxic oral interferon product potentially represents a substantial improvement in the treatment of the mouth ulcers suffered by virtually all Behcet's Disease patients.

Enrollment in Phase 2 Clinical Trial of Oral Warts in HIV+ Patients

Three more clinical sites have agreed to join the six clinical sites currently approved to enroll patients in a study of HIV+ patients suffering from oral warts. This placebo-controlled Phase 2 study is a follow-up to two successful studies that have already been completed. In the most recent study, 57% of HIV patients given the optimum dose of oral interferon experienced a complete or almost complete clearance of their oral warts. No products are currently approved by the FDA for this condition, so treatment of oral warts represents a unique market for ABI. As of today's date, 7 of 80 planned subjects have been enrolled. The goal is to complete the study in 2007.

Separately, the company announced that its annual shareholder's meeting will be held in Amarillo, Texas on Friday, June 22, 2007. The location and time of the meeting will be included in the proxy statements.

About Amarillo Biosciences, Inc.

...


Copyright 2007 Market Wire, All rights reserved.

[Turboverdichter]

Antwort auf Beitrag Nr.: 28.420.020 von Turboverdichter am 21.03.07 21:16:43

AMARILLO BIOSCIENCE AMAR (BB)


Last Change / Pct Change
0.895 0.045 / 5.29 %

[Turboverdichter]

03/29/2007

Amarillo Biosciences Posts Annual Results; Reiterate Speculative Buy

Amarillo Biosciences, Inc. (OTCBB: AMAR), lost $2.8 million, or $0.12 per share, in 2006 on operating expenses of $2.8 million. This compares with a loss of $0.7 million, or $0.04 per share, in 2005 on operating expenses of $0.7 million. We had projected that Amarillo Biosciences would lose $3.1 million, or $0.14 per share, in 2006 on operating expenses of $3.0 million.
For the final quarter of 2006, Amarillo Biosciences lost $0.4 million, or $0.02 per share, on operating expenses of $0.4 million. This compares with a loss of $0.2 million, or $0.02 per share, in 4Q05 on operating expenses of $0.2 million. We had projected that Amarillo Biosciences would lose $0.8 million, or $0.03 per share, in 4Q06 on operating expenses of $0.8 million.
Amarillo Biosciences ended 2006 with $0.2 million in cash equivalents, about the same as the end of 2005. The Company's working capital deficit reached $2.5 million by the end of 2006, again about the same as the prior yearend.
We reiterate our September 18 Speculative Buy rating on Amarillo Biosciences' stock and maintain a price target of $1.90 per share
with a target date of April 2008. This rating assumes that the Company will achieve its clinical goals or license or sell one or more of its development programs within the target time frame.
We will publish our regular update on Amarillo Biosciences with revised financial and clinical projections in the near future.

[Turboverdichter]

Antwort auf Beitrag Nr.: 28.575.562 von Turboverdichter am 29.03.07 23:41:08

Dutton hat gesprochen!

[CFalko]

Noch jemand da?
Wann geht hier wieder was?

[Turboverdichter]

Antwort auf Beitrag Nr.: 28.645.550 von CFalko am 03.04.07 18:37:47

Ich bin immer da!

Wenn du noch ein bisschen warten kannst, dann geht die Party ab!

[Turboverdichter]

Amarillo Biosciences to Be Featured in Exclusive MN1.com Interview
Tuesday April 03, 2007 08:50:31 EDT


AMARILLO, TX, Apr 03, 2007 (MARKET WIRE via COMTEX News Network) --
Joseph Cummins, CEO of Amarillo Biosciences, Inc. (OTCBB: AMAR), will join Market News First for an interview scheduled for Tuesday, April 3, 2007 at 10:15 a.m. CDT at www.mn1.com.

Amarillo Biosciences is focused on the research and development activities to develop biologics for the treatment of human and animal diseases.

Among topics of interest, Cummins will talk about the Company's ongoing clinical studies of the Turkish Behcet's Disease and the Phase II clinical trial of oral warts in HIV positive patients.

Other Amarillo Biosciences news includes its annual shareholders' meeting to take place in June and its intentions to establish commercial partnerships and licenses in 2007.

To learn more about the Company, its goals toward progression and success, log on to www.mn1.com Tuesday, April 3.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

About MN1.com

Market News First is an online market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: [e-mail]
Tel: [phone]
Fax: [phone]Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: [e-mail]
Tel: [phone] x 13
Fax: [phone]
SOURCE: Amarillo Biosciences, Inc.

[e-mail]
mailto:[e-mail]
Copyright 2007 Market Wire, All rights reserved.

[xTRADERx]

Antwort auf Beitrag Nr.: 28.647.283 von Turboverdichter am 03.04.07 20:01:42

gerade reingekommen - mit den links zum interview:


Amarillo Biosciences CEO Featured in Exclusive Interview with WallSt.net

PR Newswire -- April 4, 2007

NEW YORK, April 4 /PRNewswire/ -- On March 26, Joseph Cummins, Chief
Executive Officer for Amarillo Biosciences, Inc. (OTC Bulletin Board:
AMAR) updated the investment community in an exclusive interview with
www.wallst.net . Topics covered in the interview include an overview of
the Company and the markets it serves, recent press releases, current
capitalization, upcoming strategic and financial milestones.

To hear the interview in its entirety, visit www.wallst.net , and click
on "Interviews." The interview can be accessed either by locating the
company's ticker symbol under the appropriate exchange on the left-hand
column of the "Interviews" section of the site, or by entering the
company's ticker symbol in the Search Archive window.

About Amarillo Biosciences:

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in
global partnership with the Hayashibara Group, which also holds 13% of
Amarillo Biosciences shares and has provided over $17.8 million in
loans, grants and equity investments. The Company's primary focus is
extensive and ongoing R&D into the use of low-dose, orally administered
interferon as a treatment for a variety of conditions, including
Sjogren's syndrome, Behcet's disease, and opportunistic infections in
patients who are HIV positive. In its 22-year history, ABI has invested
nearly $38 million to establish oral interferon as a therapeutic agent.
The majority of those funds were invested in clinical trials in an
effort to achieve FDA approval for oral interferon therapies. Additional
information is available on the ABI web site at http://www.amarbio.com/


About WallSt.net:

www.wallst.net is owned and operated by WallStreet Direct, Inc., a
wholly owned subsidiary of Financial Media Group, Inc. The website is a
leading provider of financial news, media, tools and community-driven
applications for investors. www.wallst.net offers visitors free
membership to its in-depth executive interviews, exclusive editorial
content, breaking news, and several proprietary applications. In
addition to its website, WallStreet Direct organizes investor
conferences, publishes a newspaper, and provides multimedia advertising
solutions to small and mid-sized publicly traded companies. We are
expecting to receive two hundred eighty dollars from Amarillo
Biosciences, Inc. for the dissemination of this press release. For a
complete list of our advertisers, and advertising relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp .

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )

CO: WallStreet Direct, Inc.; Amarillo Biosciences, Inc.
ST: New York
IN: MTC BIO FIN OTC
SU:

[xTRADERx]

Antwort auf Beitrag Nr.: 28.660.983 von xTRADERx am 04.04.07 15:53:08

www.wallst.net

sorry

dann auf suche und AMAR eingeben

[Turboverdichter]

Neuer Report von Dutton!

http://www.jmdutton.com/research/amar/reports/amar_report_04…

[xTRADERx]

Auch wenn der Thread hier fast eingeschlafen ist....hier ne News von Amarillo.

Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C Research and Behcet’s Disease and Oral Warts Phase 2 Trials



Amarillo, Texas, May 2, 2007 - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following progress report on its influenza research, on plans for a study in 150 patients with hepatitis C, and on its Phase 2 clinical trials in Behcet’s disease and oral warts in HIV positive patients. The Company also provided information on its forthcoming Annual Meeting.



Influenza Research



Working in collaboration with ABI, Australian and United States researchers conducted a number of studies over the past 15 months exploring the efficacy of low-dose oral interferon against mouse-adapted influenza virus. A leading German research institute has continued this research the past six weeks, challenging laboratory mice with varying doses of an avian influenza strain known as fowl plague virus. Preliminary findings have shown that low-dose oral interferon provides a significant survival benefit against a fatal challenge of this virus. Moreover, when a less-than-fatal dose of the virus was introduced in mice, treatment with oral interferon (compared to placebo) resulted in less weight loss and fewer signs of disease. More work to confirm these findings will be carried out in Germany and Australia in coming weeks. ABI plans to present results of these studies - along with data from other animal research in Australia, Europe and the U.S. - as part of its campaign to gain consideration of oral interferon therapy in the debate over how best to cope with a potential flu pandemic.



Hepatitis C Study in Taiwan



In November 2006, CytoPharm, Inc, a Taipei, Taiwan-based biopharmaceutical company, entered into a license and supply agreement with ABI. Under terms of that agreement, CytoPharm has selected hepatitis C as the focus of its first human clinical study. The company earlier had licensed the clinical indications of influenza and hepatitis B. CytoPharm told ABI it hopes to begin enrollment in the 150 patient study of low-dose oral interferon in the fourth quarter of 2007. Current standard therapy for hepatitis C is usually high-dose injectable interferon and ribavirin. Low-dose oral interferon would represent a less toxic and more affordable alternative.



Behcet’s Disease Study Adds Two New Sites in Turkey



In an effort to accelerate the completion of its Phase 2 clinical trial on Behcet’s disease, an autoimmune disorder, Nobel Ilac Sanayii Ve Ticaret A.S., ABI’s Middle Eastern partner, expects to start enrollment this month of Behcet’s disease patients at two new clinical sites in Turkey. Nobel has enrolled 62 patients to date, and expects to achieve the full 90-patient enrollment by September. The study is targeted for completion by year-end 2007.



The double-blinded Phase 2 study is testing the efficacy of interferon lozenges versus placebo in the treatment and prevention of mouth ulcers suffered by virtually all Behcet’s disease patients. ABI’s non-toxic oral interferon represents a significant potential improvement over corticosteroids and other treatment products, which have significant side effects.



Enrollment in Phase 2 Clinical Trial of Oral Warts in HIV+ Patients



Three more clinical sites - in Philadelphia, Fort Lauderdale and Newark - have agreed to join the six previously announced sites approved to enroll patients in a study of HIV+ patients suffering from oral warts, a papillomavirus infection. This placebo-controlled Phase 2 study is a follow-up to two successful studies that have already completed. In the latest study, 57% of HIV+ patients given the optimum dose of oral interferon experienced complete or near complete clearance of their oral warts. As of May 1, 2007, 10 of 80 planned subjects had been enrolled in the new study; complete enrollment is expected by year-end. No products are currently approved by the FDA for this condition, so treatment of oral warts represents a unique market for ABI.



Separately, Amarillo Biosciences announced that its annual shareholders’ meeting will be held at 7 p.m. CDT on Friday, June 1, 2007, at the Ambassador Hotel, 3100 I-40 West, in Amarillo, Texas.



About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.



Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--



Greetz

xTRADERx

[Turboverdichter]

Antwort auf Beitrag Nr.: 29.099.618 von xTRADERx am 02.05.07 18:41:50

DANKE!

Ja, hier führt man oft Monologe!

[kleinerBiber]

Antwort auf Beitrag Nr.: 29.102.118 von Turboverdichter am 02.05.07 20:59:05

Hi,

Glaube ich muß mir noch ein paar abgreifen.....so ein Bauchgefühl...!!!

[Turboverdichter]

05/12/2007

Amarillo Biosciences Reports First Quarter Results; Reiterate Speculative Buy

Amarillo Biosciences (OTCBB: AMAR) reported a loss of $745,000, or $0.03 per share, in the first quarter of 2007 on operating expenses of $765,000. This compares with a loss of $771,000, or $0.04 per share, in the same quarter a year earlier on
operating expenses of $778,000. We had projected a loss of $975,000, or $0.04 per share in 1Q07 on operating expenses of
$983,000. R&D expenses were higher than a year earlier due to the start of enrollment in the Company's Phase 2 oral warts studies in the U.S. SG&A expenses were lower in 1Q07 than in the prior year's 1Q due to a one-time stock grant in 1Q06. Otherwise, SG&A would have been higher in 1Q07 than in the same quarter in the prior year as costs in every category posted increases.
Cash and cash equivalents decreased to $156,000 from $214,000 at the end of 2006 and from $379 in 1Q06. Amarillo reported a working capital deficit of $2.6 million, an increase from $2.5 million at the end of 2006 and from $2.2 million in 1Q06.
We reiterate our September 18 Speculative Buy rating on Amarillo Biosciences' stock and maintain a price target of $1.90 per
share with a target date of April 2008. This rating assumes that the Company will achieve its clinical goals or license or sell one or more of its development programs within the target time frame.
We will update our financial projections and the Company's prospects in a report scheduled for publication in the near future.

[Turboverdichter]

Antwort auf Beitrag Nr.: 29.501.352 von Turboverdichter am 28.05.07 14:07:37

Dutton von Mitte Mai

[ducatiman]

Antwort auf Beitrag Nr.: 19.798.779 von xTRADERx am 20.01.06 11:39:24

Email a Friend Print

SOURCE: Amarillo Biosciences, Inc.

May 31, 2007 11:07 ET
CytoPharm to Conduct Hepatitis C Trial and Seek Regulatory Approval for Amarillo Biosciences' Low Dose Oral Interferon
AMARILLO, TX--(Marketwire - May 31, 2007) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that CytoPharm Inc., ABI's partner in Taiwan and China, has engaged a Clinical Research Organization (CRO) to conduct a clinical trial of 152 chronic hepatitis C patients. The patients, 38 per group, will receive one of three different dosages of oral human interferon alpha or placebo. The patients must have failed to respond to injectable interferon, or relapsed after initially responding to injectable interferon. The standard of care for chronic hepatitis C is high dose (millions of IU) of human interferon alpha injected alone or in combination with Ribavirin. Typically, only about 50% of hepatitis C patients respond to the standard of care. The trial is expected to start in the 4th quarter of 2007.

Approximately 170 million people are chronically infected with hepatitis C virus worldwide. The incidence of cirrhosis in chronic hepatitis C patients is 10% to 20% and 1% to 5% develop liver cancer. Infections are transmitted primarily by direct contact with blood through transfusions not screened for hepatitis C virus, inadequately sterilized needles and syringes, sexual and perinatal transmission. There is no effective vaccine against hepatitis C virus.

In addition to studies on hepatitis C, under the terms of the License and Supply Agreement, CytoPharm will be testing oral interferon in human studies of chronic active hepatitis B patients and of influenza patients.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences shares and has provided over $12.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

About CytoPharm

CytoPharm is a closely held company focusing on the development of biopharmaceuticals for virus-infected diseases and cancers. It was founded in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. It acquired core technologies from Gene Trol Therapeutics, Inc., a California-based company through M&A. Its product pipelines contain a series of cytokines induced by its proprietary technologies, used for hepatitis, and cancers. Currently, its product is under clinical trials in China. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: Email Contact
Tel: [phone]
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: Email Contact
Tel: [phone] x 13
Fax: [phone]

[kleinerBiber]

News 06/06/2007 12:15PM - Business Wire

Dutton Associates Announces Investment Opinion: Amarillo Biosciences Rating Maintained At Speculative Buy By Dutton Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--

Dutton Associates continues its coverage of Amarillo Biosciences (OTCBB:AMAR) maintaining a Speculative Buy rating and a price target of $1.90. The 10-page report by Dutton senior analyst Wayne T. Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Amarillo Biosciences is a biopharmaceutical company developing low-dose oral natural human interferon-alpha as a safe, cost-effective therapy for several diseases or their symptoms, including influenza and HIV-related oral warts. Interferon is known for its antiviral activity and immunomodulating effects. The distinct advantages and characteristics of Amarillo Biosciences' interferon are its oral delivery and safety. Low-dose interferon-alpha is administered orally as a lozenge, which, importantly, is not swallowed, but is allowed to dissolve slowly in the mouth. Amarillo Biosciences has a Phase 2 clinical investigation using oral low-dose interferon-alpha for Behcet's disease and a Phase 2 clinical trial to treat oral warts in HIV-positive patients now underway. Recently, CytoPharm Inc., Amarillo Biosciences' partner in Taiwan, announced it will conduct a clinical trial to test low-dose oral interferon alpha in chronic hepatitis C patients. Amarillo Biosciences has been granted Orphan Drug Designation by the FDA for several of its development programs. Besides orphan drugs, one of the Company's real potential money-makers is using oral interferon for the treatment of influenza.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 09/18/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Source: Amarillo Biosciences

[Turboverdichter]

Schön, dass man hier nicht ganz alleine ist und immer mit News versorgt wird! DANKE!

[xTRADERx]

Antwort auf Beitrag Nr.: 29.883.035 von Turboverdichter am 13.06.07 23:07:07

Na, dann hier noch ne News:

Amarillo Biosciences Announces Upcoming Clinical Trial of Oral Interferon Therapy for Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKETWIRE) -- 06/15/07

http://media.marketwire.com/attachments/200501/199298_Amaril…
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Lorenz Lutherer, MD, PhD, Texas Tech University Health Services Center (TTUHSC) has been granted funding from the School of Medicine of TTUHSC to conduct a study on oral interferon therapy for chronic cough in patients with chronic obstructive pulmonary disease (COPD). The funding from the university will be available on September 1, 2007. Accordingly, ABI will immediately commence preparation of the Investigational New Drug (IND) application to the FDA. Clinical supplies of interferon lozenges and placebo will be packaged for the double-blinded, randomized clinical study.

Treatment with oral interferon or a placebo preparation will be three times per day for 4 weeks with 4 weeks of post-treatment observation to test the duration of any effect observed. The primary endpoint will be reduction in cough frequency/severity. Digital recordings will assess cough frequency and visual analog scale (VAS) will assess cough severity. Possible effects on the quality of life with suppression of the cough will also be assessed.

Dr. Lutherer noted that, "In our previous study in patients with idiopathic pulmonary fibrosis (IPF), we found preliminary evidence that treatment with oral interferon suppressed the chronic cough associated with that disease, so we are hopeful that it will have a similar effect in patients with COPD."

COPD is caused by damage to the small airways, usually due to smoking. COPD is reported to affect 10% of humans over the age of 40. By the year 2030, the World Health Organization (WHO) predicts that COPD will become the fourth most common cause of death, behind only heart disease, cerebrovascular disease and HIV/AIDS. COPD is the only common cause of death in the United States that has increased over the last 40 years in sharp contrast to the reduction in cardiovascular and infectious diseases.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Bioscience's shares and has provided over $12.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: Email Contact

Tel: [phone]

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail: Email Contact

Tel: [phone] x 13

Fax: [phone]




Greetz

xTRADERx

[xTRADERx]

Und noch eine....scheint hier irgendwie keinen zu interessieren...oder?

Verfolgt irgendwer noch AMARILLO?

Amarillo Biosciences Announces Two Additional Clinical Sites for Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKETWIRE) -- 06/21/07

http://media.marketwire.com/attachments/200501/199298_Amaril…
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that by the end of June, two new clinical sites -- in Newark, New Jersey and Philadelphia, Pennsylvania -- will be ready to enroll patients in a Phase 2 study to test low-dose interferon alpha lozenges administered orally to HIV-positive subjects with oral warts. The Company's goal is to add five more clinical sites in the next 90 days to ensure the timely enrollment and completion of the study.

Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is a group of DNA viruses, human papilloma viruses, which induce hyperplastic lesions in the oral soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia. Oral warts cause a significant reduction in quality of life due to their deleterious effects on patient appearance and potential for causing discomfort during routine activities such as eating and talking. Current treatment modalities include physical interventions such as cryosurgery, electrocoagulation, CO2 laser and excision; however, the rate of recurrence is high.

Two previous studies demonstrated the ability of interferon alpha lozenges to significantly reduce oral wart load in HIV-positive patients. If, as anticipated, ABI's new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase 3 study before filing an NDA (New Drug Application), seeking marketing approval for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.

Clinical sites in Baltimore, Boston, Chicago, Dallas, New York and San Francisco are already open for enrollment. In all, 80 patients will be enrolled in a study in which treatment will last 24 weeks. Interested patients are urged to contact Martin Cummins, Director of Clinical and Regulatory Affairs at 806-376-1741 ext. 14 or email [e-mail].

The FDA's Office of Orphan Products Development has granted Orphan Drug Designation to ABI for natural human lymphoblastoid interferon-alpha in the treatment of papillomavirus warts in the oral cavity of HIV-positive patients.

"Although anti-HIV drugs are quite helpful against most opportunistic infections in patients with HIV, the prevalence of papillomavirus, in the mouth and elsewhere, is increasing. Our Company's mission is to obtain FDA approval for our low-dose oral interferon Alpha to treat oral warts and other diseases," said Dr. Joseph M. Cummins, President and CEO, ABI. "This Phase 2 clinical study in conjunction with our ongoing Phase 2 clinical study in Turkey on Behcet's disease, are two important steps in attaining our objective," added Dr. Cummins.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 15.5% of Amarillo Biosciences shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: Email Contact

Tel: [phone]

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail: Email Contact

Tel: [phone] x 13

Fax: [phone]




Greetz

xTRADERx

Do your own DD!

[Turboverdichter]

Antwort auf Beitrag Nr.: 30.101.468 von xTRADERx am 21.06.07 21:07:31

Doch mich! Ich bin dick investiert und ganz gespannt!

Danke für die News!

[ducatiman]

Antwort auf Beitrag Nr.: 30.101.468 von xTRADERx am 21.06.07 21:07:31

Ich auch etwas, aber kaum Zeit.

Jun 21, 2007 16:52 ET
Amarillo Biosciences to Be Featured Live on Market News First on June 22
AMARILLO, TX--(Marketwire - June 21, 2007) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Joseph Cummins, President & CEO, will be featured on Market News First (www.mn1.com). The exclusive interview with the MN1 news team is scheduled for 12:15 PM EDT on June 22. Dr. Cummins will be reviewing information about the Company's last two news releases on June 15 and June 21. These news releases reported on an upcoming clinical trial on chronic cough and additional new clinical sites for the on-going Phase 2 study in HIV+ patients with oral warts.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

About Market News First (www.mn1.com)

Market News First is an online market news provider that brings investors current news on the market. Market News First is the only online live radio web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE. Through daily live pressers, Market News First brings you up to date on all the established companies and informs the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: Email Contact
Tel: [phone]
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: Email Contact
Tel: [phone] x 13
Fax: [phone]

[kleinerBiber]

Antwort auf Beitrag Nr.: 30.101.468 von xTRADERx am 21.06.07 21:07:31

Hi,

bin auch noch da........und kaufe immer noch ein....!!!!

Tschüß

[margier]

Antwort auf Beitrag Nr.: 30.101.468 von xTRADERx am 21.06.07 21:07:31

wie gesagt mit Geduld kommt irgendwann der Erfolg, "low dose interferon" wird sicher noch der Renner werden.

[kleinerBiber]

Hui,

verlieren mit kleinsten Mengen die hälfte Ihres Marktkapitals.

Wenn da eine Meldung kommt, fliegt die Kuh.....!!!!

Tschüß Ihr Lieben.......!!!!

[xTRADERx]

Und nochmal Amarillo....

Amarillo Biosciences Retains Investment Banking Firm Commonwealth Associates
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKETWIRE) -- 07/24/07

http://media.marketwire.com/attachments/200501/199298_Amaril…
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has retained Commonwealth Associates to provide general financial consulting services and assist with capital formation to accelerate ABI's ongoing Phase 2 clinical trials in oral warts in HIV+ patients and its Behcet's Disease study.

Separately, ABI announced that it has agreed to provide oral interferon to be tested as a treatment of chronic coughing associated with chronic obstructive pulmonary disease (COPD). Texas Tech University Health Sciences Center has granted funding to Dr. Lorenz Lutherer, MD, PhD, who will serve as principal investigator. The study, which is scheduled to commence in the fall of 2007, will involve 40 patients with COPD. ABI will work with Commonwealth Associates to secure funding to launch a second larger study in COPD patients as soon as positive effects of oral interferon on chronic coughing are observed in this initial study.

COPD is caused by damage to the small airways, usually due to smoking. By the year 2030, the World Health Organization predicts that COPD will become the fourth most common cause of death, behind only heart disease, cerebrovascular disease and HIV/AIDS. COPD is the only common cause of death in the United States that has increased over the last 40 years in sharp contrast to the reduction in the prevalence of cardiovascular and infectious diseases. Coughing is currently treated by antitussives, local anesthetics, expectorants, demulcents, antihistamines, bronchodilators and dietary supplements, but none are effective against chronic coughing in COPD.

"Oral interferon has been shown to relieve chronic cough in patients with Sjogren's syndrome and idiopathic pulmonary fibrosis," said Dr. Joseph Cummins, President, CEO. "COPD chronic cough represents an excellent market opportunity for ABI because present treatments are marginally beneficial and the market -- with 15 million afflicted in the United States alone -- is estimated at $1 billion annually," said Tom D'Alonzo, ABI Board member and former President of Glaxo USA.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences' shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

About Commonwealth Associates

Commonwealth Associates was founded in 1988 and is dedicated to creating long-term value for its corporate clients and investors. The firm's vision is to act as a strategic partner, providing capital, advisory services, contacts and strategic direction to maximize the success of each company. Additional information is available on the Commonwealth Associates website at www.comw.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: Email Contact

Tel: [phone]

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail: Email Contact

Tel: [phone] x 13

Fax: [phone]

[Turboverdichter]

HIER BRAUCHT MAN ECHT NERVEN!

[xTRADERx]

Mich kotzt das auch echt an...sch**ss Sommerloch.

Alles dümpelt nur so vor sich hin mit negativem Trend.


Wird Zeit dass wieder Herbst wird....



Greetz

xTRADERx

[xTRADERx]

News gibts trotz Sommerloch; gerade frisch reingekommen:

Amarillo Biosciences Plans a Human Influenza Clinical Trial in Perth, Australia



Amarillo, Texas, August 2, 2007 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has agreed to conduct human influenza research with Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, The University of Western Australia. “We have been collaborating with Dr. Beilharz for more than 10 years”, said Dr. Cummins, CEO of ABI. “During that time, Dr. Beilharz has published 10 scientific papers or abstracts on the low-dose, oral use of interferon. We are pleased to extend our research collaboration with Dr. Beilharz. His exciting discoveries regarding how oral interferon can protect against influenza are critically important as the world prepares for the next influenza pandemic,” said Dr. Joseph Cummins.



Recent publications from Freiburg, Germany by scientists (Grimm, et al. Proceeding National Academy of Sciences, April 2007) and from (Tumpey, et al. the Centers of Disease Control (CDC) and Prevention in Atlanta, J Virology, July 2007) report that a single dose of interferon placed in the nose of mice reduces mortality from 50% to 0% (CDC) or 100% to 0% (Germany) in H5N1 (“Bird flu”) influenza (CDC) or unique virulent influenza (Germany) infections.



“We published earlier in 2007 that interferon in the mouth protects mice against fatal influenza,” said Professor Beilharz. “We used a concentration of interferon similar to that used by CDC and also reported that a dosage 100 times less was also protective against fatal influenza infection in mice. Our goal from new animal research is to determine the optimal dose and timing of administration of oral interferon so we can more carefully design human clinical trials. These human clinical trials will not only address the influenza issue, but will also address a new approach to winter colds and flu-like conditions,” said Professor Beilharz.



Perth is a city in Western Australia with 2 million residents. The clinical study will be conducted there in childcare workers, school teachers and hospital workers who will be naturally exposed to infections of influenza and other respiratory pathogens. Some subjects will take placebo daily during the next “flu season” and others will take oral interferon at the dosages covered by ABI’s issued US patents. Besides ABI’s patented dose formulation, two of ABI’s issued US patents have claims which directly apply to the low-dose oral use of interferon for influenza.



About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.



Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--







Greetz

xTRADERx

Do your own DD!

[Turboverdichter]

Antwort auf Beitrag Nr.: 30.988.475 von xTRADERx am 02.08.07 18:06:56

Meine Kohle schmilzt hier wie Eis in der Sonne! Wir brauchen hier noch einen seeeehr langen Atem!

[xTRADERx]

Antwort auf Beitrag Nr.: 30.988.568 von Turboverdichter am 02.08.07 18:11:44

Da bist Du nicht allein Turbo....ich denke mal "Durchhalten" heisst die Devise. Auch wenn's mich ank*tzt...

Hey, drüben 10% hoch....bei phänomenalen 3.300 Stücken...



Greetz

xTRADERx

Do your own DD!

[Turboverdichter]

Antwort auf Beitrag Nr.: 30.988.621 von xTRADERx am 02.08.07 18:15:17

Also Dutton scheint Amarillo nicht mehr weiter zu "begleiten"... ist das ein schlechtes Zeichen?

[Turboverdichter]

Antwort auf Beitrag Nr.: 31.166.886 von Turboverdichter am 15.08.07 11:57:07

08/09/2007

Amarillo Biosciences Inc.: Termination Of Research Coverage
Effective immediately, Dutton Associates terminates research coverage of Amarillo Biosciences Inc. (AMAR).

[xTRADERx]

Antwort auf Beitrag Nr.: 31.177.117 von Turboverdichter am 15.08.07 23:26:05

Keine Ahnung wegen Dutton - wenn ich mir manche von den anderen Unternehmen angucke, die von Dutton gecovert werden dann könnte das sogar eher positiv sein

Naja, jedenfalls nochmal News bzw. ein Update von Amarillo:

Amarillo Biosciences Recaps Progress in 2007
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKET WIRE) -- 08/24/07

http://media.marketwire.com/attachments/200501/199298_Amaril…
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced the following developments:

In Turkey, enrollment is 78% complete in a Phase 2 study of Behçet's disease. In the United States, patients have been enrolled to date in a Phase 2 clinical trial of oral warts. In Australia, a human influenza study is planned in 2008. In Taiwan and China, ABI's Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the Company's ultimate goal: FDA approval for its low-dose oral interferon.

Behçet's Disease Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Enrollment in Turkey for Behçet's disease currently stands at 70 patients. Ninety patients are required in order to complete the Phase 2 clinical trial. Enrollment is expected to be completed in the fall of 2007, and data analysis will begin approximately 12 weeks after the last patient is enrolled. The Company's Turkish partner Nobel Ilac, one of the largest pharmaceutical companies in Turkey, is funding the study. Nobel Ilac may be able to use the Phase 2 data to seek approval in Turkey, assuming the data are compelling.

Oral Warts Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Our Phase 2 clinical trial is testing low-dose interferon alpha lozenges administered orally to subjects who have oral warts and are also positive for human immunodeficiency virus (HIV). Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is an oral infection with the wart-producing papillomavirus.

Eight clinical sites in San Francisco, Baltimore, Chicago, New York City, Boston, Philadelphia, Newark and Dallas are open for enrollment of patients for this study. Four new sites in Lexington, San Antonio, Ft. Lauderdale and Augusta are expected to begin enrollment in September 2007.

CytoPharm Plans for Hepatitis C Clinical Trial

The Company's licensee in Taiwan and China is CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.

Under the terms of the Agreement, between CytoPharm and ABI, CytoPharm and its subsidiary will conduct and fund all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch low dose oral interferon for influenza, hepatitis B, and hepatitis C indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct their first clinical trial in 152 hepatitis C patients. The trial is expected to commence in late 2007 or early 2008.

Texas Tech University Idiopathic Pulmonary Fibrosis and COPD Studies

Eighteen patients were enrolled in a pilot study of the use of interferon lozenges in the treatment of idiopathic pulmonary fibrosis (IPF) at Texas Tech University. Dr. Lutherer reported that more than half of his patients treated for at least one year showed no signs of disease progression as assessed by pulmonary-function testing and high-resolution CT scans of their lungs. IPF is normally rapidly progressive, so the fact that half of the patients have shown no progression of the disease during interferon lozenge treatment is encouraging. These clinical results are being submitted for publication to a major medical journal.

However, the most surprising observation from the IPF research is that low-dose oral interferon relieves chronic coughing in patients with IPF. Since chronic coughing is a major problem in Chronic Obstructive Pulmonary Disease (COPD), a Phase 2 clinical study of oral interferon treatment of chronic cough in COPD will begin in September 2007.

COPD is reported to affect 10% of humans over the age of 40. Because COPD affects many millions of people and is not an Orphan Disease (a disease that affects fewer than 200,000 people in the U.S.), the study of COPD would require a large study population and is, therefore, too costly for the Company to study beyond Phase 2 without a pharmaceutical partner. If the clinical data from Phase 2 are as positive as expected, these Phase 2 data will be shared with potential pharma partners.

Federal Funding

Amarillo Biosciences retained Hance, Scarborough, Wright, Woodward & Weisbart an Austin-based law firm to represent the Company regarding federal governmental and private source funding for influenza studies. The Company is working to obtain federal funding for clinical trials on influenza to be conducted in 2008. University institutions such as the Texas Tech University Health Sciences Center would conduct these trials. Beyond these efforts to procure federal funding, the Company seeks investor funding so that it can complete its clinical studies.

Influenza

Animal trials were conducted in 2006/2007 in Australia, USA and Germany. An oral dose of interferon was found which protected mice against a fatal influenza challenge. A human trial is planned in Perth, Australia in 2008. Dr. Manfred Beilharz, the principal investigator, was in Amarillo this month to work on the clinical protocol with staff from the Company.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences' shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the company web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: [e-mail]

Tel: [phone]

212-344-6464

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail:[e-mail]

Tel: [phone] x 13

Fax: [phone]




Greetz

xTRADERx

Do your own DD!

[Turboverdichter]

Antwort auf Beitrag Nr.: 31.285.891 von xTRADERx am 24.08.07 20:01:41

...wenn ich mir manche von den anderen Unternehmen angucke, die von Dutton gecovert werden dann könnte das sogar eher positiv sein...


Da gebe ich dir Recht!!

[Kostobeeky]

Ob man jetzt noch seinen Einstandskurs verbilligen sollte?



Kosto

[Turboverdichter]

Sieht hier eher nach baldigem Totalverlust aus!

[Turboverdichter]

[Turboverdichter]

Amarillo Biosciences Recaps Progress in 2007

Amarillo, Texas, August 24, 2007 —Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced the following developments:

In Turkey, enrollment is 78% complete in a Phase 2 study of Behçet’s disease. In the United States, patients have been enrolled to date in a Phase 2 clinical trial of oral warts. In Australia, a human influenza study is planned in 2008. In Taiwan and China, ABI’s Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the Company’s ultimate goal: FDA approval for its low-dose oral interferon.

Behçet’s Disease Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Enrollment in Turkey for Behçet’s disease currently stands at 70 patients. Ninety patients are required in order to complete the Phase 2 clinical trial. Enrollment is expected to be completed in the fall of 2007, and data analysis will begin approximately 12 weeks after the last patient is enrolled. The Company’s Turkish partner Nobel Ilac, one of the largest pharmaceutical companies in Turkey, is funding the study. Nobel Ilac may be able to use the Phase 2 data to seek approval in Turkey, assuming the data are compelling.

Oral Warts Double-blinded, Placebo-controlled Phase 2 Clinical Trial

Our Phase 2 clinical trial is testing low-dose interferon alpha lozenges administered orally to subjects who have oral warts and are also positive for human immunodeficiency virus (HIV). Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is an oral infection with the wart-producing papillomavirus.

Eight clinical sites in San Francisco, Baltimore, Chicago, New York City, Boston, Philadelphia, Newark and Dallas are open for enrollment of patients for this study. Four new sites in Lexington, San Antonio, Ft. Lauderdale and Augusta are expected to begin enro llmentinSeptember2007.

CytoPharm Plans for Hepatitis C Clinical Trial

The Company’s licensee in Taiwan and China is CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2005 revenues exceeded NTD 35 billion.

Under the terms of the Agreement, between CytoPharm and ABI, CytoPharm and its subsidiary will conduct and fund all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch low dose oral interferon for influenza, hepatitis B, and hepatitis C indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct their first clinical trial in 152 hepatitis C patients. The trial is expected to commence in late 2007 or early 2008.

Texas Tech University Idiopathic Pulmonary Fibrosis and COPD Studies

Eighteen patients were enrolled in a pilot study of the use of interferon lozenges in the treatment of idiopathic pulmonary fibrosis (IPF) at Texas Tech University. Dr. Lutherer reported that more than half of his patients treated for at least one year showed no signs of disease progression as assessed by pulmonary-function testing and high-resolution CT scans of their lungs. IPF is normally rapidly progressive, so the fact that half of the patients have shown no progression of the disease during interferon lozenge treatment is encouraging. These clinical results are being submitted for publication to a major medical journal.

However, the most surprising observation from the IPF research is that low-dose oral interferon relieves chronic coughing in patients with IPF. Since chronic coughing is a major problem in Chronic Obstructive Pulmonary Disease (COPD), a Phase 2 clinical study of oral interferon treatment of chronic cough in COPD will begin in September 2007.

COPD is reported to affect 10% of humans over the age of 40. Because COPD affects many millions of people and is not an Orphan Disease (a disease that affects fewer than 200,000 people in the U.S.), the study of COPD would require a large study population and is, therefore, too costly for the Company to study beyond Phase 2 without a pharmaceutical partner. If the clinical data from Phase 2 are as positive as expected, these Phase 2 data will be shared with potential pharma partners.

Federal Funding

Amarillo Biosciences retained Hance, Scarborough, Wright, Woodward & Weisbart an Austin-based law firm to represent the Company regarding federal governmental and private source funding for influenza studies. The Company is working to obtain federal funding for clinical trials on influenza to be conducted in 2008. University institutions such as the Texas Tech University Health Sciences Center would conduct these trials. Beyond these efforts to procure federal funding, the Company seeks investor funding so that it can complete its clinical studies.

Influenza

Animal trials were conducted in 2006/2007 in Australia, USA and Germany. An oral dose of interferon was found which protected mice against a fatal influenza challenge. A human trial is planned in Perth, Australia in 2008. Dr. Manfred Beilharz, the principal investigator, was in Amarillo this month to work on the clinical protocol with staff from the Company.



About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences’ shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the company web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--

[Xavox]

AMARILLO, Texas, Oct 09, 2007 (BUSINESS WIRE) --
Amarillo Biosciences, Inc. (ABI) (OTCBB:AMAR) today announced the following developments:

In Turkey, enrollment is 86% complete in a Phase 2 study of Behcet's disease. In the United States, four new clinical sites have been opened to enroll patients in a Phase 2 clinical trial of oral warts. In Texas, enrollment will begin in October 2007 to test oral interferon as a treatment of chronic cough in COPD (chronic obstructive pulmonary disease) patients. In Australia, a human influenza study is planned in 2008. In Taiwan and China, ABI's Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the company's ultimate goal: FDA approval for its low-dose oral interferon.

Behcet's Disease Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial

Enrollment in Turkey for Behcet's disease currently stands at 77 patients. Ninety patients are required in order to complete the Phase 2 clinical trial. Enrollment is expected to be completed in the fall of 2007, and data analysis will begin approximately 12 weeks after the last patient is enrolled. The company's Turkish partner Nobel Ilac, one of the largest pharmaceutical companies in Turkey, is funding the study. Nobel Ilac may be able to use the Phase 2 data to seek approval in Turkey, assuming the data are compelling.

Oral Warts Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial

A Phase 2 clinical trial is testing low-dose interferon alpha lozenges administered orally to subjects who have oral warts and are also positive for human immunodeficiency virus (HIV). Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is an oral infection with the wart-producing papillomavirus.

Twelve clinical sites in San Francisco, Baltimore, Chicago, New York City, Boston, Philadelphia, Newark, Dallas, Augusta (GA), Ft. Lauderdale, San Antonio and Lexington (KY) are open for enrollment of patients for this study. To date, 26 of 80 patients have been enrolled. Enrollment is expected to accelerate rapidly now that all twelve sites have been approved.

CytoPharm Plans for Hepatitis C Clinical Trial

The company's licensee in Taiwan and China is CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan, and a publicly traded company.

Under the terms of the Agreement, between CytoPharm and ABI, CytoPharm and its subsidiary will conduct and fund all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch low-dose oral interferon for influenza, hepatitis B, and hepatitis C indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct their first clinical trial in 152 hepatitis C patients. The trial is expected to commence in early 2008.

Texas Tech University Idiopathic Pulmonary Fibrosis and COPD Studies

A total of 18 patients were enrolled in the past five years in a long-term pilot study of the use of interferon lozenges in the treatment of idiopathic pulmonary fibrosis (IPF) at Texas Tech University. Dr. Lutherer, the principal investigator of the study, reported that more than half of his patients treated for at least one year showed no signs of disease progression as assessed by pulmonary-function testing and high-resolution CT scans of their lungs. IPF is normally rapidly progressive, so the fact that half of the patients have shown no progression of the disease during interferon lozenge treatment is encouraging. These clinical results are being submitted for publication to a major medical journal.

The most surprising observation from the IPF research was that low-dose oral interferon relieved chronic coughing in five of six IPF patients assessed for cough in this study. Since chronic coughing is a major problem in Chronic Obstructive Pulmonary Disease (COPD), a Phase 2 clinical study of oral interferon treatment of chronic cough in COPD will begin this month. COPD is reported to affect 10% of humans over the age of 40.

Federal Funding

Amarillo Biosciences retained Hance, Scarborough, Wright, Woodward & Weisbart, an Austin-based law firm, to represent ABI regarding federal governmental and private source funding for influenza studies. The company is working to obtain federal funding for clinical trials on influenza to be conducted in 2008. University institutions such as the Texas Tech University Health Sciences Center would conduct these trials. Beyond these efforts to procure federal funding, the company seeks investor funding so that it can complete its clinical studies.

Influenza

Animal trials were conducted in 2006/2007 in Australia, USA and Germany, and are continuing in Germany. An oral dose of interferon was found, which protected mice against a fatal influenza challenge. A human trial is planned for the upcoming cold/flu season in Perth, Australia in July-October 2008.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences' shares and has provided over $17.9 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

SOURCE: Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., Amarillo Joseph M. Cummins, DVM, PhD, 806-376-1741, ext. 13 Fax: [phone] [e-mail] or Investor Relations: PAN Consultants, Ltd. Philippe Niemetz, 800-477-7570 or 212-344-6464 Fax: [phone] [e-mail]

Copyright Business Wire 2007

[Turboverdichter]

Über 17 % + drüben und schon fast 100.000 Shares umgesetzt...

Nach den ruhigen letzten Wochen fällt das direkt auf!

Kommt hier bald mal wieder Schwung in den Laden?

[Turboverdichter]

Antwort auf Beitrag Nr.: 31.929.914 von Turboverdichter am 10.10.07 19:25:31

Schluss mit +22 %!!!

Bei den Aussichten und der Marktkapitalisierung könnte man hier ganz von Anfang an dabei sein!!

[Turboverdichter]

Amarillo, Texas, October 9, 2007

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced the following developments:

In Turkey , enrollment is 86% complete in a Phase 2 study of Behçet’s disease. In the United States , four new clinical sites have been opened to enroll patients in a Phase 2 clinical trial of oral warts. In Texas , enrollment will begin in October 2007 to test oral interferon as a treatment of chronic cough in COPD (chronic obstructive pulmonary disease) patients. In Australia , a human influenza study is planned in 2008. In Taiwan and China , ABI’s Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the company’s ultimate goal: FDA approval for its low-dose oral interferon.

Behçet’s Disease Double-blinded, Placebo-controlled Phase 2 Clinical Trial
Enrollment in Turkey for Behçet’s disease currently stands at 77 patients. Ninety patients are required in order to complete the Phase 2 clinical trial. Enrollment is expected to be completed in the fall of 2007, and data analysis will begin approximately 12 weeks after the last patient is enrolled. The company’s Turkish partner Nobel Ilac, one of the largest pharmaceutical companies in Turkey , is funding the study. Nobel Ilac may be able to use the Phase 2 data to seek approval in Turkey , assuming the data are compelling.

Oral Warts Double-blinded, Placebo-controlled Phase 2 Clinical Trial
A Phase 2 clinical trial is testing low-dose interferon alpha lozenges administered orally to subjects who have oral warts and are also positive for human immunodeficiency virus (HIV). Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is an oral infection with the wart-producing papillomavirus.

Twelve clinical sites in San Francisco , Baltimore , Chicago , New York City, Boston , Philadelphia , Newark , Dallas , Augusta (GA), Ft. Lauderdale , San Antonio and Lexington (KY) are open for enrollment of patients for this study. To date, 26 of 80 patients have been enrolled. Enrollment is expected to accelerate rapidly now that all twelve sites have been approved.

CytoPharm Plans for Hepatitis C Clinical Trial
The company’s licensee in Taiwan and China is CytoPharm, Inc., a Taipei , Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Corp. Ltd., one of the largest petrochemical companies in Taiwan , and a publicly traded company.

Under the terms of the Agreement, between CytoPharm and ABI, CytoPharm and its subsidiary will conduct and fund all clinical trials, and seek regulatory approvals in both China and Taiwan (the Territory) to launch low-dose oral interferon for influenza, hepatitis B, and hepatitis C indications. CytoPharm has entered into discussions with regulatory agencies in the Territory to conduct their first clinical trial in 152 hepatitis C patients. The trial is expected to commence in early 2008.

Texas Tech University Idiopathic Pulmonary Fibrosis and COPD Studies
A total of 18 patients were enrolled in the past five years in a long-term pilot study of the use of interferon lozenges in the treatment of idiopathic pulmonary fibrosis (IPF) at Texas Tech University . Dr. Lutherer, the principal investigator of the study, reported that more than half of his patients treated for at least one year showed no signs of disease progression as assessed by pulmonary-function testing and high-resolution CT scans of their lungs. IPF is normally rapidly progressive, so the fact that half of the patients have shown no progression of the disease during interferon lozenge treatment is encouraging. These clinical results are being submitted for publication to a major medical journal.

The most surprising observation from the IPF research was that low-dose oral interferon relieved chronic coughing in five of six IPF patients assessed for cough in this study. Since chronic coughing is a major problem in Chronic Obstructive Pulmonary Disease (COPD), a Phase 2 clinical study of oral interferon treatment of chronic cough in COPD will begin this month. COPD is reported to affect 10% of humans over the age of 40.

Federal Funding
Amarillo Biosciences retained Hance, Scarborough , Wright, Woodward & Weisbart an Austin-based law firm to represent ABI regarding federal governmental and private source funding for influenza studies. The company is working to obtain federal funding for clinical trials on influenza to be conducted in 2008. University institutions such as the Texas Tech University Health Sciences Center would conduct these trials. Beyond these efforts to procure federal funding, the company seeks investor funding so that it can complete its clinical studies.

Influenza
Animal trials were conducted in 2006/2007 in Australia , USA and Germany , and are continuing in Germany . An oral dose of interferon was found, which protected mice against a fatal influenza challenge. A human trial is planned for the upcoming cold/flu season in Perth , Australia in July - October 2008.

About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences’ shares and has provided over $17.9 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--

[kleinerBiber]

Hi,

warum setzt Du die Nachricht schon wieder rein, wird auch so weiterlaufen.

Die Aktie kannte ja Monate lang nur eine Richtung, warum sollte jetzt nicht mal die Richtung gewechselt werden.

Tschüß kleinerBiber

[Turboverdichter]

Antwort auf Beitrag Nr.: 31.936.809 von kleinerBiber am 11.10.07 11:41:56

Wieso hat ABI die Nachricht 2mal veröffentlicht!?

[kleinerBiber]

Antwort auf Beitrag Nr.: 31.937.375 von Turboverdichter am 11.10.07 12:19:56

Sorry war jemand anders......!!!!

[domba]

Hallo, weiss hier jemand, ob AMAR noch mal "auferstehen" wird oder ob man sein Geld gleich zum Fenster rausschmeißen soll?

Die Meldungen sagen mir nicht viel über Zukunftsaussichten etc.

Vor über einem Jahr war man hier froh, endlich kein Pennystock mehr zu sein und über einem Euro zu stehen, danach gings nur abwärts....

Wer kann zum AMAR was genaueres sagen?

grüße

domba

[Turboverdichter]

Antwort auf Beitrag Nr.: 32.001.948 von domba am 15.10.07 16:38:15

In dieser Branche muss man Geduld haben!

AMAR kommt mal ganz groß raus, wenn das hier alles glatt geht!!

[Kostobeeky]

Hat einer ne Ahnung, was da los ist? Das ist ja echt zum K.....!

Kosto

[Turboverdichter]

Antwort auf Beitrag Nr.: 32.358.103 von Kostobeeky am 09.11.07 10:55:49

Hier kann man nur long bleiben und die Stücke festhalten! Die brauchen noch etwas Zeit...

...Der Kurs interessiert nicht...

[kleinerBiber]

Hallo,

habe mal nee Frage an alle Amarillo Profis .... was meint Ihr wie weit die Aktie noch mit so kleinen Stückzahlen gedrückt wird.

Hier müßten ja die meisten Anleger mit dem größten Teil im Minus sein.

Tschüß kleinerBiber

[Turboverdichter]

Antwort auf Beitrag Nr.: 32.632.125 von kleinerBiber am 30.11.07 20:10:25

Ich bin kein Profi und momentan ratlos!

Keine Ahnung was hier läuft...

[Turboverdichter]

http://app.quotemedia.com/quotetools/showFilingOutline.go?sy…

[xTRADERx]

Antwort auf Beitrag Nr.: 32.649.315 von Turboverdichter am 03.12.07 17:49:32

Ist echt etwas nervig....

Aber NEWS gab's heute:

Amarillo Biosciences Files Patent Application to Treat Chronic Cough with Oral Interferon
Ticker Symbol: U:AMAR


AMARILLO, Texas -- (Business Wire) --


Amarillo Biosciences, Inc. (ABI) (OTCBB:AMAR) today announced that

it has filed a patent application with the U.S. Patent and Trademark

Office with claims to methods of treating chronic coughing by

administering interferon orally to diminish cough duration, frequency

and intensity (now published as US Patent Application Publication No.

US 2007/0237723). Although the examples in the patent application

described a method of treating idiopathic pulmonary fibrosis and

Sjogren's syndrome, it is claimed that interferon will reduce coughing

in many disease conditions, including chronic obstructive pulmonary

disease (COPD).



¶ "Because of the size of the chronic cough market, this is the most

important patent application that the company has ever submitted to

the U. S. Patent Office," said Dr. Joseph Cummins, President and CEO

of Amarillo Biosciences, Inc. "Up to 30 million people in the United

States suffer from COPD. Millions more suffer from asthma and

post-viral cough. The vast majority of these patients have a chronic

cough which is not relieved by over-the-counter cough remedies," said

Dr. Cummins.



¶ A study to confirm the efficacy of oral interferon in the

treatment of chronic cough will be launched in January at a major

Texas university. This Phase 2, double-blind, placebo-controlled trial

of 40 COPD patients is expected to be completed in mid 2008.



¶ About Amarillo Biosciences, Inc.



¶ Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating

in global partnership with the Hayashibara Group, which also holds 12%

of Amarillo Biosciences' shares and has provided over $18 million in

loans, grants and equity investments. The company's primary focus is

extensive and ongoing R&D into the use of low-dose, orally

administered interferon as a treatment for a variety of conditions,

including Sjogren's syndrome, Behcet's disease, and opportunistic

infections in patients who are HIV positive. In its 23-year history,

the company has invested nearly $38 million to establish oral

interferon as a therapeutic agent. The majority of those funds were

invested in clinical trials in an effort to achieve FDA approval for

interferon. Additional information is available at

http://www.amarbio.com/.



¶ Except for the historical information contained herein, the

matters discussed in this news release are forward-looking statements

that involve risks and uncertainties, including uncertainties related

to product development, uncertainties related to the need for

regulatory and other government approvals, dependence on proprietary

technology, uncertainty of market acceptance of oral interferon or the

Company's other product candidates and other risks detailed from time

to time in the Company's filings with the Securities and Exchange

Commission. In particular, see "Item 1. Description of Business" of

the Company's Form 10-KSB for the year ended December 31, 2006.
Contacts:

Amarillo Biosciences, Inc.

Joseph M. Cummins, DVM, PhD, 806-376-1741 x 13

Fax: [phone]

[e-mail]

or

PAN Consultants, Ltd.

Investor Relations:

Philippe Niemetz, 800-477-7570 or 212-344-6464

Fax: [phone]

[e-mail]




Greetz

xTRADERx

Do your own DD!

[kleinerBiber]

Hi,

bei dieser Aktie komme ich mir dieses Jahr vor wie beim Pokern, habe zwei Asse in der Hand und verlier ständig.

Habe aber immer noch ein gutes Gefühl da ich aber auch überhaupt nichts negatives finden kann.

[Tschulius]

Antwort auf Beitrag Nr.: 32.662.300 von kleinerBiber am 04.12.07 17:53:33

Die sind in den Testphasen. Das dauert lange wenn es gut gemacht wird--nicht wie bei GPC Biotech--wo alles in die Hose gegangen ist. Aber wenn die erstmal mit der 3 Phase anfangen dann wird es auch nicht mehr lange dauern und eine Rakete zündet.

[kleinerBiber]

Wünsche allen Investierten, Nichtinvestierten und Interessierten einen feuchtfröhlichen Rutsch und die Raketen nicht nur zu Silvester.

Auf ein besseres 2008.......!!!!!!

Tschüß kleinerBiber

[xTRADERx]

News von heute bei AMAR:

Texas Tech University to Create the West Texas Influenza Research Center
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKET WIRE) -- 01/14/08

http://at.marketwire.com/accesstracking/AccessTrackingLogSer…
Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that the Company's public policy efforts helped attract a $526,000 grant to the Texas Tech University System for the creation of the West Texas Influenza Research Center to study influenza treatments, including the use of oral interferon as a preventative and therapeutic agent.

Human clinical testing of oral interferon at the Texas Tech University System has already included a 5-year study of idiopathic pulmonary fibrosis and an ongoing study of coughing in chronic obstructive pulmonary disease (COPD). The largest earmark in the present Federal budget for the Texas Tech University Health Sciences Center is this new grant to study influenza.

Dr. Joseph M. Cummins, president & CEO, said Amarillo Biosciences is pleased that Texas Tech University Health Sciences Center has been awarded this grant to study treatments for human influenza.

"We have already successfully tested the efficacy of our oral interferon against various avian influenza (including H5N1) in mice. The same animal model was employed by the Centers for Disease Control and was used in independent laboratories in the United States, Germany and Australia, and we are extremely pleased that part of the grant can be applied to test the efficacy of oral interferon in combating influenza," Cummins said. "The time has come to begin human testing, and we eagerly await the launch of human studies which will commence in 2008."

The Company's goal is to achieve regulatory approval for low-dose interferon-alpha for oral delivery to humans and animals. Dr. Steven Berk, Dean of Texas Tech Health Science Center School of Medicine and an infectious disease trained physician, commented, "The School of Medicine is enthusiastic about developing the West Texas Center for Influenza Research, Education and Treatment. We look forward to establishing protocols to assess new treatment modalities for influenza."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences' shares and has provided over $18 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

[e-mail]

Tel: [phone]

212-344-6464

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail:[e-mail]

Tel: [phone] x 13

Fax: [phone]






Greetz

xTRADERx

Do your own DD!

[xTRADERx]

Und nochmal News:


Amarillo Biosciences Appoints Kimball Miller, MD as Medical Director


2008-01-16 06:00 ET - News Release

AMARILLO, TX -- (MARKET WIRE) -- 01/16/08


Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it had appointed Kimball Miller, MD its Medical Director. Dr. Miller will assist the Company with all its human clinical trials; including the human influenza studies that will be conducted in Australia and the USA.

Kimball Austin Miller, MD, MSHA is an academic, medical clinician, health care administrator, management consultant and primary care provider with more than 20 years' experience in clinical practices ranging from small adolescent groups to the Mayo Clinic. Dr. Miller has served in academic faculty positions in several medical and business schools, as a medical director of clinical sections in large multispecialty practices, as an administrator of a physician-hospital organization, as well as the chief medical officer of a multistate provider sponsored HMO.

"Dr. Kimball Miller will aid Amarillo Biosciences in its human clinical trials and consult with us as to the best possible means to ensure that our studies are conducted in the most efficient manner possible," said Dr. Joseph M. Cummins, President and CEO, ABI. "With Dr. Miller's contribution, we expect to accelerate the process of obtaining FDA approval for our low-dose oral interferon."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences' shares and has provided over $18 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the company has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Contact:

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: [e-mail]
Tel: [phone]
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: [e-mail]
Tel: [phone] x 13
Fax: [phone]



Greetz

xTRADERx

Do your own DD!

[dermeierhans]

Die Firma bewegt sich definitiv in die Richtung. Schade, dass es vom Kurs nicht honoriert wird.

[dermeierhans]

Antwort auf Beitrag Nr.: 33.068.562 von dermeierhans am 16.01.08 15:24:14

Gibts übrigens auch auf Deutsch:

Amarillo Biosciences Inc. / Personalie

16.01.2008

Veröffentlichung einer Corporate News, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
---------------------------------------------------------------------------

Amarillo Biosciences, Inc. bestellt Kimball Miller als medizinischen
Direktor

Amarillo, Texas, 16. Januar 2008 - Amarillo Biosciences, Inc. (ABI)
(OTCBB:AMAR) hat heute die Bestellung von Kimball Miller zum medizinischen
Leiter bekannt gegeben. Miller wird das Unternehmen bei der Durchführung
aller klinischen Humanstudien unterstützen; dazu zählen auch die
Influenzastudien, die in Australien und in den USA ausgeführt werden.

Dr. med. Kimball Austin Miller MSHA ist als Wissenschaftler, Klinikarzt, in
der Verwaltung, als Managementberater und Hausarzt tätig gewesen. Er
verfügt über mehr als 20-jährige Praxis im Klinikbereich und war u.a. auch
für die Mayo-Kliniken tätig. Miller hatte mehrere akademische Positionen an
medizinischen Fakultäten und Business-Schools inne, er war medizinischer
Leiter von klinischen Abteilungen in großen Gesundheitscentern, Verwalter
eines Verbundes von Kliniken und Ärzten sowie Chief Medical Officer einer
privaten Krankenkasse, welche ihre Leistungen in mehreren Staaten anbot.

´Dr. Kimball Miller wird Amarillo Biosciences bei den klinischen
Humanstudien unterstützen und optimal beraten, so dass die Studien so
effizient wie möglich durchgeführt werden´, sagte Dr. Joseph M. Cummins,
Präsident und CEO von ABI. ´Durch Dr. Millers Mitwirken erwarten wir, dass
der Weg zur Bewilligung unseres niedrig dosierten oralen Interferons durch
die FDA schneller zurückgelegt wird.´


Über Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. ist ein amerikanisches
Biotechnologie-Unternehmen, das in einer globalen Partnerschaft mit der
Hayashibara Gruppe operiert. Die Hayashibara Gruppe hält 12% der Anteile
von Amarillo Biosciences und hat über US$ 18 Millionen in Darlehen,
Zuschüssen und Kapitalinvestments zur Verfügung gestellt. Der Hauptfokus
der Amarillo Biosciences liegt auf der extensiven Erforschung und
Entwicklung von niedrig dosiertem, oral einzunehmenden Interferon für die
Behandlung unterschiedlicher Krankheitsbilder wie dem Sjögren Syndrom,
Morbus Behçet sowie opportunistischer Infektionen bei HIV-positiven
Patienten. In ihrer 23-jährigen Geschichte hat die Firma knapp US$ 38
Millionen investiert, um das orale Interferon als therapeutisches
Heilmittel zu etablieren. Die Mehrheit dieser Summe wurde für klinische
Studien im Rahmen des FDA-Zulassungsverfahrens für Interferon verwendet.
Zusätzliche Informationen hierzu erhalten Sie unter www.amarbio.com.


Weitere Informationen:

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: [e-mail]
Tel: [phone] x 13
Fax: [phone]

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: [e-mail]
Tel: [phone]
Fax: [phone]

Public Relations:
Privilege Relations LLP.
Tel: [phone]
Fax: [phone]

Disclaimer

Ausgenommen der hierin enthaltenen historischen Informationen beinhalten
die in dieser Pressemitteilung enthaltenen in die Zukunft blickenden
Angaben Risiken und Ungewissheiten, inbegriffen sind Unsicherheiten bzgl.
der Produktentwicklung, regularischer und staatlicher Zustimmungen,
Abhängigkeiten von proprietärer Technologie, Unsicherheiten anlässlich der
Akzeptanz von oralem Interferon oder der anderen Produktkandidaten und
weiteren Risiken, die detailliert bei der SEC (Securities und Exchange
Commission) eingereicht werden. Im Besonderen sei hier auf Item 1.
Description of Business des Firmenformulars 10-KSB für das am 31. Dezember
2006 endende Jahr verwiesen.
16.01.2008 Finanznachrichten übermittelt durch die DGAP

[xTRADERx]

Und gerade nochmal News reingekommen:

Amarillo Bioscience Partner, CytoPharm, to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKET WIRE) -- 02/19/08

http://at.marketwire.com/accesstracking/AccessTrackingLogSer…
Amarillo Biosciences, Inc.(OTCBB: AMAR) today announced that the U.S. Food and Drug Administration has allowed the Investigational New Drug (IND) application submitted by the Company to test its low dose oral interferon in a Phase 2 hepatitis C clinical trial to go into effect. Accordingly, CytoPharm Inc., the Company's partner in Taiwan, will fund and conduct a clinical trial of 144 chronic hepatitis C patients in Taiwan. The patients will receive one of two different dosages of oral human interferon alpha or placebo.

The aim of the trial is to reduce relapse rate for those patients who have completed the standard combination therapy, consisting of high dose injectable interferon alpha and Ribavirin given orally. Although most patients respond to the standard therapy, up to 40% of those with certain viral genotypes relapse after treatment. The trial is expected to start in the 2nd quarter of 2008.

Approximately 170 million people are chronically infected with hepatitis C virus worldwide. The incidence of cirrhosis in chronic hepatitis C patients is 10% to 20% and 1% to 5% develop liver cancer. Infections are transmitted primarily by direct contact with blood through transfusions not screened for hepatitis C virus, inadequately sterilized needles and syringes, sexual and perinatal transmission. There is no effective vaccine against hepatitis C virus.

In addition to studies on hepatitis C, under the terms of the License and Supply Agreement, CytoPharm will be testing oral interferon in human studies of chronic active hepatitis B and influenza.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 11% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at http://www.amarbio.com/.

About CytoPharm

CytoPharm is a closely held company focusing on the development of biopharmaceuticals for virus-infected diseases and cancers. It was founded in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. It acquired core technologies from Gene Trol Therapeutics, Inc., a California based company through M&A. Its product pipelines contain a series of cytokines induced by its proprietary technologies, used for hepatitis, and cancers. Currently, its product is under clinical trials in China. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2006 revenues were approximately NTD 39 billion.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

e-mail: [e-mail]

Tel: [phone]

212-344-6464

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail: [e-mail]

Tel: [phone] x 13

Fax: [phone]






Greetz

xTRADERx

Do your own DD!

[trommlerUK]

Hier tut sich was. Heute kam eine Empfehlung von Trend Stock. Umsätze gehen schon los...

[goldenticket]

Neue Studie: Aussicht auf positive Studienergebnisse könnte Aktie beflügeln

[colop]

Hier geht was. Das Research klingt gut und sollte der Aktie einen Schub geben.
Kennt sich hier jemand mit den verschiedenen Studienphasen aus? Wie viele gibt es?

[silversurfer_f4]

Es gibt vier Phasen. Soweit ich weiß, befindet sich Amarillo in mehreren Phase II Studien.

[colop]

Hört sich sehr gut an, da Amarillo schon fast mit Phase 2 durch ist.

Ab welcher Phase ist es möglich mit den Medikamenten Geld zu verdienen?

[whitey1]

Wo liegen eure Kursziele bis Ostern (23.März)?

Mein Tip: 0,28€

Auf Basis der Studie sicherlich gerechtfertig.

[silversurfer_f4]

Mit den Medikamenten werden jetzt schon Umsätze generiert.

[colop]

Antwort auf Beitrag Nr.: 33.500.358 von whitey1 am 28.02.08 10:26:44

0,30€

Bin halt Optimist

[colop]

Antwort auf Beitrag Nr.: 33.500.365 von silversurfer_f4 am 28.02.08 10:27:59

Sehr gut. Habe in der Studie auch was von Orphan Drug Status gehört. Damit lässt sich ja auch schon was verdienen und man kann einen Teil der Forschungskosten decken.

[goldenticket]

ich halte mich an colop mit 0,30.

[whitey1]

Habe das Gefühl, dass meine 0,28€ nicht lange halten.

Sind jetzt schon bei +5,24% (0,221€)

[KingkaiMZ]

Antwort auf Beitrag Nr.: 33.500.604 von whitey1 am 28.02.08 10:45:58

Habe den Kurs schon länger auf meiner Watchlst und freue mich daher, dass hier wieder was passiert.

Der Research Report sollte einigen Anlegern das nötige Vertrauen geben hier einzusteigen. Werde mir jetzt auch ein paar Aktien in mein Langfristdepot legen.

[Turboverdichter]

Was ist denn hier plötzlich los??

[goldenticket]

Antwort auf Beitrag Nr.: 33.500.648 von Turboverdichter am 28.02.08 10:48:52

kam research report
Die vollständige Studie ist auf www.trendstock-research.de erhältlich.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/10474.pdf
Die Studie ist zudem auf www.performaxx.de erhältlich.

[silversurfer_f4]

Antwort auf Beitrag Nr.: 33.500.507 von colop am 28.02.08 10:39:13

Vor allem bedeutet der Status für 7 Jahre(USA) bzw. 9 Jahre (EU) Exklusivität im Markt.

[KingkaiMZ]

Antwort auf Beitrag Nr.: 33.500.358 von whitey1 am 28.02.08 10:26:44

Hatte ich vorhin vergessen:

Kursziel: 0,35€

[silversurfer_f4]

Neues von Amarillo!

DGAP-News: Amarillo Biosciences Inc.: Amarillo Biosciences Registrierung für Orale-Warzen-Studie am Zwischenziel




Amarillo Biosciences Inc. / Zwischenbericht/Kooperation

03.03.2008

Veröffentlichung einer Corporate News, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
---------------------------------------------------------------------------



Amarillo Biosciences Registrierung für Orale-Warzen-Studie am Zwischenziel

The Patient Recruitung Agency zur Beschleunigung der Registrierung
beibehalten


Amarillo, Texas, 29. Februar 2008 - Amarillo Biosciences, Inc. (ABI)
(OTCBB:AMAR) gab heute bekannt, dass die Registrierung für die klinischen Phase 2 Studie zu oralen Warzen eine Zahl von 40 Patienten und somit bereits die Hälfte des Ziels der Registrierung von 80 Patienten für eine Teststudie zur oralen Anwendung von low dose interferon alpha in Form von Lutschtabletten bei Testpersonen mit positivem Humanen Immundefizienz-Virus (HIV) mit oralen Warzen erreicht hat. 13 klinische Stellen nehmen an der Studie teil: Augusta (GA), Baltimore, Boston, Chicago, Dallas, Ft. Lauderdale, Lexington (KY), New Orleans, New York City, Newark, Philadelphia, San Antonio und San Francisco. Interessierte Patienten werden
angehalten, sich mit Martin Cummins, Vice President, Clinical and
Regulatory Affairs per Telefon unter 806-376-1741 unter der Nebenstelle -14 oder per Email unter [e-mail] für Informationen über klinische Stellen in Verbindung zu setzen.

In Verbindung zu dieser Entwicklung kündigte ABI an, dass es The Patient Recruiting Agency (TPRA) in Austin damit beauftragt hat, die Registrierung für die klinische Phase 2 Studie mit HIV-positiven Patienten mit oralen Warzen zu beschleunigen. TPRA wird eine Multi-Media-Kampagne entwerfen, die sowohl Print-, Television- als auch Internet-Werbung mit einem zusätzlichen Bestreben nach Basis-Bewusstsein beinhaltet. Dieses Bestreben wird durch eine studienspezifische Website unterstützt. Die Anzeigen werden im März
2008 in den 12 Medienmärkten beginnen, in denen das Unternehmen klinische Stellen betreibt.

Zwei vorausgehende Studien demonstrieren bereits die Fähigkeit der
Interferon alpha Lutschtabletten, die oralen Warzen bei HIV-positiven Patienten zu reduzieren. Sollte, wie schon erwartet, ABIs neue Studie die Effizienz und Sicherheit dieser Behandlungsmethode unter Beweis stellen, beabsichtigt ABI die Durchführung einer Phase 3 Studie vor der Beantragung des NDA (New Drug Application), um so die Genehmigung für die Vermarktung von Interferon alpha Lutschtabletten zur Behandlung von oralen Warzen bei HIV-positiven Patienten zu erhalten.

Über Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. ist ein amerikanisches
Biotechnologie-Unternehmen, das in einer globalen Partnerschaft mit der Hayashibara Gruppe operiert. Die Hayashibara Gruppe hält 11% der Anteile von Amarillo Biosciences und hat über US$ 18 Millionen in Darlehen, Zuschüssen und Kapitalinvestments zur Verfügung gestellt. Der Hauptfokus der Amarillo Biosciences liegt auf der extensiven Erforschung und Entwicklung von niedrig dosiertem, oral einzunehmenden Interferon für die Behandlung unterschiedlicher Krankheitsbilder wie dem Sjögren Syndrom,
Morbus Behçet sowie opportunistischer Infektionen bei HIVpositiven
Patienten. In ihrer 23-jährigen Geschichte hat die Firma knapp US$ 39 Millionen investiert, um das orale Interferon als therapeutisches Heilmittel zu etablieren. Die Mehrheit dieser Summe wurde für klinische Studien im Rahmen des FDA-Zulassungsverfahrens für Interferon verwendet. Zusätzliche Informationen hierzu erhalten Sie unter www.amarbio.com.

Über The Patient Recruiting Agency
The Patient Recruiting Agency (TPRA) hat sich auf die Produktion und Platzierung von maßgeschneiderter Direkt-an-Patienten Werbung sowie auf technische Lösungen zur Unterstützung von Sponsoren, CROs, SMOs und Versuchsleitern in deren Rekrutierungs- und Retentionsbemühungen spezialisiert. TPRA hat bereits mehr als 1.800 Anwerbungskampagnen in mehrfachen Sprachen zur Unterstützung von über 90 verschiedenen Indikationen abgeschlossen. Da Einzigartige an TPRA ist, dass alle Produktionen, Medienplatzierungen, Online-Bestreben sowie Nachverfolgungs-
und Managementtechniken von einem eigenen ´in-house´ Team ohne Outsourcing kreiert und implementiert werden. Dieses Betriebsmodel reduziert beträchtlich die gesamten Rekrutierungskosten für Sponsoren und bietet eine größere Flexibilität für eine schnellere Kampagnenentwicklung mit größerer Beratungswirkung. Das Endergebnis der Sponsoren ist, dass wesentlich mehr Studien für weniger Geld pünktlich abgeschlossen werden können.


Disclaimer

Ausgenommen der hierin enthaltenen historischen Informationen beinhalten die in dieser Pressemitteilung enthaltenen in die Zukunft blickenden Angaben Risiken und Ungewissheiten, inbegriffen sind Unsicherheiten bzgl. der Produktentwicklung, regularischer und staatlicher Zustimmungen, Abhängigkeiten von proprietärer Technologie, Unsicherheiten anlässlich der Akzeptanz von oralem Interferon oder der anderen Produktkandidaten und weiteren Risiken, die detailliert bei der SEC (Securities und Exchange
Commission) eingereicht werden. Im Besonderen sei hier auf Item 1.
Description of Business des Firmenformulars 10-KSB für das am 31. Dezember 2006 endende Jahr verwiesen.



Weitere Informationen:

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: [e-mail]
Tel: [phone] x 13
Fax: [phone]

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: [e-mail]
Tel: [phone]
Fax: [phone]


03.03.2008 Finanznachrichten übermittelt durch die DGAP

---------------------------------------------------------------------------



© EquityStory AG
EquityStory AG

[colop]

Ich kann nicht verstehen, warum mit der Aktie nichts passiert.
Super Potential, sehr weit fortgeschrittene Studien und sehr erfahrenes Management.
Warum wird hier niemand auf diesen Topwert aufmerksam?

[kleinerBiber]

Antwort auf Beitrag Nr.: 33.606.047 von colop am 11.03.08 11:21:35

Hi,

das wissen nur die Sterne.......aber Börse ist zur Zeit eh Sch...e...!!!

Wird schon noch....!!!

[colop]

Natürlich wird das noch.

Der Marktwert von 4,56 Mio ist gradezu lächerlich, wenn man bedenkt, dass bereits erfolgreich über 38 Mio investiert wurden und man bereits erste Zulassungen erhalten hat.

[KingkaiMZ]

Das mit dem Kursziel von 0,35€ zu Ostern sollte knapp werden.

Trotzdem halte ich an meiner positiven Aussicht zu AMARBIO fest. Sobald die ersten Phase-II Studien beendet sind und Ergebnisse vorliegen, sollte es hier einen Sprung geben, trotz drohender Rezession.

[colop]

Antwort auf Beitrag Nr.: 33.680.821 von KingkaiMZ am 19.03.08 09:22:33

Selbst meine 0,30€ waren wohl etwas zu optimistisch für Ostern.

Bin allerdings der selben Meinung wie du, dass es hier in Zukunft weiter nach oben gehen wird. Bei der aktuellen Marktlage wundert es mich nicht, dass diese vermeintliche Perle nicht aus den Löchern kommt.

Mal schauen, was in den nächsten Wochen noch so passiert.

[goldenticket]

hier sollte man wirklich langfristig am Ball bleiben.

[xTRADERx]

Operativ scheint's ja voran zu gehen...

News:

Amarillo Biosciences Enters Into a License and Supply Agreement with CytoPharm for Low Dose Oral Interferon Use in Animal Diseases in China and Taiwan



CytoPharm to Conduct Animal Clinical Trials and Seek Regulatory Approval for

Amarillo Biosciences’ Low Dose Oral Interferon



Amarillo, Texas, and Taipei, Taiwan, March 25, 2008 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that it has entered into a license and supply agreement (Agreement) with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company and specialty Clinical Research Organization in Taiwan specializing in pharmacogenomics.



Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all animal (swine, poultry, cattle) clinical trials and seek regulatory approvals in both China and Taiwan to launch ABI’s low dose oral interferon for animal diseases. CytoPharm has already commenced clinical studies in which low doses of interferon are given orally to treat or prevent swine diseases. According to the Agreement, CytoPharm will make payments to ABI upon reaching certain milestones and will also pay royalties on low-dose oral interferon sales in the Territory.



“With the fast growing economies and vastly improving animal health care systems in both China and Taiwan, producers’ demands for newer and better drugs have become much stronger,” said Dr. Ellson Chen, Chairman of CytoPharm, and founder of Vita Genomics. “Blue Ear Disease – a highly infectious disease that has swept the Chinese swine population and driven up pork prices in China-- is a major disease in the region, and governments are spending billions of dollars and committing vast economic resources to deal with this deadly disease. This agreement with Amarillo Biosciences demonstrates CytoPharm’s commitment to assist in improving the health and well-being of China’s and Taiwan’s animal populations.”



Dr. Joseph M. Cummins, President and CEO of ABI said, “This agreement is of major significance to ABI because our low dose oral interferon will be tested in diseases which annually impact livestock worldwide. We are especially pleased by the professionalism and diligence which CytoPharm has demonstrated in our dealings to date, and are also pleased that they share our vision that low dose oral interferon can be a therapeutic agent against a wide array of animal diseases.”



Dr. Stephen T. Chen, President of STC International and an ABI Board member living in Taiwan, made the introduction of ABI to CytoPharm and was instrumental in negotiations of the Agreement. "I am very pleased to see these two fine companies collaborate on the development of low dose oral interferon. In my estimation, this product will be a huge success in the Asian marketplace," said Dr. Chen.



About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 11% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at http://www.amarbio.com/.



About CytoPharm

CytoPharm is a closely held company focusing on the development of biopharmaceuticals for virus-infected diseases and cancers. It was founded in 2002 by Ho Tung Chemical, Vita Genomics, and banks and venture capital firms. Its product pipelines contain a series of cytokines induced by its proprietary technologies, used for hepatitis, and cancers. Currently, its product is under clinical trials in China. Both CytoPharm and Vita Genomics are affiliates of Ho Tung Chemical Inc., one of the largest petrochemical companies in Taiwan, and a publicly traded company whose 2006 revenues were approximately NTD 39 billion.



Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” of the Company’s Form 10-KSB for the year ended December 31, 2006. --END--






Greetz

xTRADERx

Do your own DD!

[colop]

Gibts auch auf Deutsch:

Amarillo Biosciences Inc. / Kooperation/Vertrag

25.03.2008

Veröffentlichung einer Corporate News, übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
---------------------------------------------------------------------------

Amarillo Biosciences geht einen Lizenz und Liefervertrag mit CytoPharm für
die Anwendung von niedrig dosiertem oralen Interferon für die Behandlung
von Tierkrankheiten in China und Taiwan ein.

Cytopharm führt klinische Tierversuche durch und bemüht sich um
regulatorische Zulassung von Amarillo Biosciences niedrig dosiertem
Oralinterferon

Amarillo, Texas, und Taipei, Taiwan, 25. März 2008, - Amarillo Biosciences,
Inc. (ABI) (OTCBB: AMAR), hat heute bekannt gegeben, dass man ein Lizenz-
und Lieferabkommen (Abkommen) mit CytoPharm, Inc., einem im Taiwanesischen
Taipeh sitzenden Biopharmaunternehmen, dessen Muttergesellschaft Vita
Genomics, Inc. das größte Biotechunternehmen welches auf die Organisation
spezieller klinischer Forschungsstudien mit dem Schwerpunkt Pharmakogenomik
in Taiwan ist.

Unter den Bedingungen des Abkommens werden CytoPharm und seine
Tochtergesellschaften alle klinischen Tierversuche an Schweinen, Geflügel
und Rindern durchführen und sich um eine regulatorische Zulassung in China
und Taiwan für das niedrig dosierte Oralinterferon bemühen, um mit der
Markteinführung für tierische Krankheiten zu beginnen. CytoPharm hat
bereits klinische Studien begonnen und niedrig dosiertes Interferon oral
verabreicht, um der Schweinepest vorzubeugen und diese zu behandeln. Gemäß
dem Abkommen, wird CytoPharm Zahlungen in Abhängigkeit vom Erreichen
gesetzter Meilensteine an ABI machen und auch Tantiemen aus den Verkäufen
aus diesen Gebieten an ABI weiterleiten.

´Mit den schnell wachsenden Wirtschaften und den sich schnell verbessernden
Tiergesundheitssystemen in China und Taiwan, wurde die Nachfrage der
Produzenten für neuere und bessere Medikamente immer stärker´, sagte Dr.
Ellson Chen, Vorsitzender von CytoPharm und Gründer von Vita Genomics.
´Seuchenhafter Spätabort der Schweine - eine hochansteckende Krankheit
welche die chinesische Schweinepopulation erfasste und die chinesischen
Schweinefleischpreise in die Höhe trieb, ist eine Hauptkrankheit in der
Region und die Regierung gibt Milliarden an Dollar aus und bindet große
wirtschaftliche Kapazitäten, um dieser tödlichen Krankheit Herr zu werden.
Das Abkommen mit Amarillo Biosciences zeigt CytoPharms Engagement bei der
Verbesserung der Gesundheit und des Wohlbefindens von Chinas und Taiwans
Tierpopulation.´

Dr. Joseph M. Cummins, Präsident und CEO von ABI sagte, ´Dieses Abkommen
ist von großer Bedeutung für ABI, weil unser niedrig dosiertes Interferon
an Krankheiten getestet wird, welche jährlich Tierbestände weltweit
betreffen. Wir sind besonders erfreut über die Professionalität und den
Eifer den CytoPharm bis heute in unseren Geschäften an den Tag gelegt hat
und freuen uns auch darüber, dass sie unsere Vision teilen, dass niedrig
dosiertes Oralinterferon als therapeutisches Mittel gegen eine Vielzahl an
Tierkrankheiten eingesetzt werden kann.´

Dr. Stephen T. Chen, Präsident von STC International und in Taiwan
lebendendes Vorstandsmitglied von ABI stellte ABI CytoPharm vor und war
behilflich bei den Verhandlungen dieses Abkommens. ´Ich bin hoch erfreut
diese zwei ausgezeichneten Unternehmen zusammen an der Entwicklung von
niedrig dosiertem Oralinterferon arbeiten zu sehen. In meiner Einschätzung
wird dieses Produkt ein großer Erfolg auf dem asiatischen Markt,´ sagte Dr.
Chen.

Über Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. ist ein amerikanisches
Biotechnologie-Unternehmen, das in einer globalen Partnerschaft mit der
Hayashibara Gruppe operiert. Die Hayashibara Gruppe hält 11% der Anteile
von Amarillo Biosciences und hat über US$ 18 Millionen in Darlehen,
Zuschüssen und Kapitalinvestments zur Verfügung gestellt. Der Hauptfokus
der Amarillo Biosciences liegt auf der extensiven Erforschung und
Entwicklung von niedrig dosiertem, oral einzunehmenden Interferon für die
Behandlung unterschiedlicher Krankheitsbilder wie dem Sjögren Syndrom,
Morbus Behçet sowie opportunistischer Infektionen bei HIV-positiven
Patienten. In ihrer 23-jährigen Geschichte hat die Firma knapp US$ 39
Millionen investiert, um das orale Interferon als therapeutisches
Heilmittel zu

etablieren. Die Mehrheit dieser Summe wurde für klinische Studien im Rahmen
des FDA-Zulassungsverfahrens für Interferon verwendet. Zusätzliche
Informationen hierzu erhalten Sie unter www.amarbio.com.

Über Cytopharm

CytoPharm ist eine Gesellschaft mit einer geringen Anzahl von Aktionären,
dessen Fokus auf der Entwicklung von Biopharmazeutika gegen vireninfizierte
Krankheiten und Krebs liegt. CytoPharm wurde 2002 von Ho Thung Chemical,
Vita Genomics, Banken und Venture Capital Unternehmen gegründet.
Kerntechnologien erwarb es von Gene Trol Therapeutics, Inc., einem in
Kalifornien ansässigen Unternehmen, durch einen Zusammenschluss. GTT´s
Produktleitungen enthalten eine Reihe von Cytokinen, induziert durch seine
urheberrechtlich geschützte Technologie, die für die Behandlung von
Hepatitis und Krebs bestimmt sind. Momentan werden die Produkte in China in
klinischen Tests geprüft. Sowohl CytoPharm als auch Vita Genomics sind
Tochterunternehmen von Ho Thung Chemical Inc., einem der größten
petrochemischen Unternehmen in Taiwan, das öffentlich gehandelt wird und
dessen Einnahmen sich 2006 auf 39 Milliarden NTD beliefen.

Disclaimer

Ausgenommen der hierin enthaltenen historischen Informationen beinhalten
die in dieser Pressemitteilung enthaltenen in die Zukunft blickenden
Angaben Risiken und Ungewissheiten, inbegriffen sind Unsicherheiten bzgl.
der Produktentwicklung, regularischer und staatlicher Zustimmungen,
Abhängigkeiten von proprietärer Technologie, Unsicherheiten anlässlich der
Akzeptanz von oralem Interferon oder der anderen Produktkandidaten und
weiteren Risiken, die detailliert bei der SEC (Securities und Exchange
Commission) eingereicht werden. Im Besonderen sei hier auf Item 1.
Description of Business des Firmenformulars 10-KSB für das am 31. Dezember
2006 endende Jahr verwiesen.

Media Contact:
Ching-Yuan Lee
CytoPharm, Inc.
Tel: [phone]
Fax: [phone]
Email: [e-mail]

Investor Relations:
Chance Sheu
CytoPharm, Inc.
Tel: [phone]
Fax: [phone]
Email: [e-mail]

Media Contact:
Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
Tel: [phone]
Fax: [phone]
Email: [e-mail]

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
Tel: [phone] [phone]
Fax: [phone]
Email: [e-mail]

[colop]

Das habe ich grade auf ad-hoc-news.de gefunden.




Amarillo Biosciences
... ist Biotech vom Feinsten aus den USA.
Autor: Mischa Hampe
Amarillo Biosciences, Inc. – Biotech vom Feinsten aus den USA


Die Yalta AG freut sich Ihnen heute die Aktie von Amarillo Biosciences aus den USA vorstellen zu dürfen.

Unsere Empfehlung:
„Buy“

„Amarillo Biosciences (AMAR) ist Biotech vom Feinsten. Gegründet bereits im Jahre 1984, war und ist die Entwicklung oraler Anwendungsformen von Interferon (Interferon Alpha – IFNΩ) zur Behandlung verschiedener Krankheiten bei Menschen und Tieren das vorrangige Unternehmensziel.“


Unser Fazit:

„Die Aktie steht momentan bei 0,198 EUR – Market Cap liegt bei ca. 6 Mio. EUR – und ist unserer Meinung nach stark unterbewertet. (…) Aus unserer Sicht ist AMAR einer der verheißungsvollsten Werte überhaupt. Enorme Marktpotentiale und mehrfache Vervielfachungen sind Möglich – da die ersten Zulassungen in den nächsten 12 Monaten zu erwarten sind.“

Wir freuen uns, allen Interessierten einen aktuellen Researchbericht zu Amarillo Biosciences präsentieren zu können. Auf unserer Website www.yalta.ag unter Rubrik Research – oder direkt unter dem Link:

YALTA AG RESEARCH REPORTS
(http://yalta.ag/index.php?id=79&L=3)

erhalten Sie noch mehr interessante Details und Ausführungen zu besagtem Unternehmen.

Gute Geschäfte wünscht Ihnen
Ihr Mischa Hampe

Kontakt für Rückfragen:
Yalta AG
Mischa Hampe
Westendstraße 74
60325 Frankfurt am Main
T: [phone]
E: [e-mail]

[dermeierhans]

Antwort auf Beitrag Nr.: 33.808.833 von colop am 04.04.08 12:52:29

Danke hatte ich noch nicht gesehen. Werde mir den Report gleich mal anschauen.

[goldenticket]

Ich denke, das bestätigt die bisherige Taktik. Halten.

[dermeierhans]

Antwort auf Beitrag Nr.: 33.808.897 von goldenticket am 04.04.08 12:58:23

Nicht nur halten.
Ich bin immer noch sehr überzeugt von der Firma und zu dem Preis kann man nur sagen zu schlagen.

[silversurfer_f4]

Soweit haben sie sich sehr gut präsentiert. Die Testreihen dauern halt. wann kommen noch mal die nächsten Ergebnisse?

[clajwat]

Antwort auf Beitrag Nr.: 33.808.930 von dermeierhans am 04.04.08 13:00:35

Warum bist Du so von dem Unternehmen überzeugt?

[dermeierhans]

Antwort auf Beitrag Nr.: 33.808.997 von clajwat am 04.04.08 13:07:32

Das würde eine lange Liste werden, deshalb hier mal meine Mainpoints:

- erfahrenes Managementteam, teilweise seit 1984 dabei
- verheisunglsvoller Markt
- Marktpotential von ca. 2 Mrd.!!!
- erste sehr positive Testergebnisse
- weitreichende Distributions- und Lizenzverträge in Keymärkten

Wenn man diese Faktoren und noch einige mehr zusammenfasst und dann mit dem Aktienkurs vergleicht, sieht ein Blinder mit Krückstock im Dunkeln, dass hier Potential drin steckt.

[KingkaiMZ]

Habt ihr mal auf die erste Seite geschaut?

Amarillo ist "AKTIE IM FOKUS"!

Hier wird jetzt kräftig was getan, um den Kurs endlich dem tatsächlichen Wert des Unternehmens anzupassen.

[dermeierhans]

Habe den Report von Yalta jetzt gelesen und er bestätigt meine gewonnenen Eindrücke zusätzlich.

Was haltet ihr von dem Report? Wie seht ihr die Chancen von Amarillo und vor allem der Aktien?

[colop]

Die Chancen stehen weiterhin sehr gut.

Außerdem bei einem Risiko/Chancen Verhältnis von 1:4 sollte man zuschlagen. Man bekommt nicht den Status als Orphan Drug, wenn das Medikament nicht wirken würde.

[whitey1]

Es freut mich zu sehen, dass hier endlich Bewegung in die Sache kommt. Hoffentlich passt sich der Kurswert bald dem wirklichen Unternehmenswert an.

Mein Kursziel für Pfingsten (Schlusstag 09.05.)
0,29

[trommlerUK]

die sind jetzt schon so lange dran und durch ihre partner in den einzelnen ländern werden sie schon bald einige zulassungen erhalten und dann sehen wir ganz andere kurse...

[trommlerUK]

@dermeierschwanz der report ist klasse der von performaxx gefällt mir allerdings auch sehr gut.

[trommlerUK]

ich frage mich wo die ganzen basher sind?

[colop]

Ich bin etwas optimistischer:
0,31€

[silversurfer_f4]

Antwort auf Beitrag Nr.: 33.811.907 von colop am 04.04.08 17:18:43

Schließe mich Dir an. vielleicht sogar 0,35?

[colop]

HIer gibt es nichts zu bashen, ist ein astreiner Wert. An der schwierigen Marktlage können die auch nichts ändern

[KingkaiMZ]

Antwort auf Beitrag Nr.: 33.812.006 von colop am 04.04.08 17:26:57

Sehe ich auch so.

Zum Schluss hat das Volumen endlich ein wenig angezogen und der Kurs befindet sich endlich auch wieder über 0,20€.

[RealBild]

Hallo Leute - ich habe hier gesehen, das zu diesem Wert eine Empfehlung von der YALTA AG abgegeben wurde.
Um die Güte von solchen Empfehlungen besser einschätzen / vergleichen zu können, möchte ich Euch darauf hinweisen, das diese YALTA AG auch eine Empfehlung zu der Pacific-Lottery AG abgegeben hat mit Kurszielen von weit über 1,60 € (Nachlesbar !!!)
Die momentane Situation / Aktienkurs von Pacific kann jeder hier nachlesen.
Desweiteren sehe ich, das der User "dermaierhans" hier schreibt und wenn ich mich recht entsinne, schreibt der auch im Pacific-Lottery-Thread...vielleicht gibt der Euch noch ein paar Infos

[colop]

Danke für die Info.

Kaum ist die Aktie ein wenig gestiegen, gibt es schon Gewinnmitnahmen, hat denn heutzutage keiner mehr ein wenig Geduld?

[Xavox]

Antwort auf Beitrag Nr.: 33.830.779 von colop am 07.04.08 21:38:31

???!

[colop]

Antwort auf Beitrag Nr.: 33.832.027 von Xavox am 08.04.08 00:59:40

Sorry für die späte Antwort.
Aber deine ??? verstehe ich nicht

[domba]

Bisher bleiben die Bemügungen ohne Erfolg, in den Kurs von AMAR etwas Aufwind rein zu bekommen.

Mal sehen, ob sich diese Woche noch etwas tut...

domba

[domba]

Antwort auf Beitrag Nr.: 33.844.648 von domba am 09.04.08 12:27:40

...Bemühungen meinte ich...ups

domba

[Xavox]

Antwort auf Beitrag Nr.: 33.842.696 von colop am 09.04.08 09:33:31

Sorry für die späte Antwort.
Aber, was für Gewinnmitnahmen? Alle, die nach Yalta gekauft haben, sind im minus.

[colop]

Antwort auf Beitrag Nr.: 33.879.005 von Xavox am 14.04.08 13:16:28

Nach dem Yalta-Report und "Aktie im Fokus" aus Wstand die Aktie kurzzeitig über 0,20€. Allerdings hat sich diese Marke grade mal einen Tag gehalten, deshalb bin ich hier von kleinen Gewinnmitnahmen ausgegangen.

[colop]

Des Weitern kann man den Einstieg von Herrn Dr. Müller bei AMARBIO nur begrüßen. Er hat einen super Trackrecord und wird dem Unternehmen entscheidend weiterhelfen.

[domba]

Geht heute was?

Gemäß der Chart-Technik heute ein klares Kaufsignal.

Vom Gefühl sind heute 10% drinn.....aber keine Kauf- oder sonstige Empfehlung!

domba

[colop]

In der Theorie sollte hier jeden Tag was gehen. Aber der Markt ist nicht so leicht zu überzeugen

[kleinerBiber]

Hallo,

es ist etwas am Laufen, wenn ich mir den Umsatz heute in Frankfurt so betrachte.


Tschüß....!!!!

[colop]

Irgendwas muss passiert sein oder wird in Kürze passieren. So ein Volumen hatten wir schon lange nicht mehr. Es waren ca. 250.000 Stücke gestern.

[colop]

Habe ich übers Wochenende von einem Bekannten bekommen. Das würde das Volumen erklären.


Datum: 15. Mai 2008
Ausgabe 52/2008
Unternehmen: Amarillo Biosciences Inc.
WKN: 917640
Aktueller Kurs: 0,194 Euro
Market Cap: 5,68 Mio. Euro
ISIN: US02301P1066
Kursziel: 0,30 - 0,40 Euro

web: www.amarbio.com <http://www.amarbio.com>


Amarillo Biosciences Inc.
Trading-Chance - jetzt noch schnell einsteigen!


Bereits am 28. Februar 2008 haben die Analysten von Performaxx eine Studie über Amarillo Biosciences mit einer "trading buy" Empfehlung veröffentlicht.
Diese Original-Studie von Performaxx können sie hier (download <http://www.financial-newsline.com/research/performaxx-amaril… ) herunterladen.

Das Team von Financial Newsline hat nun Joseph M. Cummins, den Präsidenten und CEO des Unternehmens, zur positiven Entwicklung des Unternehmens interviewt.


Financial News Line: Interview with Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc.


FNL: Mr. Cummins, you are the President and CEO of a very interesting biotech company. What does your company specialize in?
Cummins: Amarillo Biosciences, Inc., (AMAR) is a biopharmaceutical specialty company dedicated to the development of oral application of interferon alpha as a therapeutic. We initiated research in 1984 and are regarded as a leader in the research and development of oral cytokines. Recently we have started expanding our focus towards the development of human therapeutic applications.
The most advanced product under development for the human therapeutic market is low-dose, orally administered intereferon alpha.

What is the market potential of your products?
In our ongoing research studies we developed a potential blockbuster targeting chronic cough in COPD (chronic obstructive pulmonary disease) which occurs in 10% of the population over 40 years of age – making it a billion dollar market. In addition, we are currently researching the use of interferon alpha on hepatitis C and influenza in low doses with little to no side effects. Alone for hepatitis C, according to WHO estimates, the number of sick people is at 170 million. In industrialized countries interferon alpha is already used for treatment of hepatitis C, but in the high-dose injectable version with many side-effects, which we target to eliminate with our low-dose oral variant.

Your recent press releases and various publications of research reports on your company seem to have been ignored by the market. What do you think are the reasons?
The biotech market has been in very bad shape over the recent months and was struggling along with the general financial crisis. But with the general indexes recovering, our industry and well positioned and established companies, like Amarillo Biosciences, have the potential to gain momentum over the next months. Also we will continue with our strategy on constantly informing the public about our developments on our promising research studies and other business developments.

In your latest press release you announced the hiring of Dr. Peter Müller as the company’s new COO and head of the research department. How important is he for Amarillo Biosciences?
Dr. Müller has more than 20 years of professional experience in the global pharmaceutical industry. Prior to his engagement with Amarillo he was Vice President of Global Marketing & Medical Information Technology for Aventis Pharmaceuticals, Vice President of Global Marketing Business & Marketing Services for Hoechst Marion Russel and in 2001 founded his own company, Epicenter Consulting Inc.
Dr. Müller will primarily focus his attention on the treatment of chronic cough in COPD which currently affects more than 600mn people worldwide and offers great market potential. He will also work on forming strategic alliances with the large global pharmaceutical companies as he knows due to his proven track record what major pharmaceutical companies are looking for in research partners. Not only in this area will Dr. Müller be an invaluable asset to the company.

Three Phase II test results are expected to be announced in 2008. Can you give us an indication on when to expect them?
A FDA Phase II study for oral interferon treatment of Behcet’s disease was completed in Turkey in April 2008. Results are expected by the end of the second quarter of 2008. A FDA Phase II study for oral interferon treatment of oral warts (human pappilomavirus) in HIV+ patients in the US is more than 50% enrolled and results are expected at the end of 2008. Texas Tech University has launched an oral interferon treatment of chronic cough in COPD patients Phase II proof of concept study that is expected to be completed later in 2008. Amarillo Biosciences also plans to start a chronic cough Phase II study involving 4 weeks of treatment with a 4 week follow up.
Results are expected by the end of 2008.

What is your company’s short / long term focus?
Our short-term focus is to complete a Phase II proof of concept chronic cough study in COPD patients. Then proceed to start a Phase IIb chronic cough dose-ranging study and identify partners for global commercialization.
Our longer-term focus will be on other diseases such as hepatitis C and influenza that affect large populations because these have much greater sales potential, like Chronic Obstructive Pulmonary Disease (COPD).

Taking all that into account, how do you believe this is reflected in your current share price?
We believe that our shares are strongly undervalued. We are currently finishing important Phase II studies, which will bring us closer to FDA approval. Also with Dr. Müller we gained an important asset and see us in a very strong position to negotiate strategic alliances with big pharmaceuticals for the final phase of the research studies. As many big pharmaceuticals have empty pipelines, they will be looking for research partners like us to deliver them blockbusters on a global scale, which we know we have.

Mr. Cummins, thank you very much for answering our questoins.



Weitere Informationen von Amarillo Biosciences finden sie hier direkt <http://www.amarbio.com> :

Stammdaten

Ausstehende Aktien: 29,3 Mio.
Aktienkurs: 0,194 Euro
Marktkapitalisierung: 5,68 Mio. Euro


Die umfangreiche Research Studie von Performaxx finden Sie hier:
Performaxx Research Studie zu Amarillo Biosciences Inc.
<http://www.financial-newsline.com/research/performaxx-amaril…

[colop]

Hier sind doch noch sicherlich mehr investierte dieser Aktie unterwegs, oder nicht?

[colop]

Endlich mal wieder eine Woche im Plus abgeschlossen.
Allen investierten ein schönes Wochenende.

Liest hier noch jemand mit?

[colop]

Die grüne Phase geht weiter...

[colop]

Mal wieder über 0,20€ mal schauen, wie lange das hält.

[xTRADERx]

Es tut sich was auf der Newsseite:

Amarillo Biosciences Files Patent to Treat Obesity With Oral Interferon
Ticker Symbol: U:AMAR


AMARILLO, TX -- (MARKET WIRE) -- 06/11/08

http://at.marketwire.com/accesstracking/AccessTrackingLogSer…
Amarillo Biosciences, Inc. (OTCBB: AMAR), a specialty pharmaceutical company focused on low-dose orally administered interferon as a treatment for a variety of conditions, today announced that a patent has been filed with the United States Patent and Trademark Office on the oral use of interferon to treat obesity.

The company recently conducted a review of clinical data from four studies that it had conducted wherein 582 women were treated for autoimmune diseases or fibromyalgia syndrome over three to six months with one of 5 different low daily doses of oral interferon or placebo. This review found that a significantly greater proportion of women given two specific doses of oral interferon experienced at least a 5% weight loss, compared to the women given placebo. This surprising benefit occurred in the women given oral interferon without a significant increase in adverse events.

The World Health Organization predicts that by 2015, approximately 2.3 billion adults will be overweight and more than 700 million will be obese. In the U.S. and Canada, half of all adults are likely to be obese within eight years, with only one in five people of healthy weight. The market for weight-loss drugs in the U.S., Europe and Japan totaled around US$600 million in 2005, and is expected to rise globally to approximately $2 billion by 2010.

"While we clearly need to conduct additional studies to establish the efficacy of low-dose oral interferon as a weapon against the growing obesity pandemic, the filing of this patent could be enormously valuable to Amarillo Biosciences in the long term," said Dr. Peter Mueller, COO, ABI. "We will continue to focus our resources on our ongoing clinical studies, especially on chronic cough in COPD (Chronic Obstructive Pulmonary Disease), but believe that this recent patent filing is a substantial addition to our Intellectual Property portfolio."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which owns 10.5% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments to the company. Amarillo Biosciences' primary focus involves extensive and ongoing R&D into the utilization of low-dose, orally administered interferon as a treatment for a variety of conditions, including chronic cough (COPD), influenza, and opportunistic infections in patients who are HIV positive. In its 23-year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for low-dose oral interferon. Additional information is available on the web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2007.


Investor Relations:

Philippe Niemetz

PAN Consultants, Ltd.

[e-mail]

Tel: [phone]

212-344-6464

Fax: [phone]



Joseph M. Cummins, DVM, PhD

Amarillo Biosciences, Inc.

e-mail:[e-mail]

Tel: [phone] x 13

Fax: [phone]




Greetz

xTRADERx

Do your own DD!

[colop]

Ich bin nicht der absolute Börsenprofi, aber wie kommen denn diese Kursschwankungen ganz Volumen zu stande? Versucht der Market Maker den Kurs durch Extremwerte in irgendwelche Charts zu bringen, um Aufmerksamkeit zu generieren?

[Tschulius]

Neue Homepage
Abwarten und Tee trinken--wird sich lohnen!!

[colop]

Antwort auf Beitrag Nr.: 34.360.270 von Tschulius am 24.06.08 10:57:48

Schöne neue Seite und sehr übersichtlich.
Habe mich gleich für den Newsletter eingetragen

Es geht hier konstant weiter...

[kleinerBiber]

Hui,

mit unserer Aktie gehts ja richtig in den Keller....haben es die Ammi`s doch echt mit 20000 Dollar geschaft ...... das MK um ein viertel zu reduzieren.

[colop]

Hat mir grade der Google Alert geschickt:


Amarillo Biosciences to Support Western Australian Government Sponsored Human Influenza Clinical Trial in Perth, Australia

Last update: 10:05 a.m. EDT Aug. 1, 2008
AMARILLO, TX, Aug 01, 2008 (MARKET WIRE via COMTEX) -- Amarillo Biosciences, Inc. (AMAR:
Amarillo Biosciences Inc
News, chart, profile, more
Last: 0.20-0.01-4.76%
9:43am 07/31/2008
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
AMAR 0.20, -0.01, -4.8%) today announced that it has agreed to provide interferon lozenges and other support for Western Australia's government (Department of Health) sponsored human influenza clinical trial led by Dr. Manfred Beilharz, Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, Faculty of Life and Physical Sciences, The University of Western Australia.
Dr. Beilharz has received and accepted a grant from the Department of Health, Government of Western Australia to undertake a project entitled "Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention/Amelioration of Winter Colds and Flu in Perth, Western Australia." The study is to be completed by September 24, 2009.
"We have been collaborating with Dr. Beilharz for more than 10 years," said Dr. Cummins, CEO of Amarillo Biosciences, Inc. "During that time, Dr. Beilharz has published 10 scientific papers or abstracts on the low-dose, oral use of interferon. We are pleased to extend our research collaboration with Dr. Beilharz. His exciting discoveries regarding how oral interferon can protect against influenza are critically important as the world prepares for the next influenza pandemic."
"We published in 2007 that interferon in the mouth protects mice against fatal influenza," said Dr. Beilharz. "Our goal in our new human research is to determine if oral interferon will not only address the influenza issue, but will also address a new approach to winter colds and flu-like conditions," said Dr. Beilharz.
Perth is a city in Western Australia with 2 million residents. The clinical study will be conducted there in childcare workers, schoolteachers and hospital workers who will be naturally exposed to infections of influenza and other respiratory pathogens. Some subjects will take placebo daily during the next "flu season" and others will take oral interferon at the dosages covered by the company's issued US patents. Besides patented dose formulation, two of the company's issued US patents have claims which directly apply to the low-dose oral use of interferon for influenza.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which owns 10.5% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments to the company. Amarillo Biosciences' primary focus involves extensive and ongoing R&D into the utilization of low-dose, orally administered interferon as a treatment for a variety of conditions, including chronic cough (COPD), influenza, and opportunistic infections in patients who are HIV positive. In its 23-year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for low-dose oral interferon. Additional information is available on the web site at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2007.

Contact:

Investor Relations:
Philippe Niemetz
PAN Consultants, Ltd.
e-mail: [e-mail]
Tel: [phone]
212-344-6464
Fax: [phone]

Joseph M. Cummins, DVM, PhD
Amarillo Biosciences, Inc.
e-mail: [e-mail]
Tel: [phone] x 13
Fax: [phone]




SOURCE: Amarillo Biosciences, Inc.

[e-mail]
mailto:[e-mail]

[colop]

So Google Alerts sind doch was feines:

Pinnacle Digest: Amarillo Biosciences Labeled Company Of Interest By Leading Online Investment Club


Monday, August 04, 2008; Posted: 04:05 AM
7 Stocks You Need To Know For Tomorrow -- Free Newsletter
Aug 04, 2008 (M2 PRESSWIRE via COMTEX) -- AMAR | Quote | Chart | News | PowerRating -- www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Amarillo Biosciences, Inc. (OTCBB: AMAR | Quote | Chart | News | PowerRating) announcing that it has agreed to provide interferon lozenges and other support for Western Australia's government (Department of Health), our team has launched their exclusive investor controlled forum. Our staff and members have requested that all Amarillo Biosciences shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.

Once a member of PinnacleDigest.com you will have access to all our Amarillo Biosciences research. It is our goal to find viable opportunities for each one of our members.

Join PinnacleDigest.com to

Find out if Amarillo Biosciences makes it as a Pinnacle Featured Company

Chat with other shareholders invested in Amarillo Biosciences

Explain to our investor community what differentiates this company

Connect with investors and professionals in the equity markets

Meet the thousands of investors who have already become members of the Pinnacle community.

PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

PinnacleDigest.com has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.

CONTACT: Pinnacledigest.com WWW: http://www.pinnacledigest.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

[domba]

Weiß jemand, warum wir heute in USA so eine Verkaufspanik haben? Sehr untypisch für die letzten Tage.....

Gibts was fundamentales? Ich konnte nichts finden....

domba

[domba]

Antwort auf Beitrag Nr.: 34.797.362 von domba am 21.08.08 16:32:03

...sorry! falscher Thread!

....

[domba]

Antwort auf Beitrag Nr.: 34.797.377 von domba am 21.08.08 16:33:09

....jetzt binn ich aber verwirrt...doch der richtige Thread....

ich meine AMAR....und dass ist hier....

Also...meine Frage von eben gilt weiterhin....

domba

[Tschulius]

Antwort auf Beitrag Nr.: 34.797.433 von domba am 21.08.08 16:35:22

Wo ist denn hier eine Verkaufspanik ?
Das ist eine Aktie für die Zukunft Ende 2008 oder 2009.
Die Verkäufer können halt nicht abwarten--und wo verkauft wird, da wird auch gekauft. Also abwarten--die kommt schon noch !
Fundamental alles auf dem richtigen Kurs.

[Tschulius]

Antwort auf Beitrag Nr.: 34.810.645 von Tschulius am 22.08.08 13:46:37

Als innovatives Biotechnologie-Unternehmen arbeite Amarillo an mehreren aussichtsreichen Medikamenten mit einem Milliardenpotenzial. Das erste Präparat könnte im Jahr 2011 an den Markt gebracht werden. Unter fundamentalen Gesichtspunkten erscheine der Zeitpunkt für einen Einstieg in die Aktie daher recht früh. Allerdings dürfte Amarillo im laufenden Jahr 2008 mehrere Phase-II-Studien abschließen, was im Erfolgsfall eine signifikante Höherbewertung des Unternehmens bewirken könnte. Aktuell liege die Marktkapitalisierung bei lediglich 5,9 Mio. Euro. Vor diesem Hintergrund sehe man eine interessante Trading-Chance. Anleger sollten sich rechtzeitig positionieren und bei guten Nachrichten dann auch mal Gewinne mitnehmen

[domba]

Antwort auf Beitrag Nr.: 34.810.645 von Tschulius am 22.08.08 13:46:37

Danke für Deine Info, ich dachte schon, dass sich hier niemand mehr fü AMAR interessiert.

Dem letzten Filling kann ich aber entnehmen, dass hier einige Zahlungen mit Aktienwandlungen etc. erfolgen.....der Kurs könnte somit nochmals etwas abrutschen.....na ja, irgend wann wird AMAR einen guten Boden gefunden haben.....und dann kann die Rakete starten.

Ich pers. vermute jetzt auch so gegen Mitte bis Ende 2009.

domba

[Kostobeeky]

Wat is los? Wer weiß was?

[Xavox]

Heavy down ohne news!?
Jemand Ahnung?